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Abstract 
 
Polyelectrolyte microcapsules were first established in 1998 as a potential drug delivery 
vehicle. Despite being well-established, microcapsules have not yet been thoroughly 
considered as a viable means of targeted drug delivery. This is largely due to the fact that 
microcapsules are inherently prone to unspecific binding to cells and proteins. Targeted 
delivery of drugs to specific diseased sites in the body is an area of research that has 
attracted many studies, particularly in drug deliveries that utilise microparticles. By 
achieving targeted delivery of a drug, one can increase the efficacy of the treatment, thus, 
reducing unwanted side effects.  This thesis investigates methods which can modify these 
microcapsules in order to fine tune the release of the encapsulated drug as well as site-
specific delivery of these vesicles i.e. obtain spatiotemporal control. To this end, 
biodegradable microcapsules of varying constituents are manufactured and their 
biodegradability is indirectly measured through quantification of the release of an 
encapsulated fluorescent protein (Rhodamine B-BSA). Fluorometry analysis of the 
supernatants of these microcapsule suspensions indicated that microcapsules synthesised 
from poly-L-arginine and poly-L-glutamic acid have the ability to encapsulate bovine 
serum albumin (BSA) with a high encapsulation efficiency (79.7%). Furthermore, they 
are able to produce a sustained release of BSA over a period of 5 Days.  
 
To complement this controlled-release study, an investigation into self-degradable 
microcapsules was undertaken. To achieve this, proteinase was encapsulated in both 
biodegradable and non-biodegradable microcapsules of different thickness. Analysis of 
the protein release over a period of 24 hours revealed that the release profiles of these 
iii 
 
microcapsules can be successfully controlled. Biodegradable microcapsules released 87% 
more protein than their non-biodegradable counterpart after 2 hours of incubation in 
deionised water. This provides conclusive evidence that the biodegradable microcapsules 
were, indeed, self-degradable.  
 
The latter part of this thesis focuses on achieving specific and exclusive targeted delivery 
using polyelectrolyte microcapsules, with respect to protein substrates. This is 
accomplished by creating an antibody-functionalised poly(ethylene glycol) (PEG) 
assembly within the microcapsule structure. Site-specific adsorption of these 
microcapsules is tested using protein micropatterns. Results obtained from adsorption 
assays using anti-collagen type IV-functionalised microcapsules show a 600-fold 
increase in binding to collagen type IV islands, compared to control proteins (fibronectin 
and BSA). This proves that significant adsorption was achieved on the target protein, 
with unspecific adsorptions being heavily suppressed on control proteins. Furthermore, 
similar results were found when microcapsules were functionalised with anti-fibronectin 
and exposed to fibronectin, highlighting the versatility of this type of 
biofunctionalisation. 
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1. Introduction 
 
Drug delivery systems have been in use for decades with the first mechanisms including 
administration by simple intravenous injections or ingestion of white powder tablets. 
However, these methods may not always be applicable to a particular drug treatment e.g. 
structural changes of a chemical due to interaction with the gastro-intenstinal tract may 
occur, rendering the drug inactive. To a certain degree, capsules, usually made from 
gelatin, have circumvented this problem. However, the control of release of such 
capsules is challenging. Research in biomaterials has led to the production of 
microcapsules that have the ability to encapsulate materials with reasonable success. 
These microcapsules can then be held in a suspension which can be injected directly into 
the body, thus bypassing the harsh environment of the gastro-intestinal tract. The use of 
such microcapsules may indeed be a viable option for drug delivery, however, research 
into more specific diseases that are not systemic in nature, has increased the demand for 
smarter more advanced drug delivery mechanisms. Control over both the site-specific 
delivery and rate of release of a drug from microcapsules are therefore of paramount 
importance.   
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The work presented in this thesis aims to develop a novel method for targeted delivery 
and controlled release of therapeutic drugs using polyelectrolyte microcapsules, with the 
intention of treating diseases that are site-specific. An example of a site-specific disease 
is atherosclerosis, a leading cause of death in the western world (Phipps, 2000). The 
disease shall be briefly discussed, highlighting current surgical treatments available. 
 
1.1 Atherosclerosis 
Atherosclerosis is a cardiovascular disease by which macrophages and low density 
lipoprotein cholesterol infiltrate the endothelium and form an atherosclerotic plaque also 
known as an atheroma. This plaque is sealed via a fibrous cap which is formed by smooth 
muscle cells as shown in Figure 1.  
 
 
Figure 1. Atherosclerotic Artery. Adapted from (Thompson, 2008). 
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Over time, the plaque may either occlude the lumen or become unstable, releasing its 
thrombogenic contents which ultimately results in thrombus formation leading to total 
vessel occlusion. This may lead to the occurrence of a stroke or myocardial infarction 
depending on the location of the occlusion (Channon, 2002).  
The normal inner wall of a blood vessel is made up of the endothelium and the 
underlying basement membrane. The endothelium lines the lumen of the vessel. It is 
made up of a monolayer of endothelial cells. These cells are in direct contact with the 
blood flow in the lumen. Endothelial cells are able to respond to physiological stimuli 
(e.g. shear stress) and do so by producing signalling molecules that have effects on the 
endothelium, blood cells and neighbouring smooth muscle cells. 
 
A vital signalling molecule produced by endothelial cells is nitric oxide (NO). This is 
produced by endothelial nitric oxide synthase. When synthesised, NO diffuses into the 
lumen and the neighbouring smooth muscle cells in the media. This leads to an 
enzymatic reaction which leads to an increase in intracellular cyclic guanosine 
monophosphate (cGMP) which causes smooth muscle relaxation in smooth muscle cells. 
cGMP also has an inhibitory effect on platelets. This relaxation of the smooth muscle 
cells helps prevent atherosclerosis. This is known as endothelium-dependent relaxation. 
In atherosclerosis, oxidised low-density lipoprotein (ox- LDL) inhibits agonist stimulated 
endothelium dependent relaxation. Endothelial dysfunction is characterised by a loss in 
NO bioactivity resulting in predisposition to inflammatory cell adhesion and recruitment 
and thrombosis. A study had shown that upon introducing NOS inhibitors to an artery 
could lead to the acceleration of neointimal formation and consequently, acceleration of 
atherogenesis (Marek et al., 1995).  
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1.2 Current surgical treatments for Atherosclerosis 
Angioplasty is a common surgical procedure used to remove atherosclerotic plaque. It is 
a mechanical treatment where the plaque is destroyed. Percutaneous transluminal 
angioplasty is generally carried out by using inflatable balloons, however, there is an 
increasing trend towards the use of expandable stents to remove plaque. Briefly, a 
catheter with a balloon attached at its tip, is inserted percutaneously into the affected 
artery as shown in Figure 2. 
 
 
Figure 2. Inflation of balloon inside artery. Adapted from (Inflation of Balloon Inside a 
Coronary Artery, 2011). 
    
Once at the site of the plaque, the balloon is inflated to break the plaque and increase the 
lumen area to improve blood flow. The procedure is done under fluoroscopy to visually 
aid the surgeon. This solution indeed offers short term relief, however, over time, 
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restenosis is likely to occur. Restenosis is where stiffening and intimal hyperplasia 
reoccurs after angioplasty. Its prevalence is reported to be as high as 50% in all cases 
worldwide (Horlitz et al., 2002). It is believed to take place in response to endothelium 
injury, where endothelial cells are removed from the inner lining of the artery, exposing 
the underlying thrombogenic  basement membrane. Exposure of the basement membrane 
results in platelet adhesion which leads to the release of various growth factors that 
promote vascular smooth muscle cell migration and proliferation (Farb et al., 1999). In 
an attempt to maintain an adequate lumen cross-sectional area, expandable stents which 
are permanently installed in the atheromatous region, have been developed. Research 
suggests that patients are less likely to experience restenosis under stenotic treatment, 
however, patients are required to take anticoagulants on a regular basis to prevent 
thrombosis. It has been established that even a small thrombosis located on the 
endothelium has the ability to act as a scaffold for smooth muscle cell migration and 
consequential restenosis. This migration is stimulated by the release of various factors 
from activated platelets (Lowe et al., 2001).  Furthermore, as can be seen in Figure 3, 
stent treatment still results in endothelium denudation where the stent is forced against 
the surface of the vessel, rendering intimal hyperplasia a possibility (Harnek et al., 1999). 
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Figure 3. Scanning electron microscope image of stent-injured endothelium. Adapted from 
(Harnek et al, 1999). 
 
In response to the aforementioned complications, drug eluting stents have been 
developed. Such stents release drugs to help restrict intimal hyperplasia. Typical drugs 
include paclitaxel (Kivela and Hartikainen, 2006) and sirolimus (Qian et al., 2009). More 
recently, a study assessed a dual drug eluting stent that eluted drugs to combat 
thrombosis as well as smooth muscle cell proliferation (Venkatraman et al., 2010). The 
cobalt-chromium stents were coated in a biodegradable polymer (PLGA) which would 
serve as a controlled release carrier. The polymer was preloaded with Sirolimus and 
Triflusal to control cell proliferation and thrombosis respectively. In-vivo results 
indicated a substantial decrease in platelet aggregation and smooth muscle proliferation. 
However, a long term in-vivo study has not been performed. This would help determine 
the viability of this concept as a long term treatment.  
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In patients with severe atherosclerosis, where the plaque has grown to an extent where 
occlusion of a blood vessel occurs, balloon angioplasty is often required. This is where a 
balloon is percutaneously inserted near the site of the disease and subsequently inflated 
and deflated until the plaque is sufficiently removed (Harnek et al., 1999). A common 
problem with this technique, as described earlier, is the occurrence of restenosis. This is 
where vascular endothelial injury post angioplasty exposes the thrombogenic 
subendothelium (basement membrane) results in platelet adhesion and results in the 
release of various growth factors that promote vascular smooth muscle cell migration and 
proliferation (Farb et al., 1999) . This ultimately results in excessive extracellular matrix 
production, known as neointimal hyperplasia.  More recent developments using stent 
technology has reduced the prevalence of restenosis, however, it still occurs in 
approximately 15-20% of procedures within 6 months of the operation (Horlitz et al., 
2002). By targeting the exposed membrane with microcapsules encapsulated with the 
aforementioned drugs, restenosis may be preventable. To determine the suitability of 
microcapsules for the treatment of this disease as well as other applications that require 
controlled and targeted drug delivery, polyelectrolyte microcapsules are henceforth 
discussed. 
 
1.3 Microencapsulation 
Encapsulation and release of drugs is an essential field of study in biomedical research. 
More specifically, research has suggested that encapsulation of pharmaceutical drugs 
using microcapsules, with a diameter of approximately 4μm, is a promising new mode of 
drug delivery. The fabrication of such capsules is usually achieved by applying the so-
called layer-by-layer (LbL) technique. This method is based on the sequential deposition 
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of oppositely charged polyelectrolytes onto a colloidal core. Such cores are usually made 
from materials such as calcium carbonate, cross-linked melamine formaldehyde, 
polystyrene, magnesium carbonate and silicon dioxide (De Temmerman et al., 2011).  
 
1.3.1 Synthesis 
The layer-by-layer technique was first established in 1991 (Peyratout and Dähne, 2004). 
The technique was initially applied to planar substrates e.g. silica glass slides. By 
sequentially adsorbing cationic and anionic polymers onto the surface, thin polymer films 
are formed, with each individual layer being held by electrostatic attraction. This method 
of synthesising polymer films has proven to be popular in the field of materials science 
due to the ability to form bespoke films which can be functionalised with various 
functional groups. It is also a relatively inexpensive way of forming polymer films. 
Briefly, the substrate is submerged in a polyelectrolyte solution to allow the 
polyelectrolyte to electrostatically adsorb to the surface until the surface is saturated. 
After washing off excess polyelectrolyte that has not been adsorbed, the substrate is 
submerged into a counterpolyion solution, where the oppositely charged polyelectrolytes 
adsorb and saturate the surface. This self-assembly process is repeated until the desired 
film thickness has been reached. Each polyelectrolyte layer is approximately 2 nm in 
thickness (Mermut et al., 2003). However, this can be altered by changing the ionic 
strength/pH of the polyelectrolyte solutions. In deionised water, the charges along the 
polymer chain repel one another allowing the polymer chains to adopt a more linear 
conformation. When ions are present in the solution, these repulsion forces are shielded, 
hence the chains adopt a more globular conformation leading to the development of a 
thicker polymer layer (Ragnetti and Oberthür, 1986). 
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This layer-by-layer technique can be applied to micro-sized colloidal cores which serve 
as microscopic spherical templates. A crucial characteristic of cores used in this process 
is the ability to be dissolved. After layer-by-layer polymer adsorption and subsequent 
dissolution of the cores, hollow microcapsules are formed. The most commonly used 
template is calcium carbonate. This is easily synthesised by a co-precipitation technique 
whereby sodium carbonate is mixed with calcium chloride in a 1:1 molar ratio. After 30 
seconds of vigorous stirring, colloidal cores are formed with a diameter ranging between 
3 and 6 µm. It is important to realise that this step is crucial in producing a non-
aggregated and monodisperse suspension of microcapsules. Calcium carbonate naturally 
forms into three distinct crystalline forms, the most common being calcite, as shown in 
Figure 4B. The other 2 crystal species are aragonite and vaterite (Figure 4A), the latter of 
which is the most ideal template for polyelectrolyte microcapsules. 
 
Figure 4 - SEM micrographs showing the vaterite (A) and calcite (B) crystals of calcium 
carbonate (Adapted from Tong et al., 2004) 
 
 This form is favourable since the cores are porous, thus facilitating the entrapment of 
molecules to be encapsulated in the so-called pre-loading technique. Furthermore, 
vaterite usually exists as spherical cores, which are ideal templates for microcapsules. 
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Thirdly, unlike calcite, large aggregates are not present, allowing individual 
microcapsules to be formed during the layer-by-layer process. A major disadvantage of 
using calcium chloride as a template is that the co-precipitation method usually results in 
a slightly aggregated sample that is not entirely monodisperse. Alternatively, where 
monodispersity is required, silica particles may be used. However, these cores are not 
porous and hence cannot be preloaded with molecules. When forming calcium carbonate 
from sodium carbonate and calcium chloride, the size and the crystal structure is 
influenced by many aspects of the methodology used including: time left to crystallise, 
temperature and the speed of stirring. More research must be conducted to fully 
understand how these aspects influence the core formation. In light of this, a study has 
shown that by forming calcium carbonate cores in the presence of aspartic acid, one can 
control the crystal structure and prevent the formation of calcite (Tong et al., 2004).  
 
1.3.2 Morphology 
The morphology of polyelectrolyte microcapsules can be visualised through SEM 
techniques. Typically, microcapsules formed on calcium carbonate or melamine 
formaldehyde colloidal cores exhibit a grainy surface topology. These nano-sized 
structures are believed to be manifested from segregated polyelectrolyte complexes and 
have been reported to be as large as 124 +/- 10 nm. In general, biodegradable 
microcapsules exhibit a rougher surface topology than non-biodegradable microcapsules, 
as depicted in Figure 5 (Gao et al., 2000). 
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Figure 5. SEM images of non-biodegradable PAH/PSS microcapsules (A) and 
biodegradable protamine/dextran sulphate microcapsules (B). Adapted from (Köhler et al., 
2004, Palamà et al., 2010). 
 
 
The schematic shown in Figure 6 demonstrates the manufacturing process for 
polyelectrolyte microcapsules. The macromolecule is co-precipitated with calcium 
carbonate resulting in colloidal cores with embedded macromolecules (A). Then the LbL 
process proceeds with a cationic polymer layer (highlighted in red) electrostatically 
absorbed onto the calcium carbonate core followed by an anionic polymer layer 
(highlighted in blue) (B). When using calcium carbonate as the core, either polyanion or 
polycation can be adsorbed first since the core has regions of positive and negative 
charge. It is recommended to perform a zeta potential measurement to determine the net 
charge and hence initiate the process with an oppositely charged polymer. When the 
desired number of layers has been reached, the calcium carbonate core is dissolved using 
EDTA (C). The Ca
2+
 and CO3
2-
 ions are able to pass through the porous capsule 
membrane, resulting in a microcapsule with encapsulated macromolecules. 
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Figure 6. Schematic drawing of the fabrication of microcapsules using the LbL technique. 
Adapted from (De Geest et al., 2009b). Calcium chloride and Sodium carbonate are mixed 
with a protein solution (1). After co-precipitation (A), colloidal cores are formed with 
impregnated protein (2). Polyelectrolytes of alternating charge are then sequentially 
deposited on the cores (B) resulting in an encapsulated core (3). Cores are finally dissolved 
using EDTA (C) resulting in a microcapsule with encapsulated protein (4). 
 
In between the polyelectrolyte deposition steps, the microcapsules must be separated 
from the solution to allow for washing of the sample. This is usually carried out by 
centrifugation, typically at 1500 rpm for polyelectrolyte-coated cores, and 5000 rpm for 
hollow microcapsules. This action often results in loss of particles, particularly if they are 
small. The high force of centrifugation can lead to damage of the microcapsules, 
ultimately resulting in shell rupture. Instead of subjecting the microcapsules to 
centrifugal force, the washing steps may be entirely eliminated by adding the exact 
amount of polymer required to coat the particles in the suspension, then adding the 
second polymer in a similar fashion. A major limitation of this method is the inevitable 
production of free polyelectrolyte complexes in the solution as polymers of opposite 
charges electrostatically bind. This is likely to result in unwanted aggregation. This 
problem can be bypassed by filtration using a filter with pores smaller than the 
microcapsules themselves. In addition to providing less stress to the microcapsules, this 
technique can be up-scaled to an industrial production level (Peyratout and Dähne, 2004).  
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1.3.3 Materials for fabrication 
The most popular polyelectrolyte combination for microcapsule fabrication is 
polyallylamine hydrochloride and polystyrene sulfonate. This combination is favoured 
for its high reproducibility and lack of capsule aggregation during and after synthesis (De 
Geest et al., 2007). Although biocompatible, these synthetic polymers are not 
biodegradable. Biodegradable polymers used in microcapsule fabrication include 
polysaccharides such as dextran sulphate and polypeptides such as poly-L-arginine. Such 
microcapsules offer more complex drug release rate profiles that are dependent on 
enzyme concentration of the environment. A study by Sah et al. (1995) showed that a 
sustained release could be achieved over a period of 24 days using biodegradable poly-
D,L-lactide-co-glycolide/ poly-D,L-lactic acid microcapsules. This was reflected in a 
more recent study which highlighted a similar drug release profile study which used 
chitosan/alginate microcapsules (Wang et al., 2007b). The release profile generated from 
this study can be seen in Figure 7. Over a period of 200 hours, the ibuprofen-loaded 
capsules had released most of their contents, with over 50% of the total amount expelled 
within the first 24 hours. This initial burst is a common characteristic of all capsules 
including synthetic non-biodegradable variants. 
 
14 
 
 
Figure 7. IBU (Ibuprofen) release profile of poly(3-hydroxybutyrate-co-3-hydroxyvalerate 
(PHBV) microparticles coated with various polymer coatings including: chitosan (CHI) 
sodium alginate (ALG), poly(diallyldimethylammonium chloride) (PD) and sodium 
(polystyrene sulfonate) (PSS). Adapted from (Wang et al., 2007b).  
 
A problem with enzyme-sensitive microcapsules is that enzymes are ubiquitous in-vivo 
and prolonged exposure to these enzymes may result in unwanted liberation of the 
encapsulated drug, hence unwanted side effects are likely to be experienced. To 
overcome this, the microcapsules may be adapted to specifically adhere to regions of the 
disease. This may be achieved by functionalising the capsule membrane with specific 
ligands (Toublan et al., 2006). Chemotherapy is a well-established technique for the 
treatment of cancer, however, due to a lack of specific targeting, many side effects are 
experienced. Toublan et al (2006) exploit the fact that integrin receptors are more heavily 
expressed on tumours and hence decided to functionalise microcapsules with integrin-
receptor specific peptide ligands. Ligands consisted of short polylysine units with an 
RGB (arginine-glycine-aspartic acid) motif incorporated into different regions of the 
polylysine chain. The RGB motif has a strong affinity to integrin-receptors. These 
ligands were conjugated to the membrane of the microcapsules via electrostatic attraction 
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between the cationic polylysine chain and the anionic bovine serum albumin outer 
surface of the microcapsules. The adhesive microcapsules were preloaded with Nile red 
dye and incubated with colon tumour cells. After washing, it was noticed that the 
microcapsules were successfully retained on the surface of the cells.  
 
1.3.4 Permeability of microcapsules 
The microcapsules fabricated using the LbL technique are moderately porous. As a result 
it is recommended that the size of the molecule to be encapsulated should be greater than 
5kDa in order for successful retention. Smaller molecules will simply transverse the 
porous capsule membrane (Sukhorukov et al., 1999). The ionic strength of the dispersant 
increases the permeability of the polyelectrolyte shells due to competition with salt ions. 
As salt ions neutralise the charges of the polyelectrolytes, the electrostatic attraction 
between adjacent layers diminishes resulting in instability within the shell. Furthermore, 
by varying the pH of the dispersant, the permeability/stability of polyelectrolyte 
microcapsules can be altered. For example, in acidic conditions, the H
+
 ions decreases the 
charge per unit length on polyanions, thus leading to repulsion between cationic layers 
within the layer-by-layer structure, ultimately resulting in shell disintegration (Haynie et 
al., 2005). The general mechanism responsible for the change in porosity associated with 
weakly charged biodegradable microcapsules is based on the premise that the charge of a 
polymer/protein is dependent on the pH of the solution they are dissolved in. It is 
therefore dependent on the isoelectric point of the polymer. The isoelectric point (pI) can 
be described as the pH at which the electrostatic charge of the polyelectrolyte is zero. At 
a pH above this isoelectric point, the polymer will carry a net negative charge and at a pH 
below this isoelectric point, the polymer will carry a net positive charge. As changes in 
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the pH strengthen/weaken the electrostatic charges of the polyelectrolytes, the shell loses 
integrity and the porosity subsequently alters (Zhao and Li, 2008).  
 
This characteristic of polyelectrolyte microcapsules aids in the post-loading mechanism 
of encapsulating molecules. One can alter the ionic strength or pH of the solution to 
increase the porosity of the polyelectrolyte shell, thus allowing molecules to enter the 
interior of the capsules. Once loaded, the ionic strength or pH may be reversed to reduce 
the porosity of the shell and hence lock in the contents. This is rarely performed however, 
since preloading typically yields higher encapsulation efficiencies (Vergaro et al., 2011).  
 
1.4 State-of-the-art polyelectrolyte microcapsules 
Current literature highlights various types of microcapsules that utilise different 
technologies in order to react to different external stimuli. These numerous techniques 
prove the versatility of microcapsules as a means of drug delivery that is capable of 
releasing their payload with precise control. The state-of-the-art polyelectrolyte 
microcapsules are extensively reviewed henceforth.   
 
1.4.1 Triggered release of encapsulated contents from polyelectrolyte microcapsules 
Infrared radiation is well established as a sufficient method of triggering the release of 
encapsulated drug. One can exploit its ability to penetrate through soft tissues, hence 
microcapsules in-vivo can be externally triggered with high efficiency. Sensitivity to 
infrared radiation can be achieved by incorporating gold nanoparticles in the shell. Gold 
nanoparticles can be easily trapped between the layers of the layer-by-layer-constructed 
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shell. As the infrared is pulsed onto the capsules (short pulses of less than 10 ns), these 
gold nanoparticles absorb the energy and transform it into heat, which damages the shell 
of the capsules (Angelatos et al., 2005, Radt et al., 2004, Skirtach et al., 2005). 
Depending on the extent of the damage, the capsule porosity will increase or the capsule 
shell may rupture, thus releasing the encapsulated contents. However, when release is 
desired in a deeper region in vivo, the infrared may be adsorbed before it reaches the 
microcapsules, hence the release cannot be triggered. A recent study has shown that a 
similar kind of release mechanism can be obtained without the use of infrared (Carregal-
Romero et al., 2015). The authors successfully show that local heating and subsequent 
rupture of the microcapsule shells can be achieved through magnetism, more specifically, 
application of an alternating magnetic field. The absorption of this field by soft tissue is 
negligible, thus circumventing the problems associated with infrared. Briefly, iron oxide 
nanoparticles of diameter of 18 nm were integrated within the layer-by-layer structure of 
the microcapsules. Upon application of an alternating magnetic field, the microcapsules 
were seen to heat up and rupture, ultimately releasing the encapsulated cascade blue-
dextran within.  
 
1.4.2 Encapsulation of low molecular weight molecules 
Ordinarily, microcapsules are unable to retain drugs/molecules with sub-kilodalton 
molecular weights, due to their relatively large shell pore size of approximately 10 nm 
(Song et al., 2009b). Molecules with a lower molecular weight will diffuse through most 
microcapsules. Recent studies have addressed this problem in order to retain therapeutic 
drugs, which typically have a molecular weight of less than 1 kDa. Conversely, a more 
recent study has successfully demonstrated that low molecular molecules (<1kDa) can be 
well retained within microcapsules made from conventional polystyrene sulfonate and 
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polyethylene imine (Manju and Sreenivasan, 2011). In this study, curcumin (MW 
368.38) was effectively encapsulated and well retained with a curcumin release of just 
2.77% of the total release, within one week. This is an extremely slow initial release of 
capsular content, considering the low molecular weight of the substance. The authors 
suggest that this slow release may have arisen due to build-up of curcumin on the inner 
surface of the membrane leading to pore occlusion. A slow rate of release may have also 
arisen as a result of the large number of polyelectrolyte layers used to construct the 
microcapsules. The authors used 12 layers in total, which is larger than typical 
polyelectrolyte microcapsules which are generally made from between 4 and 8 layers. 
The outcome of this study was confirmed by a small total release in comparison to the 
initial encapsulated amount. This may be disadvantageous since the total release of the 
drug may be inadequate in producing a significant therapeutic effect. 
 
 A more recent study by Yi and Sukhorukov (2013) showed that upon ultraviolet (UV) 
irradiation of microcapsules fabricated from diazonium and sulfonate groups, the 
electrostatic interactions between the layers were replaced by covalent bonds. This led to 
the generation of a hydrophobic shell and consequently a stable microcapsule capable of 
retaining Rhodamine B, a low molecular weight dye with a molar mass of 479 g mol
-1
 
(Yi and Sukhorukov, 2013). UV irradiation has also been utilised for triggered release of 
encapsulated contents in polyelectrolyte microcapsules. These so-called photo-cleavable 
microcapsules have the ability to rupture on exposure to UV irradiation. Triggered 
release by light can be achieved by incorporating light absorbing nanoparticles e.g. gold 
or silver nanoparticles within the microcapsule shell. By utilising chemical groups such 
as azobenzenes, which change shape upon irradiation, UV irradiation can consequently 
lead to rupture of the capsule shell.  A more recent study has demonstrated that 
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microcapsules synthesised from polyurea, can also produce a similar response upon UV 
irradiation (Dispinar et al., 2013).   
 
Further research has demonstrated that cross-linking between the layers in a layer-by-
layer fabricated microcapsule can be achieved without the use of UV irradiation. The 
research group exploited the reaction between azlactone groups and amine groups in 
order to crosslink polymers with both constituents. Upon dissolution of the calcium 
carbonate core, the fabricated microcapsules were able to retain FITC-dextran. More 
significantly, the FITC-dextran was retained despite the capsules being subjected to harsh 
pH values and ionic strengths. Remarkably, the microcapsules were able to withstand 
both basic and acidic environments (5M sodium hydroxide and 5M hydrochloric acid) 
for at least 22 hours (Saurer et al., 2011).  
 
Research has shown that microcapsules synthesised from polypeptides can also been 
cross-linked via disulphide bridges. Interestingly, the inspiration for this method was 
taken from the well-known stabilisation of hormones e.g. insulin, by disulphide bridges 
(Haynie et al., 2005). This biomimetic solution is achieved by incorporating the sulphur-
rich peptide, cysteine within the polyelectrolyte layers. 12 bilayers were formed using 
peptides containing glutamic acid, tyrosine, lysine, valine and glycine, in addition to the 
aforementioned cysteine. Disulphide bond formation was achieved by immersing the 
capsules in diemethyl sulfoxide (DMSO), an oxidising agent. For control purposes, a 
sample was left to incubate without the addition of DMSO. Experiments were carried out 
in acidic conditions (pH 1.6) i.e. in an environment which favours microcapsules 
disintegration, as explained earlier. After 30 days, the majority of the capsules in the 
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control sample were degraded, leaving only 10% of the original quantity intact. 
Remarkably, this figure was increased by three-fold once the disulphide bonds were 
formed, effectively proving that by cross-linking layers with disulphide bonds, a greater 
level of stability is achieved. These studies conclusively demonstrate that the drawback 
of instability of microcapsules due to changes in pH and ionic strength can be 
circumvented. 
 
1.4.3 Cellular uptake of polyelectrolyte microcapsules 
Due to their microscopic dimensions, microcapsules also possess the ability to be 
internalised by cells via phagocytosis. Research has demonstrated that capsule uptake by 
cells is dependent on the surface properties of the microcapsules. Internalisation is 
favoured by microcapsules terminated with a positively charged polyelectrolyte, in order 
to allow for electrostatic interactions between the microcapsule and the negatively 
charged cellular surface. Atomic force microscopy (AFM) analysis of PAH-terminated 
microcapsules on human epithelial cells revealed that only 44% of the cells had not 
ingested microcapsules after 1 hour of incubation. In contrast, for the anionic PSS-
terminated microcapsules, 82% of the cells failed to ingest microcapsules. Phagocytic 
cells e.g. cancer and immune cells are able to uptake microcapsules more readily, as 
demonstrated by a study that revealed that breast cancer cells can uptake approximately 
30 PAH/PSS microcapsules with a diameter of 5 μm (Sukhorukov et al., 2005).  Recent 
research has shown that microcapsules can be internalised by non-phagocytic cells such 
as Human Umbilical Vein Endothelial cells (HUVECs). This has been achieved by 
encapsulating neuraminidase within polystyrene sulfonate/polyallylamine hydrochloride 
microcapsules and allowing the neuraminidase to passively diffuse and subsequently 
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cleave the glycocalyx. Once cleaved, the microcapsules are free to enter the HUVECs 
(Liu et al., 2014). 
 
1.4.4 Biodegradable polyelectrolyte microcapsules 
As previously explained, biodegradable microcapsules can be synthesised simply by 
incorporating biodegradable polyelectrolytes within the layer-by-layer assembly. The 
disintegration of these microcapsules are regulated entirely by enzymatic degredation of 
the polymers. Further research has led to the development of microcapsules that can be 
degraded without enzymatic intervention. So-called charge shifting polymers are able to 
achieve this feat, by alternating their charge and consequently leading to repulsion and 
ultimate destruction of the layer-by-layer constructed shell. An example of such polymer 
is Poly(HPMA-DMAE), which consists of amine groups bound to the polymer backbone 
by carbonate ester bonds. When in the presence of a physiological buffer at 37 °C, the 
ester bonds are hydrolysed causing the cationic amine groups to dissociate, thus creating 
a neutral polymer (De Geest et al., 2006). 
 
1.4.5 Polyelectrolyte microcapsules in bio-sensing   
As described earlier, the properties of the polymer shells which make up microcapsules 
are heavily influenced by the external environment.  To this end, microcapsules can be 
employed as biosensors for various applications. Polyelectrolytes constructed of weak 
polyelectrolytes will ultimately suffer swelling and decomposition as the pH of the 
surrounding solution passes the pKa of at least one of the polyelectrolytes used, due to 
the decrease in electrostatic attraction between the polymers in the capsule shells (Sato et 
al., 2011). Such capsules may be loaded with a fluorescent dye which would be released 
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as a consequence of the destruction of the microcapsule shell. Although, responsive to 
pH, these microcapsules maintain their structure to a certain degree and may not respond 
when the environment changes from basic to acidic or vice versa. This limitation has 
been circumvented by a study that encapsulated seminaphtharhodafluor (SNARF) in 
polyelectrolyte microcapsules. SNARF is a pH-sensitive fluorescent molecule which 
emits red and green fluorescence when in the presence of basic and acidic environments, 
respectively. This proved particularly useful when determining whether microcapsules 
had been internalised by cells which are slightly acidic due to the endosomal 
environment (Kreft et al., 2007). 
 
1.4.6 Polyelectrolyte microcapsules in cancer therapy 
A number of investigations have been conducted to test the potential of microcapsules as 
a drug delivery mechanism in cancer therapy. To discuss the potential, it is vital to 
understand the interaction between polyelectrolyte microcapsules and cancer cells. As 
demonstrated by Sukhorukov et al, breast cancer cells readily uptake polyelectrolyte 
microcapsules via phagocytosis (Sukhorukov et al., 2007). By conducting in-vitro 
experiments, with the nuclei stained with DAPI, De Geest et al. has shown that the 
microcapsules refrain from penetrating the nucleus itself. In fact, the study proves that 
upon internalisation, the microcapsules are contained within acidic vesicles, as indicated 
by fluorescent lysosomal staining (De Geest et al., 2006). This was confirmed by a study 
which utilised the biosensing capabilities of microcapsules as described earlier. SNARF 
was encapsulated within the microcapsules confirmed that the microcapsules were in an 
acidic endosomal/lysosomal environment (Kreft et al., 2007). With respect to drug 
encapsulation, polyelectrolyte microcapsules are an ideal form of encapsulation, 
particularly when the drug is non-soluble.  
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When drugs are kept in a non-soluble state, layer-by-layer assemblies can be applied to 
the crystals directly. This is particularly advantageous when sensitive drugs must be 
protected from harsh in-vivo environments in order to remain functional. Several drugs 
have been encapsulated using this principle, including ibuprofen and furosemide 
(Vergaro et al., 2011). To kick-start the layer-by-layer process, drug crystals are often 
treated with surfactants in order to give them a specific charge to allow for electrostatic 
adsorption of the first polyelectrolyte (Caruso et al., 2000). An advantage of this direct 
coating method is that the encapsulation efficiency is likely to be higher since drug 
elution from the core, a problem associated with the pre-loading method, is entirely 
circumvented.  
 
To assist with the release of the drug, once the capsules have been internalised, the 
capsules are usually manufactured from enzyme-cleavable polyelectrolytes e.g. poly-L-
arginine and dextran sulfate. These layers can easily be degraded by intracellular 
proteases, resulting in the release of the drug (De Geest et al., 2006). Crucially, 
experiments have revealed that the phagosomal membrane which encapsulates the 
microcapsule ruptures upon capsule disintegration, thus releasing the drug into the 
cytoplasm of the cancer cell (Skirtach et al., 2008).  
 
In order to be a viable method of drug delivery, microcapsules must be tested in an in-
vivo environment to ensure that unwanted side effects associated with interactions with 
biological tissue are not experienced. The tissue response was tested by De Koker et al. 
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(2007). Commonly used poly-L-arginine and dextran sulphate microcapsules were 
subcutaneously injected into a mouse. An inflammatory response was detected by an 
increase in the level of macrophages and fibroblasts at the site of injection. A pronounced 
reaction was recorded 18 days after the injection with a significantly high occurrence of 
new vascularisation Interestingly, there was no mention of the capsules being sterilised 
prior to use, however, the reaction is assumed to be a direct result of the microcapsules 
which are detected as foreign bodies by the immune system (De Koker et al., 2007). This 
immune response, albeit moderate, may be reduced by functionalising the surface of the 
microcapsules with polyethylene glycol (PEG). Researchers speculate that this so-called 
PEGylation could have a profound desensitising effect on the immune response, 
however, this is yet to be elucidated (Vergaro et al., 2011).  
 
This thesis herein presents research that has been conducted in order to further the 
development of targeted drug delivery using microcapsules, an area that has been given 
little attention with respect to layer-by-layer fabricated polyelectrolyte microcapsules. 
Specifically, chapters 2 and 3 focus on controlled release of molecules from 
biodegradable microcapsules in order to demonstrate the ability to fine-tune the release 
kinetics of the encapsulated contents. Chapters 4, 5 and 6 focus on methods of 
functionalising polyelectrolyte microcapsules in order to achieve exclusive binding to 
protein substrates. The final chapter explores the use of functionalised microcapsules in 
an ex-vivo setting in order to determine their viability as a potential drug carrier.  
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2. Controlled release of protein from 
biodegradable polyelectrolyte microcapsules 
 
2.1 Introduction 
A major factor, which is often critical in drug delivery systems is the ability to control the 
release of the drug. As explained in the previous chapter, restenosis of arteries after 
surgical intervention is one such complication that requires a sustained release of 
therapeutic drug to control the disease. Polyelectrolyte microcapsules are porous, and 
therefore offer a degree of control over the release of the encapsulated drug. This can be 
further enhanced by incorporating biodegradable polyelectrolytes into the layer-by-layer 
structure, as explained in the previous section.  
 
Following preliminary tests, it was determined that Poly-L-arginine and Poly-L-glutamic 
acid were ideal materials to fabricate biodegradable microcapsules. Both polypeptides are 
cleavable by proteases within the body and therefore should biodegrade in-vivo and 
release its contents accordingly. The aim of this chapter is to develop a system by which 
one can easily measure the effects of enzyme concentration on the release of 
encapsulated contents. It is assumed that a higher concentration will lead to more 
degradation of the capsule shell and subsequently, more release of the encapsulated 
material, thus highlighting the sensitivity of these potential drug carriers. 
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2.2 Materials 
Bovine serum albumin (cat. no. A2153), poly-L-arginine hydrochloride (15-70 kDa) (cat. 
no. P7762), poly-L-glutamic acid (kDa) (cat. no. P4761), protease from streptomyces 
grisius (cat. no. P5147), Rhodamine B isothiocyanate (cat. no. R1755), boric acid (cat. 
no. 202878) were purchased from Sigma Aldrich Co. 
 
2.3 Method 
Bovine serum albumin (BSA) was selected as the protein to be encapsulated in order to 
test the release kinetics of the biodegradable polyelectrolyte microcapsules. This serum 
protein was chosen as it is an inexpensive protein which can be easily labelled 
fluorescently by using isothiocyanate derivatives of fluorescent dyes. To label the 
protein, BSA was dissolved in a borate buffer, made from 0.1M boric acid and 0.15M 
sodium chloride. 1mg Rhodamine-B isothiocyanate was dissolved in 5ml ethanol and 
added to the protein solution. After 24 hours of incubation at room temperature, under 
gentle stirring, the solution was dialysed using cellulose dialysis tubes to remove any 
unconjugated Rhodamine-B. The external water was replenished daily until diffusion of 
Rhodamine ceased.  
 
2.3.1 Microcapsule preparation 
The capsules were fabricated via the well-established layer-by-layer technique. Briefly, 
calcium carbonate cores embedded with Rhodamine-labelled BSA were co-precipitated 
by adding 24ml Rhodamine-BSA (1.8mg/ml) to 24ml 0.33M CaCl2 and finally adding 
24ml 0.33M Na2CO3. The mixture was stirred vigorously for 30 seconds and the 
resulting CaCO3 was left for 5 minutes to allow the formation of a monodisperse 
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population of spherical cores with diameters ranging between 4 and 6μm. The cores were 
washed by centrifugation at 1500 rpm for 1 minute, followed by aspiration of supernatant 
and subsequent re-dispersion in deionised water. After 3 of these wash/centrifuge cycles, 
the CaCO3 cores were coated by immersing the cores in 10ml of 1mg/ml Poly-arginine. 
To allow the sedimentation process to occur, and to ensure complete coverage of cores, 
the solution was placed on a vortex machine for 20 minutes. This was followed by 3 
wash/centrifuge cycles to remove the excess polymer that had not been adsorbed. The 
same procedure was applied for the next layer (Poly-glutamic acid), resulting in the 
formation of a single bilayer. The process was continued until four bilayers were made. 
To dissolve the calcium carbonate cores and hence complete the fabrication process, 
ethylenediaminetetraacetic acid (EDTA) was used. 5ml of 0.2M EDTA was added to the 
capsules for 7 minutes and an additional 5ml for a further 7 minutes. This was followed 
by 3 wash/centrifuge cycles using EDTA and 3 wash cycles using deionised water.  
 
2.3.2 Encapsulation efficiency 
The supernatants of each wash cycle performed throughout the fabrication process were 
collected to determine the encapsulation efficiency of the capsules which is governed by 
the following equation: 
(
        
  
)      
where Mi is the initial mass of BSA added, Ml is the mass of BSA present in the 
supernatants during layer-by-layer deposition (including the supernatant collected after 
core formation) and Md is the mass of BSA in the supernatants collected during the core 
dissolution. BSA was assayed using a fluorescence spectrometer. Emission and 
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excitation slits were set to 1nm and the excitation wavelength and emission detection 
range was set to 540 nm and 580 – 640 nm, respectively, in accordance with the 
excitation and emission wavelengths of Rhodamine B. A calibration curve was generated 
by testing known concentrations of BSA  
 
2.3.3 Fluorometry analysis 
The bulk microcapsule sample was divided into 35 aliquots. Solutions of protease from 
Streptomyces Griseus (Sigma Aldrich, UK) of concentrations 1mg/ml, 100μg/ml, 
10μg/ml, 1μg/ml, 100ng/ml and 10ng/ml were made. Each of the enzyme concentrations 
were placed in 5 eppendorf tubes with microcapsules. The remaining 5 microcapsule 
samples were immersed in water as a control. All samples were stored in the refrigerator 
at 4°C. A sample was taken from each protease concentration groups after 24hrs. After 
centrifugation, the supernatants were analysed using fluorescence spectroscopy (Perkin 
Elmer LS 55) to determine the amount of Rhodamine-BSA released. This process was 
repeated for 5 consecutive days to build a protein release profile. A calibration curve was 
created by analysing 5 samples of known BSA concentration to determine the 
concentration of BSA in each experimental sample. 
 
2.3.4 Scanning electron microscopy analysis 
Scanning electron microscopy (SEM) images were taken using a FEI Inspect-F scanning 
electron microscope. Samples of biodegradable microcapsules were taken after 5 days of 
incubation to determine their morphology after degradation. Control samples, devoid of 
enzyme exposure were analysed to confirm whether the degradation was purely a result 
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of enzymatic action. Samples were gold-sputtered to render the surface electrically 
conductive. SEM images were subsequently acquired using a 10 kV beam.  
 
2.4 Results and Discussion 
The calibration curve generated from Rhodamine-BSA calibration can be seen in Figure 
8. Known concentrations of BSA were made by weighing BSA using a microbalance and 
dissolving it in known volumes of PBS. As expected, an increase in BSA concentration 
led to an increase in fluorescence intensity recorded by the fluorometer. This confirms 
that the BSA had been successfully labelled with Rhodamine.  
 
 
Figure 8. Fluorometry calibration. BSA-Rhodamine was assayed using fluorescence 
spectroscopy. 
 
y = -622979x2 + 51832x + 2.1067 
0
200
400
600
800
1000
1200
0 0.005 0.01 0.015 0.02 0.025 0.03 0.035
Fl
u
o
re
sc
e
n
ce
 in
te
n
si
ty
 (
R
e
la
ti
ve
 
fl
u
o
re
sc
e
n
ce
 u
n
it
s)
 
BSA concentration (mg/ml) 
Fluorimetry calibration 
30 
 
 
Figure 9. Cumulative protein release profiles obtained from biodegradable microcapsules 
under different external enzyme concentrations (highlighted by key). Protein release is 
given as a percentage of the initial mass of encapsulated BSA (n = 3). 
 
The results shown in Figure 9 clearly highlight a more pronounced protein release in 
samples with high concentration of proteinase (1mg/ml, 100mg/ml and 10mg/ml). 
Furthermore, results show that at enzyme concentrations of 100ng/ml and below, there is 
no significant enhancement of protein release since the supernatants of these samples 
contained similar levels of protein to the control sample throughout the 5 days of testing. 
 
Protein release for the 1mg/ml and 100μg/ml samples appeared to decrease on day 2. 
Theoretically, this is impossible since the capsule dispersant can only accumulate more 
protein after another 24hrs, unless the protein re-entered the intra-capsular space, which 
is highly unlikely. These apparent anomalies can be explained by the fact that the day 2 
samples of these concentrations had less microcapsules to begin with, hence even after an 
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additional 24hrs, the samples appeared to release less than what they released on the first 
day. Indeed it was assumed that by shaking the bulk sample, the microcapsules were 
uniformly dispersed in solution and therefore by separating the solution into aliquots of 
equal volume, each sample would contain the same amount of capsules. In reality it is 
impossible to obtain a perfectly uniform capsule dispersion due to gravitational effects as 
well as aggregation of microcapsules. To avoid this in the future, samples should be 
weighed to ensure that capsule concentration is approximately the same.  
 
Another characteristic of this protein release profile that does not bode well with typical 
findings published in the literature is the significant difference in the end point protein 
release values. This suggests that the protein is still being liberated at day 5. It can also be 
an indication that the pores of the capsules were occluded due to the accumulation of 
BSA on the inner surface of the capsules. With regard to the 1mg/ml sample, it is clear 
that the protein concentration is still rising to a degree, although the low gradient of the 
line between days 4 and 5 suggest that these capsules have almost reached the point 
where protein release ceases.  
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Scanning Electron Microscope Results 
 
Figure 10. SEM image of BSA-loaded microcapsules without exposure to proteinase. T = 5 
days. 
 
 
Figure 11. SEM image of remnants of BSA-loaded microcapsules after 5 days exposure to a 
1mg/ml solution of proteinase 
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It is clear from the micrographs that higher concentration enzyme solutions led to the 
degradation and rupture of capsules. There was significantly less capsules in the 1mg/ml 
sample in comparison to the 100μg/ml sample, after 5 days. Incidentally, this decrease 
was noticed with an increase in material on the surface of the slide. This material is 
undoubtedly the residual polymer from the capsules that have been completely degraded, 
as shown in Figure 11. 
 
 
Figure 12. SEM image of BSA-loaded microcapsules after 5 days exposure to a 100ng/ml 
proteinase solution. 
 
Analysis of the acquired micrographs reveal that more than 50% of the microcapsules 
resemble tori and have apparent holes in them. This phenomenon is consistent with all 
samples, even in the control sample where no enzyme is present. It may be that these are 
not holes and in fact these are deep folds of the capsule membrane leading to a concave 
structure. If they are holes, it is unlikely that these holes manifested due to enzymatic 
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action since these holes are even noticed in the control sample. Furthermore, the surface 
topology is more regular than surfaces noticed on microcapsules that have been 
convincingly degraded by high enzyme concentrations. Also if these holes were a result 
of peptide hydrolysis, higher concentrations of BSA would have been detected in the low 
enzyme concentration samples. However, no such burst release was shown suggesting 
that this burst release occurred during the manufacturing process, before enzymes were 
introduced to the capsule. 
 
Another possible explanation could be insufficient coating of the calcium carbonate cores 
during synthesis due to an insufficient polymer. To prevent the occurrence of this, a 
sample of calcium carbonate cores were counted using a haemocytometer, and the total 
surface area of the cores was calculated. According to G. Sukhorukov, 1mg of polymer 
has the ability to cover a surface of approximately 1m
2
,  thus the calculated total surface 
volume of 0.35m
2
 should adequately be covered by the 10mg of polymer used in each 
layer. Taking this in consideration, it can be concluded that these are not holes and are in 
fact folds in the capsule membrane. 
35 
 
 
Figure 13. A single microcapsule from the control sample i.e. not exposed to proteinase 
(Diameter 5.1μm). 
 
 
Figure 14. A single microcapsule from the control sample i.e. not exposed to proteinase, 
showing an apparent hole (Diameter 10.4μm). 
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From Figure 13 and Figure 14 it is clear that the capsules are polydisperse with 
microcapsule diameters ranging from 5-10μm. This resulted due to the formation of 
polydisperse calcium carbonate cores. It is unclear why this occurred. In future 
experiments, the cores shall be left to crystallise for a shorter time period to prevent the 
formation of excessively large cores. 
 
Encapsulation Efficiency 
Taking into consideration the number of layers and associated washing cycles applied, an 
encapsulation efficiency of 79.7% highlights the excellent retention properties of the 
fabricated capsules. It was noted that after each poly-L-glutamic acid layer, a high 
concentration of Rhodamine-BSA was found in the supernatant after deposition. No such 
burst-release was noticed in the supernatants collected from poly-L-arginine deposition. 
To maintain enzyme stability and to prevent the occurrence of microbial infection, the 
protein release study was conducted at 4°C. However, this temperature is not 
representative of the environment in-vivo. Indeed, at this temperature the protease 
activity is likely to be low. It will be challenging to maintain enzyme stability at body 
temperature for 5 days. With the aid of metabolic inhibitors such as sodium azide, this 
may be feasible.  
 
2.5 Conclusion 
In conclusion, biodegradable polyelectrolyte microcapsules were successfully fabricated 
using the layer-by-layer technique. As shown in the protein release profile, an elevated 
concentration of enzyme in the supernatant led to a higher rate of release of BSA, 
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unquestionably as a consequence of polyelectrolyte shell degradation. The 
microcapsules, constructed of 4 bilayers, are able to encapsulate high molecular weight 
molecules, as shown by a high encapsulation efficiency of BSA (79.7%). Significantly, 
the largest amount of BSA was lost in the core-dissolution step. Comparatively fractional 
liberation was noticed during layer deposition. This will be taken into consideration when 
approximating encapsulation efficiency for future experiments.  
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3. Self-degradable microcapsules 
 
3.1 Introduction 
The previous chapter has demonstrated that biodegradable microcapsules can be 
synthesised to be responsive to an enzymatic environment. In a situation where enzymes 
are not present, or not in abundance, these microcapsules may not be able to release their 
payload as efficiently as desired. Previous studies have been reported on “self-degradable 
microcapsules”, highlighting possible mechanisms to overcome this. This chapter 
consists of a study conducted with the purpose of fine-tuning the response of “self-
degradable” microcapsules for desired release rates, where the environment is devoid of 
enzymes.  
 
As highlighted in chapter 1, current techniques of controlling the rate of release require 
some form of external stimuli. This may be unfeasible under certain circumstances. For 
example, changing the pH in a biological environment may lead to the denaturation of 
proteins. The previous section relies on external triggers i.e. enzymes within the 
dispersant, to break down the capsule shell and release the contents. This limitation can 
be circumvented by encapsulating enzymes within the microcapsules so they can be 
degraded from the inside. Proteases have been used in the pilot study in the previous 
chapter. In order to utilise them effectively, their structure and function must be fully 
understood. 
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3.1.1 Proteases 
Proteases are a family of enzymes which have the ability to break down proteins i.e. they 
facilitate proteolysis. More specifically, they target the amide bonds within proteins and 
catalyse the hydrolysis reaction, ultimately breaking the protein down into smaller 
peptides/oligopeptides and amino acid residues. In doing so, proteases regulate the vast 
majority of chemical reactions that take place within cells. Proteases, themselves, are 
proteins, synthesised by ribosomes in the traditional manner. They are usually secreted as 
a latent form, known as a zymogen, which effectively has the active site “shielded” by a 
peptide domain, known as the pro-domain (Barrett et al., 2012). This so-called active site 
is the area where cleavage of the protein substrate occurs.  
 
Working principle  
With the pro-domain intact, the active site has no physical access to the cleavable regions 
of the protein i.e. the peptide bonds. In order to be activated, the pro-domain must be 
cleaved by another enzyme. Once this is removed, the protease is in its active form. In a 
similar fashion to all enzymes, proteases have an optimum working temperature. For the 
gold standard protease mixture, pronase, this temperature lies between 30-40 °C. At a 
temperature above 60°C, the proteases, themselves, begin to denature, rendering them 
dysfunctional (Potier et al., 1990).  
 
There are many different types of proteases, each with a different crystallographic 
structure, and different mechanisms for catalysis of peptide bond hydrolysis. The 
differences in structure, particularly at the active site, complement their specific 
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substrates. This is often described as the lock and key theory, as proposed by Hermann 
Emil Fischer in 1890. In essence, this theory states that in order to achieve enzyme-
substrate complexation, and subsequent peptide bond cleavage, there must be a degree of 
complementarity, both electrostatically and geometrically.    
 
Self-degradable microcapsules have been previously synthesised and studied within the 
last decade (Borodina et al., 2007). This particular work effectively proves that the 
presence of proteinase (a mixture of proteases from Streptomyces griseus) increases the 
degradation of the capsule shell and hence increases the rate of release of the 
encapsulated DNA within the microcapsules. These particular microcapsules were 
constructed from two polypeptides, namely, poly(L-arginine) and poly(L-aspartic acid). 
The study concluded that without co-encapsulation with protease, the DNA remained 
trapped within the microcapsules after 40 hrs. In contrast, when protease was 
encapsulated, the entire payload was liberated within 2.5 hours, with 80% liberated 
within 1 hour. The concentration of proteinase encapsulated during the fabrication 
process was 3mg/ml. Taking into consideration the aggressive release kinetics associated 
with these microcapsules, one can conclude that this is an extremely high concentration 
of protease.  
 
If a more sustained and controlled release profile is desired, the concentration of the 
encapsulated enzyme should be reduced drastically. Indeed, prior research has indicated 
that reducing the concentration of encapsulated enzyme alone, the drug release rate can 
be increased from seconds to days (Borodina et al., 2007). A major limitation of this 
method of encapsulation is the restriction of the type of drugs that can be loaded which is 
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limited to species that are not reactive to, or cleavable by the encapsulated enzyme. For 
example, if a protein, with a specific structure and function, suited for a particular 
treatment, is co-encapsulated with protease, the protease is likely to denature the 
therapeutic protein, rendering the treatment useless.  
 
The aim of this chapter is to create self-degradable microcapsules similar to the kind used 
in the study by Borodina et al., (2007) and demonstrate the ability to fine-tune the release 
of encapsulated contents within these microcapsules. This will be achieved by a 
combination of creating microcapsules of different number of polyelectrolyte layers and 
encapsulating different quantities of proteinase. Instead of encapsulating DNA, the 
release of the proteinase itself, will be monitored to show whether the capsule shell is 
permeable to larger molecular weight species. Microcapsules, of different thickness and 
different constituents (biodegradable and non-biodegradable) will be produced, in order 
to demonstrate the ability to control the release of the encapsulated proteinase. This shall 
be monitored using UV-vis spectrophotometry. 
 
3.1.2 UV-vis spectrophotometry: 
Ultraviolet-visible (UV-vis) spectrophotometry is a routinely used spectroscopic 
technique which utilises ultraviolet light within the visible range (380nm to 750nm) and 
the invisible range (190-380nm). UV light of a predetermined wavelength is passed 
through a sample contained within a clear glass or PMMA cuvette, where a certain 
amount of light is absorbed due to the solutes within the sample, e.g. protein or DNA. 
More specifically, the non-bonding electrons within the molecule absorb the light and 
consequently become excited to a higher energy level orbital (Skoog et al., 2013). For 
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this reason it is often referred to as UV absorption spectroscopy. The level of absorbance 
by the sample is proportional to the concentration of the solute, hence this technique can 
provide quantitative data with respect to the concentration of a sample (Skoog et al., 
2000). This study will be monitoring the level of proteinase, a protein. Proteins 
characteristically absorb ultraviolet light at approximately 240-300nm (Grimsley and 
Pace, 2004). More specifically, tryptophan, tyrosine and cysteine residues within the 
protein give rise to absorption at 280 nm. The differences in concentration and ratios of 
these residues create a shift in the peak absorbance of a protein, which is evidently 
unique for each individual protein. For the purposes of this study, the specific optimal 
properties which correspond to the peak of the absorbance graph is not important, since 
there is only one protein i.e. proteinase which is being analysed. The use of UV 
spectroscopy is much preferred than the previously used fluorescence spectroscopy, as 
used in the previous chapter. By using UV spectroscopy, effects such as photobleaching 
of the sample are eradicated. Furthermore, the sample doesn’t require labelling which is 
time consuming and could lead to inaccuracies. 
 
3.2 Materials 
Calcium chloride dihydrate (CaCl2.2H2O), sodium carbonate (Na2CO3), 
ethylenediaminetetraacetic acid disodium salt dihydrate (C10H14N2Na2O8·2H2O), 
dextran sulfate sodium salt (Mol. Wt. ∼40 kDa), poly-L-arginine hydrochloride (mol wt 
15−70 kDa), Poly(allylamine hydrochloride) (mol wt 65 kDa), Poly(sodium 4-
styrenesulfonate) (mol wt 70 kDa), Protease from Streptomyces griseus, were purchased 
from Sigma Aldrich Co. 
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3.3 Method 
3.3.1 UV spectroscopy protocol 
A Perkin Elmer Lambda 35 UV-vis spectrophotometer was used to analyse the samples. 
The slit width and data acquisition intervals were kept constant throughout (at 1 unit). 
Absorption detection range was set to 190-300 nm in accordance with the absorption 
wavelength of protein. A calibration curve was generated by measuring absorbance 
values for 14 samples with known concentrations ranging from 1 μg/ml to 1 mg/ml.  
 
3.3.2 Microcapsule fabrication 
Microcapsules were fabricated in a similar fashion to those made in chapter 2. The 
polycationic and polyanionic constituents of the layer-by-layer assembly were poly (L-
arginine) and dextran sulphate, respectively. Dextran sulphate, a member of the 
polysaccharide family was chosen to monitor the effects of release, in the case where 
only one of the layer-by-layer constituents is cleavable by the encapsulated enzyme. For 
control purposes, synthetic microcapsules, comprised entirely by non-biodegradable 
polyelectrolytes, were produced. The polycation, and polyanion for these microcapsules 
were PAH and PSS, respectively. Microcapsules synthesised for this study were loaded 
via a preloading technique, previously described in section 2.2. 6 and 12 layer 
microcapsules were synthesised in order to determine the effects of the number of layers 
on the protein release profile. Each supernatant during the fabrication process was 
collected and analysed for proteinase content to determine the encapsulation efficiency.  
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3.3.3 Sample preparation and proteinase concentration analysis. 
Once the cores had been dissolved, the 6 and 12 layer microcapsules were re-suspended 
in water. The concentration of each sample was measured using a haemocytometer, an 
apparatus traditionally used for determining the red blood cell count.  The concentrations 
were equalised by dilution to allow a direct comparison to be made between the 
proteinase release profiles for the 6 and 12 layer biodegradable/non-biodegradable 
microcapsules. At various time points after initial incubation: t= 0.25, 0.5, 0.75, 1, 1.25, 
1.5, 1.75 and 2 hours, the samples were centrifuged at 1500 rpm for 1 minute. In addition 
to these time points, the 12 layer samples were analysed up to t = 24 hours. The 
supernatant was then carefully transferred to a cuvette ensuring that no capsules were 
taken in the process. After UV spectroscopy analysis of the supernatant, the supernatant 
was promptly returned to their respective Eppendorf tubes and the capsules were re-
suspended to allow further release of the encapsulated enzymes. After checking the 
supernatant at different time points over a period of 21 hours, a proteinase release profile 
was generated to demonstrate the release kinetics of the 6 and 12 layer microcapsules. 
The samples were kept at room temperature throughout the study to ensure the 
proteinases remained active.  
 
3.3.4 Encapsulation efficiency 
The encapsulation efficiency for the 12 layer microcapsules was calculated, to determine 
whether there is a significant amount of proteinase within the microcapsules at the end of 
the fabrication process. Previous experience, from the encapsulation efficiency 
calculation performed in chapter 2 suggests, that there are specific steps within the 
manufacturing process, where significant levels of encapsulated contents are lost. The 
supernatants were subsequently analysed by UV spectrophotometry as previously 
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described. The total amount of protein lost during the synthesis of the microcapsules was 
subsequently calculated to determine the encapsulation efficiency.  
 
3.3.5 Epifluorescence imaging of microcapsules 
Fluorescent 6 layer microcapsules were fabricated by replacing the second polyarginine 
layer within the LbL structure with FITC-labelled polylysine. As per usual, these 
microcapsules were preloaded with protease and left to incubate for 1 hour. Images were 
taken in order to visualise the integrity of the polyelectrolyte shells.  Micrographs were 
taken using a Leica DMI4000B epifluorescence microscope, coupled to a Leica 
DFC300FX digital colour camera. The excitation wavelength of the FITC used was 488 
nm, hence the excitation beam was filtered with a blue prism. 
 
3.4 Results  
3.4.1 Haemocytometry 
Haemocytometry analysis of each sample highlighted a significant difference between 
the 4 different samples. These differences are likely to have arisen due to human error, 
particularly during the washing steps of the fabrication process, where capsules may 
accidently be removed during pipette aspiration of the supernatant after centrifugation. 
The recorded microcapsule counts can be seen in Table 1. The suspensions were diluted 
accordingly to equalise the microcapsule concentrations. 
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Table 1. Haemocytometry calculations. 
 Biodegradable 
capsules (millions) 
Non-biodegradable capsules 
(millions) 
6 
layer 
12 layer 6 layer 12 layer 
Capsule concentration (caps/ml) 10.68 29.5 44.4 88.4 
Desired concentration (caps/ml) 10.68 
Volume of sample required (ml) 2 0.72 0.48 0.24 
Volume of DI H2O for dilution (ml) 0 1.28 1.52 1.76 
 
3.4.2 Calibration 
As expected, the UV absorbance peak measured at 280 nm, increased in amplitude as the 
concentration of proteinase increased. This confirms that the UV spectrophotometer is 
responsive to the presence of proteinase within a deionised water solution. Furthermore, 
the apparatus is responsive to concentrations as low as 1 μg/ml, confirming the apparatus 
as a viable means of measuring proteinase release. Once the calibration curve was 
plotted, a trendline for the curve was added, with the equation displayed in Figure 15. 
The intercept for the trendline is set to zero to satisfy the condition of zero absorbance for 
a solution void of proteinase.  
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Figure 15. Calibration graph for proteinase absorbance calculated using UV-vis 
spectroscopy. Error bars indicate standard deviation (n = 3). 
 
3.4.3 Protein release profiles 
  
Figure 16. Protein release profile for 6 layer microcapsules. Protein release is expressed as a 
percentage of total protease encapsulated at t = 0.  Error bars indicate standard deviation 
(n = 5). 
 
 
y = 0.0007x 
0
0.2
0.4
0.6
0.8
1
0 200 400 600 800 1000 1200
A
b
so
rb
an
ce
 
Proteinase concentration (ug/ml) 
Calibration  
48 
 
As depicted in Figure 16, the level of released proteinase generally increases for both 
groups. The decrease in protein release for the non-biodegradable microcapsules is 
undoubtedly an anomalous result, since the accumulated proteinase diffused into the 
supernatant is unlikely to be reduced. At all time points, the biodegradable microcapsules 
released more proteinase than the non-biodegradable microcapsules. The most significant 
increase was noticed at t = 1.25 hours where a 5-fold increase in protein release was 
observed.  
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Figure 17. Protein release profile for 12 layer microcapsules between t=0 and t=2 hours 
(Panel A). Panel B shows a long term release profile. Error bars indicate standard deviation 
(n = 5) 
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Figure 18. Fluorescent micrograph of 6 layer biodegradable microcapsules after 1 hour of 
incubation, highlighting the presence of partially degraded microcapsules (shown by yellow 
arrows). Green fluorescence is achieved by a single PLL-FITC layer was incorporated into 
the layer-by-layer construct. 
 
Results obtained from the 12 layer microcapsules, as shown in Figure 17, indicate that in 
general, less proteinase was released, when compared to the thinner 6 layer microcapsule. 
With reference to the biodegradable microcapsules, despite an extremely long incubation 
time of 24 hours, only 13.1% of the encapsulated protease was liberated. When compared 
to the 6 layer biodegradable microcapsules, it is evident that after just 2 hours, 21% of 
the contents were liberated. Similarly to the proteinase concentrations recorded from the 
6 layer microcapsules, the biodegradable 12 layer microcapsules also show a higher 
degree of liberation than the non-biodegradable 12 layer microcapsules, with a three-fold 
increase in protease liberation recorded at t = 0.5 hours. Furthermore, at t = 2 hours, the 
protease liberation seems to plateau at approximately 13% and 4% for the biodegradable 
and non-biodegradable samples respectively. 
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3.4.4 Encapsulation Efficiency 
The encapsulation efficiency was determined by accumulating the masses of proteinase 
recorded after each significant stage in the manufacturing process, where significant 
levels of proteinase will be liberated, as displayed in Table 2. This was measured by UV-
spectrophotometry. This total value is then subtracted from the original proteinase 
amount incubated during core formation (2000 µg per sample) to determine the amount 
taken up by the microcapsules. It is then displayed as a percentage of the original 
amount, i.e. the encapsulation efficiency, as shown in Table 3. 
 
Table 2. Measured proteinase concentration after each significant step of the LbL process. 
Biodegradable microcapsules Non-biodegradable microcapsules 
Stage Concentration 
(µg/ml)
 
Stage Concentration 
(µg/ml) 
Core formation 94.64 Core formation 94.64 
Core wash 1 87.26 Core wash 1 87.26 
Core wash 2 38.72 Core wash 2 38.72 
Core wash 3 96.55 Core wash 3 96.55 
Core dissolution 71.88 Core dissolution 9.56 
EDTA wash 1 59.25 EDTA wash 1 0.95 
EDTA wash 2 85 EDTA wash 2 0.15 
EDTA wash 3 55.94 EDTA wash 3 0.67 
H2O wash 1 2.67 H2O wash 1 0 
H2O wash 2 1.28 H2O wash 2 0 
H2O wash 3 1.76 H2O wash 3 0 
 
Table 3. Encapsulation efficiency calculation for 12 layer microcapsules. 
 Biodegradable 
microcapsules 
Non-biodegradable 
microcapsules 
Total proteinase lost 1189.9 µg 603 µg 
Total remaining in 
capsules  
810 µg 1397 µg 
Encapsulation efficiency 40.5% 69.85% 
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3.5 Discussion 
The main purpose of this study was to determine whether the rate of content release of 
biodegradable microcapsules could be altered in an environment where enzymes were 
not present. This was achieved by pre-encapsulating proteinase within the microcapsules 
so they can be degraded from the inside, rather than externally. Unlike previous studies, 
this study uses microcapsules, synthesised of both polyaminoacids and polysaccharides, 
hence only one component within the layer-by layer structure is cleavable by the 
encapsulated proteinase.  
 
Encapsulation efficiency calculations were performed on the synthetic and biodegradable 
12 layer microcapsules, to determine whether there was any proteinase left within the 
capsules. Most of the contents are naturally liberated during the core dissolution step, 
since the cores trap the contents within their porous surface, releasing a vast amount 
through the microcapsule membrane as the core is disintegrated and dissolved. Another 
more important step with respect to encapsulation efficiency is the step where the 
protein/drug is taken up (absorbed and adsorbed) to the cores i.e. during core production. 
It is very feasible to find a large proportion of the protein/drug left in the supernatant 
formed immediately after core preparation. Washing during the layer-by-layer process is 
unlikely to liberate much proteinase, since the vast majority of the proteinase will be 
adsorbed and absorbed to the surface of the calcium carbonate core. Taking this into 
consideration, the supernatants were removed and retained at the core preparation and 
core dissolution stages. Determination of the encapsulation efficiency is essential for 
determining whether the microcapsules, are indeed, self-degradable. If all of the 
proteinase was liberated, the efficacy of the self-degrading mechanism would be severely 
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reduced, and hence the quantity of drug released, in a clinical setting, would be heavily 
reduced. Encapsulation efficiencies of 40.5% and 69.85% were calculated for the 
biodegradable and non-biodegradable microcapsules, respectively. The lower 
encapsulation efficiency of the biodegradable microcapsules, suggests that the proteinase 
enzymes were acting on the capsule shell even at this early stage. Larger losses of 
proteinase were found once the cores were dissolved. During this step, the proteinase is 
released from the confinements of the cores, thus allowing the active sites of the 
proteinase to contact the inner surface of the capsule shell, and subsequently hydrolyse 
the peptide bonds within the Poly (L-Arginine) component of the capsule wall. 
 
 In contrast, the synthetic PAH/PSS microcapsules, are non-biodegradable, hence they 
remain relatively sealed when the proteinase makes contact with the inner capsule shell. 
Some proteinase, however, is lost during the core dissolution and subsequent washing 
steps of the synthetic microcapsules. This is likely to have occurred as a result of passive 
diffusion of the proteinase through the porous capsule shell. Studies have shown that the 
capsule wall of polyelectrolytes are porous to proteins of molecular weights similar to 
that of the proteinase (16-27 kDa) used in this study (She et al., 2010a). Another 
explanation for this loss could be the incoherence of the capsules themselves. During the 
layer-by-layer process, some cores are incompletely covered by the polyelectrolytes. This 
commonly occurring phenomenon could result in a burst in proteinase release during this 
part of the fabrication process. Furthermore, this dissolution step results in the formation 
of carbon dioxide from the EDTA complexion with the calcium ions from the calcium 
carbonate core. This sudden increase in pressure has been shown to shock the capsules, 
often resulting in capsule rupture, ultimately leading to the complete liberation of all its 
internal contents. Care was taken, when dissolving the cores to prevent the occurrence of 
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ruptured capsules, by agitating the suspension gently and opening the Eppendorf tube to 
allow the CO2 gas to vent freely.  This undoubtedly helped reduce the loss of proteinase 
at this step remained low (19.12 µg).  Regardless of these losses, both synthetic and 
biodegradable microcapsules retained a significant level of proteinase.  
 
When comparing Figure 16 and Figure 17 it is clear that the 6 layer microcapsules 
released a greater amount of proteinase than the 12 layer microcapsules at all time points. 
Neglecting the effects of the proteinase, this is likely to occur naturally under normal 
conditions due to the presence of a thicker, less porous polyelectrolyte shell. The action 
of the proteinase within the capsules is only realised when the biodegradable and 
synthetic microcapsules are compared. There is a relatively large increase in amount of 
proteinase released in the 6 layer biodegradable microcapsules, compared to the 12 layer 
biodegradable capsules. This large increase is not noticed in the non-biodegradable 
samples. This suggests that the non-biodegradable capsules remain well-sealed and have 
not been degraded by the proteinase, as expected i.e. these are not technically self-
degradable microcapsules. Taking this into consideration, the reduction in proteinase 
release in the 12 layer biodegradable capsules with respect to the 6 layer microcapsules 
may also have occurred as a result of the enzymes not being able to digest the capsule 
shell as effectively. 
 
Further analysis of the 6 layer proteinase release profile, indicates that the 6 layer 
biodegradable microcapsules liberated most of its total amount lost during the early 
stages of incubation (within 1.5 hours). This was not noticed with the synthetic 
microcapsules. This notion offers further proof that the proteinase begins to act upon the 
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capsule shell from the onset. The epifluorescence image show in Figure 18 may provide 
evidence to support this statement. A number of capsules (highlighted) seem to have a 
lower fluorescent intensity than others. Irregularities are noticed in the fluorescence of 
the capsule wall of these particular capsules. This may indicate that the wall is being 
partially degraded. In contrast, these discrepancies may have arisen due to incomplete 
coverage of PLL-FITC during the layer-by-layer process.  
 
As expected, the most stable and well-sealed capsules were the 12 layer synthetic batch. 
The capsules within this sample are comprised of a thick shell that is non-responsive to 
enzymatic treatment. Indeed, research has shown that when PAH/PSS layer-by-layer 
assemblies are placed within a biological environment, the layers remain fully intact 
virtually indefinitely (Kerdjoudj et al., 2008). The supernatant corresponding to this 
batch of capsules showed no significant increase, after the initial burst, even after 24 
hours.  
 
The general trend of all proteinase release profiles as shown in Figure 16 and Figure 17 is 
well described by the hypothesis of the mechanism behind the self-degradable 
microcapsules. However, on closer inspection, there are some inconsistencies with the 
graphs. In theory, the total amount of proteinase in the supernatant should not decrease, 
as the same supernatant is used at each time point where the sample was analysed. 
Furthermore, the concentration gradient between the proteinase inside and outside of the 
microcapsules should dictate the outward diffusion of the proteinase, hence the 
supernatant concentration should not decrease. The slight decrease in supernatant 
proteinase content, noticed in all profiles could be a result of the accidental aspiration of 
56 
 
microcapsules while transferring the supernatant to the cuvette for UV 
spectrophotometry.  If this were to occur, the measured absorbance will be the total 
absorbance of the proteinase within the supernatant as well as the absorbance attributed 
to the microcapsules with encapsulated proteinase. This would ultimately produce a 
higher than expected supernatant proteinase concentration. If the next transfer of the 
supernatant from the capsule sample to the UV cuvette resulted in a pure supernatant 
without contamination with microcapsules, the perceived absorbance will be lower than 
the previous measurement. Another explanation for the slight decline in proteinase 
supernatant concentration towards the end of all release profiles could be due to the 
adsorption of proteinase on the Eppendorf tubes that contain the sample. It is a well-
known fact that proteins adsorb to plastics over time largely due to electrostatic and 
hydrophobic interactions (Karlsson et al., 2005). The Eppendorf tubes used are 
constructed from polypropylene. It is likely that over time, the proteinase in the 
supernatant may have deposited to the surface of the tubes, resulting in a slightly lower 
proteinase supernatant concentration. 
 
In the case of both 12 layer microcapsule samples, the total amount of proteinase released 
into the supernatant, once stability had been established (t = 24), was less than 10% of 
the encapsulated proteinase, determined by encapsulation efficiency calculations, 
suggesting that the surface of the microcapsules were not as porous as envisaged, even in 
the case of the biodegradable microcapsules. This apparent decrease in porosity may 
have arisen due to the proteinase adsorbing to the inner surface of the microcapsules and 
aggregating to the point where the pores would become partially/fully occluded. This is 
likely to restrict further diffusion of proteinase into the supernatant. 
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Interestingly, it was discovered that the 6 layer biodegradable microcapsules reached 
maximum proteinase secretion in approximately 2 hours, which is roughly the same 
amount of time taken for the medium concentration, microcapsule sample to reach 
maximum secretion of DNA, in the study by Borodina et al. (2007). The main differences 
between these two samples are 4-fold. Firstly, the amount of proteinase per capsule in the 
former study was 0.808 pg versus 0.037 pg in the present study. Secondly the dextran 
sulfate used in this study is replaced with poly (L-aspartic acid) in the former study. 
Thirdly, the capsule shells in the study by Borodina et al. (2007) had an extra layer of 
polyelectrolyte. Most crucially, however, the species being measured in the former study, 
is DNA. More specifically, the study used double-stranded DNA from herring testes. 
This form of DNA typically ranges between 12 and 1000 kDa. Unfortunately, the 
molecular weight of the DNA used was not disclosed in the paper. The similarity of the 
results found could be attributed to  the DNA used in the study by Borodina et al., 
(2007), providing that low molecular weight DNA was used. If this were the case, the 
present study has encapsulated contents of a significantly higher molecular weight 
(typically between 20 and 60 kDa). By intuition, it is clear that the proteases would take 
longer to diffuse through the capsule shells. This notion leads to further evidence to 
suggest that the proteinase diffusion was halted by blockage of the pores by the large 
protease molecules within the microcapsule shell. Indeed, the study analysing DNA 
secretion showed that almost 100% of the DNA was secreted within 2 hours.  
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3.6 Conclusion 
In conclusion, self-degradable microcapsules have been successfully prepared and tested. 
The protein release profiles coupled with visual evidence from epifluorescent microscopy 
clearly indicate that the microcapsules made from cleavable polypeptide (poly-L-
arginine) have been degraded by the proteinase encapsulated within. Furthermore the 
release is progressive in nature, with significant protease being liberated after t = 1.5 
hours for 6 layer self-degradable microcapsules. This progressive release profile has 
manifested through peptide hydrolysis of the poly-L-arginine component of the capsule 
shell. This is confirmed by low levels of protease being liberated from the non-
biodegradable PAH/PSS control sample. In addition, microcapsules with a thicker shell 
were less susceptible to degradation by the encapsulated protease. Three main parameters 
are key to controlling the rate of release of encapsulated contents, namely: the amount of 
encapsulated protease, the thickness of the shell and the proportion of shell constituents 
that are biodegradable. By adjusting these parameters, self-degradable microcapsules can 
be tailor-made for specific applications that are dependent on the rate of release and 
external protease concentrations.   
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4. Targeted delivery of polyelectrolyte 
microcapsules 
 
4.1 Introduction 
As mentioned in the introductory section, targeted delivery of polyelectrolyte 
microcapsules is an essential requirement for the treatment of site-specific diseases. This 
chapter aims to develop mechanisms by which microcapsules can increase adsorption to 
collagen type IV, in attempt to help the microcapsules target the basement membrane. 
Furthermore, an investigation into the suppression of non-specific adsorption to 
endothelial cells will be conducted in order to prevent microcapsules from adsorbing to 
the undamaged regions of the endothelium.  
 
4.1.1 Protein adsorption 
Non-specific protein adsorption is the key contributor to the unspecific adhesion of 
polyelectrolyte microcapsules to protein and cellular surfaces. For these reasons, the 
mechanisms of protein adsorption must be fully understood.  
Adsorption refers to the action by which substances accumulate and adhere to surfaces. 
Specifically, proteins adsorb through a variety of mechanisms including: intermolecular 
forces, ionic bonding, electrostatic interactions and hydrogen bonding (Kurki et al., 
1989). These mechanisms arise directly from the intrinsic structure of proteins. As 
discussed earlier, proteins are long polyamino acid chains that have come together in a 
bundle which is maintained by hydrogen bonding, electrostatic interactions between 
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charged amino acids, and disulphide bonds (Hautanen et al., 1989). Due to their 
hydrophilicity, charged amino acids within a protein preferentially locate towards the 
periphery of the molecule, thus allowing these charged amino acids to interact with 
surfaces (Launes and Hautanen, 1988). These electrostatic forces are more prominent 
when the surface is charged e.g. a polyelectrolyte. Surface energy and texture of the 
surface also influence the degree of protein adsorption. 
 
Conditions also have a profound effect on adsorption. By changing the pH, the overall 
charge of proteins can be altered (Pierschbacher and Ruoslahti, 1987). Proteins can be 
described as amphoteric i.e. they have regions of cationic and anionic charge. Most 
charges from proteins arise from dissociation/association of hydrogen ions from 
carboxylic acids and amine groups respectively. These mechanisms are driven by the 
amount of hydrogen atoms (H
+
) and hydroxide ions (OH
-
) ions there are in the solution. 
If the pH of the solution were to be near the isoelectric point (pI) of the proteins, protein 
adsorption should be largely reduced since this is one of the main adsorption 
mechanisms. 
 
Proteins are relatively large polymers (MW usually greater than 10,000) with a complex 
tertiary structure. They are comprised of amino acids. In total, there are 20 naturally 
occurring amino acids each of which has a specific charge. This gives rise to anisotropic 
charges within the protein superstructure. Instead, a net charge is used to describe the 
overall charge of the protein. It is important to realise that should a protein have a net 
positive charge, it is not impossible for this protein to be absorbed to a positively charged 
surface since some regions of the protein may be negatively charged. The region where 
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this attachment may occur is commonly referred to as a charge patch. This explains why 
proteins readily adsorb to charged surfaces. 
 
Other factors that affect protein adsorption include the concentrations of the protein 
solutions involved as well as the molecular weight of the proteins. Lower molecular 
weight proteins exhibit higher mobility and thus adsorb at a faster rate. These proteins 
may then be displaced at a later stage by heavier proteins which have a higher affinity to 
this particular surface. This time-dependent competitive adsorption is known as the 
Vroman effect (Vilaseca et al., 2012).  
 
4.1.2 Basement membrane anatomy 
Since the ultimate aim of this study is to create microcapsules which adhere to sites of 
endothelial damage i.e. where the basement membrane is exposed, this structure must be 
studied in depth. 
The vascular basement membrane serves as a foundation for which the endothelial cells 
reside on. The primary function of basement membrane is to provide structural support to 
the cells. The main components of basement membrane include heparan sulphate 
proteoglycans (e.g.perlecan), nidogen/entactin, laminin and type IV collagen, the latter 
being the most abundant protein (50% of basement membrane proteins) (Kalluri, 2003). 
This is therefore a potential target for microcapsule delivery in cases where the 
endothelial lining has been damaged, and the underlying basement membrane is exposed. 
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The second most abundant protein is laminin. Both collagen and laminin have the ability 
to self-assemble into three dimensional structures. It has been discovered that although 
perlecan, nidogen and entactin do not possess the ability to form such suprastructures, 
they are essential in providing complexes between type IV collagen and laminin 
(Aumailley et al., 1993). Figure 19 illustrates thenidogen and perlecan-dependent  
binding of laminin to collagen type IV. 
 
 
Figure 19. Basement membrane structure. Adapted from (Kalluri, 2003). 
 
Collagen type IV structure 
In order to find suitable collagen type IV binding polymers, it is important to understand 
the structure and chemical components of the protein which differs vastly from other 
interstitial collagens. Collagen is the main component of connective tissue in mammals. 
It is also the most abundant protein in animals (Friedman et al., 2000). The protein is 
composed of a collagenous region (1400 residues long) and a non-collagenous region 
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(230 residues long). The majority of collagen proteins are made up of three alpha chains 
which each have the following amino acid repeat unit in their collagenous domains: 
[Gly-Xaa-Yaa]n 
where Gly is a glycine residue and Xaa and Yaa are other residues (usually either proline 
or hydroxyproline. 
 
The glycine is an essential part of collagen which contributes to the triple helical 
structure (also known as tropocollagen). Its small size allows the alpha chains to be 
tightly packed to create a robust structure. The highly abundant proline and 
hydroxyproline residues are also essential in maintaining such a rigid structure since 
these residues form hydrogen bonds between the chains. A suprastructure is formed by 
dimer and tetramer bonds at the C termini and N termini respectively. Intermolecular 
bonds come in the form of disulphide bonds which are able to form due to the presence 
of cysteine in the non-collagenous ends of the tropocollagen molecules (Leinonen, 
1999).A bundle of these tropocollagen molecules are called a collagen fibril. When 
combined, they form a structure with high tensile strength. 
 
As all collagens, the amino acid repeat unit is also found in type IV collagen; however 
the sequence is interrupted 25 times along a single chain with regions that are unable to 
form a triple helix due to lack of hydroxyproline, an essential amino acid which provides 
hydrogen bonding. This gives rise to the flexible sheet-like structure of type IV collagen 
as shown in Figure 21 (Hudson et al., 1993). 
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Figure 20. Schematic drawing highlighting the triple helical structure of a tropocollagen 
molecule. Adapted from (Kalluri, 2003). 
 
 
 
Figure 21. Schematic drawing highlighting the suprastructure of type IV collagen showing 
the dimer (NC1 bonds) and tetramer bonds. Adapted from (Kalluri, 2003). 
 
As mentioned earlier, we are required to target the basement membrane of damaged 
blood vessels. Using the technique discussed earlier, we aim to functionalise the 
biodegradable microcapsules with the heptapeptide that has a specific affinity to collagen 
type IV. 
 
4.2 Suppression of capsule retention by endothelial cells 
 
As mentioned earlier, polyelectrolyte microcapsules are typically made from PAH and 
PSS. These polymers are known to have strong adhesive properties due to their 
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electrostatic charges.  Since the aim of this project is to produce microcapsules which do 
not stick to cells, weakly charged polyelectrolytes were used. The polymers tested are 
listed below. 
 
4.2.1 Materials and Methods 
 Dextran sulphate (DexS), a negatively charged polysaccharide was used to make 
[PArg/DexS]4 capsules with dextran sulphate used as the terminal layer.  
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Figure 22. Skeletal structure of dextran sulfate. 
 
Poly-L-arginine (PArg) terminated microcapsules were made with the structure 
[PArg/DexS]3-PArg. 
O
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Figure 23. Skeletal structure of poly-L-arginine. 
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Poly-L-glutamic acid, a negatively charged polyamino acid was used along with poly-L-
arginine to make microcapsules with the following conformation: [PArg/PGlut]4. 
NH
O
O OH
n
 
Figure 24. Skeletal structure of poly-L-glutamic acid. 
 
As a control, polyethylene glycol (PEG) terminated capsules were synthesised by 
adsorbing poly-L-lysine-grafted PEG onto [PArg/PGlut]4 capsules. The positively 
charged PLL side chains of the PLL-PEG serve to anchor the PEG to the negatively 
charged terminal layer (poly-glutamic acid) via electrostatic binding. PEG, also referred 
to as poly(ethylene glycol) is insusceptible to unspecific binding to proteins. The non-
fouling properties of PEG manifest from the existence of a stable interfacial water layer 
which acts as a physical barrier and effectively prevents direct contact between the 
protein and the PEG surface (Boughton, 1985, Yang et al., 2012b).  
O
HO
H
n  
Figure 25. Skeletal structure of PEG. 
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Figure 26. Skeletal structure of PLL-Grafted PEG. Adapted from (Müller et al., 2003). 
 
Additionally, the dense PEG brush layer that is formed on the surface of the 
microcapsules help shield the electrostatic charges of the underlying polyelectrolyte 
layers. This prevents electrostatic interactions between the surface and proteins, a force 
which is assumed to be one of the major contributors of protein adsorption (Lvov et al., 
1995). By functionalising the microcapsules with PEG, they should not bind to collagen 
type IV or endothelial cells (Benhabbour et al., 2008). 
To see whether the number of layers has an effect on the adhesion properties of the 
microcapsules, 4 layer and 8 layer microcapsules were prepared. Microcapsules were 
synthesised as described in chapter 2.  
 
4.2.2 Experimental procedure 
Endothelial cells (HUVEC) were seeded onto a 40mm diameter petri dish at a 
concentration of 30 kcell/ml with cell culture medium and fetal bovine serum (10%). The 
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cells were subsequently incubated at 37°C in air supplemented with 5% carbon dioxide. 
Cell culture medium and fetal bovine serum was replenished every 48 hours. 2ml 
microcapsule suspension samples at a concentration of approximately 5 million 
capsules/ml were pipetted onto the cells once they  had reached confluence. The size of 
the microcapsules produced ranged between 3 and 6 μm. The cells were then incubated 
for 15 minutes at 37°C to allow the capsules to sink to the bottom and come into contact 
with the cells. After the incubation period, images were taken using an optical 
microscope in bright-field mode before and after washing. Briefly, the washing protocol 
consisted of three wash/aspiration cycles with HEPES buffer (3x2ml). The numbers of 
capsules before and after washing were quantified using ImageJ software. From this data, 
percentage retention was calculated. For comparison, the same batch of  8 layer 
microcapsules were tested on collagen type IV substrates for the same length of time. 
Substrates were prepared by preparing a 1mg/ml collagen type IV solution with PBS and 
immersing glass slides in the solution for 1 hour. Excess collagen was removed by 
pipette-washing. 
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4.2.3 Results 
 
Figure 27. Percentage retention of capsules with different terminal layers incubated on 
endothelial cells. Error bars indicate standard deviation (n = 5). 
 
The adsorption assays performed on the HUVECs as shown in Figure 27, indicate that 
the PEGylated microcapsules predominantly refrained from adsorbing to cells, with an 
average percentage retention of 3.4% and 2.9% for 4 and 8 layered microcapsules 
respectively. There was no significant difference between 4 and 8 layered microcapsules 
bar one, namely the polyarginine-terminated microcapsules, which showed a 64.5% 
increase in retention when the number of layers used were halved.  
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Figure 28. Percentage retention of capsules with different terminal layers, incubated on 
collagen type IV. Error bars indicate standard deviation (n = 5). 
 
Similarly to the adsorption assays performed on HUVEC cell cultures, the assays 
performed on collagen type IV substrates revealed a negligible degree of binding from 
PEGylated microcapsules (1%). Retention on all other microcapsules were less than 
10%, with the exception of PSS which displayed a high affinity for collagen type IV 
(77.5%). 
  
4.2.4 Discussion 
From the results, it is clear that the difference in adsorption onto the cells using 4 layers 
and 8 layers is largely insignificant except for the arginine terminated microcapsules 
which showed an increase in percentage retention of 65%. It is unclear how this increase 
manifested. It may be that the 4 layer microcapsules offered more flexibility, allowing 
more of the surface of the capsule to contact the endothelial surface. In contrast, an 
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increase in the number of layers has been shown to improve the integrity and density of 
the terminal layers, which should in theory increase the positivity of the terminal layer. 
This should lead to an increase in binding of microcapsules to the anionic surface of the 
cells. However, the results presented contradict this statement. 
 
As expected, the PEG-terminated microcapsules showed negligible adhesion to both the 
cells and the collagen type IV. Therefore this is not a suitable terminal layer. Despite this 
shortcoming, PEG should not be disregarded since its protein resistance is key to 
reducing unspecific protein binding, especially since it does this by shielding strong 
electrostatic forces. Instead, ways of functionalising PEG with anti-col IV shall be 
investigated. 
 
The primary advantage of functionalising PEG-terminated microcapsules with anti-col 
IV is that it should theoretically result in a drug carrier system that is extremely specific 
to collagen type IV. The combination of the protein resistance and reduction of PEG 
coupled with the high specificity of anti-col IV should ensure the capsules have a high 
affinity for collagen type IV whilst at the same time have a much lower affinity to other 
protein-based substrates as well as cell cultures. 
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4.3 Microcapsule surface modification for the enhancement of cell targeting 
 
4.3.1 Introduction 
It is a well-established fact that in an in-vitro environment, polyelectrolyte microcapsules 
adhere to cells (Liu et al., 2014). This fact is supported by the data represented in the 
previous subchapter (Figure 27). This phenomenon is believed to occur as a result of the 
non-specific electrostatic interactions between the layer-by-layer polyelectrolytes and the 
cell membrane. Research into specific targeting of polyelectrolyte microcapsules is 
scarce. If the cell membrane structure is fully understood, it may be possible to enhance 
the binding of microcapsules to cells to improve the efficacy of drug delivery. For this 
reason, the detailed structure of the cell-membrane, is henceforth examined. 
 
4.3.2 Cell membrane structure 
The eukaryotic cell is primarily composed of a phospholipid bilayer, which is a bilayer 
made out of phospholipid molecules. The phospholipid molecule, as shown in Figure 29 
is made out of a hydrophilic (polar) head and a hydrophobic (non-polar) tail. 
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Figure 29. Diagram showing a schematic (left) and formulative (right) representation of the 
phospholipid molecule. Adapted from (Alberts et al., 2002). 
 
More specifically, the hydrophilic head is comprised of three subunits, namely, choline, 
phosphate and glycerol. The lipid-based tail is composed of fatty acids and contribute to 
50% of the mass of the cell membrane. The bilayer is spontaneously self-assembled as a 
result of the hydrophobicity of the fatty acid tails resisting contact with water, while the 
hydrophilic heads naturally favour the water-based extracellular fluid. This results in a 
bilayer configuration where the non-polar tails are orientated inwards and the polar heads 
are orientated externally, as shown in Figure 30. The abundant negatively charged 
phospholipid, phosphatidylserine, is believed to contribute to the anionic charge of cell 
membranes (Yeung et al., 2008). 
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Figure 30. Schematic diagram representing the tightly-packed phospholipid bilayer. 
 
 
Cell membranes are also comprised of various proteins. The protein component of the 
cell membrane accounts for 50% of the membrane volume (Alberts et al., 2002). Located 
within the phospholipid bilayer are embedded proteins, known as transmembrane 
proteins. These proteins, as suggested by their name, cross straight through the 
membrane and in some cases, create a channel, where ions and small molecules can 
diffuse through via passive diffusion or active transport.  In addition to these 
transmembrane proteins, there exist surface proteins which are located peripherally on 
the cell. As a result of their location, these particular proteins are more relevant to this 
study and shall therefore be explained in more detail.  
 
Cell adhesion molecules 
Cell adhesion molecules (CAMs), are responsible for cell-cell and cell-extracellular 
matrix interactions. These are the proteins that help anchor a cell to its environment. 
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These are therefore vital in terms of cell attachment and may offer a potential binding site 
for microcapsules. The types of CAMs are henceforth described. 
 
Integrin 
Integrins are proteins which are classed as transmembrane receptors. In essence, these 
proteins are responsible for sensing external triggers, usually by binding to trigger 
molecules. Subsequently, this triggers the integrin to send a chemical message to the 
interior of the cell, which triggers an appropriate response i.e. they are signal transducers 
(Tarone et al., 2000). Integrins bind various extracellular matrix proteins including: 
laminin, collagens and fibronectin, hence they also function as cell-anchoring proteins 
(Ruoslahti, 1991). 
 
Cadherin 
Cadherins are cell surface glycoproteins. They serve as adhesive proteins which are able 
to bind cells to one another both in-vitro and in-vivo. A member of the glycoprotein 
family, their structure is primarily based on a protein with short sugar molecules 
(oligosaccharides) covalently bound to the polypeptide side chains. Their function is an 
active process which can only take place in the presence of calcium ions, Ca
2+
 (Halbleib 
and Nelson, 2006). As a result of their function, the location of cadherins is restricted to 
the cell-cell junctions, and hence this is not an ideal target for microcapsule delivery.  
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Selectin 
Unlike the aforementioned proteins, selectins are a type of lectin, and hence have the 
ability to sugar groups. In particular, E-selectin, a protein involved in the inflammatory 
response, is expressed on endothelial cells and is therefore the relevant molecule to 
analyse for this particular application. E-selectin loosely binds to sialylated  
carbohydrates present on the cell surface of leukocytes. The low affinity of this 
interaction leads to the formation and breakage of bonds, which, in turn contribute to the 
characteristic rolling action of leukocytes at the inflammatory site (Kunkel and Ley, 
1996). For this reason, this would not be an interaction worth exploiting. A high binding 
affinity would be more desirable.  
  
Glycocalyx 
In addition to the earlier described proteins, there exists a significant structure on the 
periphery of the luminal cell membrane, namely the glycocaylx which can be seen in 
Figure 31.  
 
 
Figure 31. Schematic drawing of an endothelial cell showing  the glycocalyx on the apical 
side. 
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This densely packed “brush-like” assembly, is expressed in all cells, including 
endothelial cells. Within an in-vivo environment, the endothelial glycocalyx undergoes 
deformation due to the shear stress exerted by the blood flow. The glycocalyx in turn 
transduces this signal to the internally located cytoskeleton and subsequently triggers an 
intracellular response e.g. an inflammatory response (Weinbaum et al., 2007). Other 
research has shown the glycocalyx to play a role in the regulation of vascular 
permeability and the prevention of  erythrocyte build-up on the vessel wall (Kolářová et 
al., 2014). Previous studies have shown it to be a very stable component of the cell 
membrane, with a full regrowth time of 14 days after degradation via neuraminidase, in 
an in-vitro environment (Bai and Wang, 2012). 
 
The structure of the glycocalyx can be clearly seen in Figure 32. It is made up of various 
sugar chains, including heparan sulfate, a glycosaminoglycan (GAG). These GAG chains 
are found covalently bound to core proteins, to create structures known as proteoglycans. 
This is the most abundant GAG in the glycocalyx, is heparan sulfate proteoglycan, which 
contributes to 50-90% of the total proteoglycan content (Ihrcke et al., 1993).  
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Figure 32. Schematic drawing of the glycocalyx highlighting the sugar chain and 
transmembrane protein components. Adapted from (Cruz-Chu et al., 2014). 
 
Heparan sulfate proteoglycans are made up of a core protein which is primarily linked to 
heparan sulfate GAG side-chains as well as chondroitin sulfate side-chains. The 
glycocalyx has an overall anionic charge, due to the presence of sulfate groups on the 
GAG chains. This electrostatic charge, combined with the negatively charged 
phospholipid bilayer, unquestionably renders the entire cell surface negatively charged. If 
the cells were to be targeted via electrostatic force, it is essential to have a cationic outer 
layer or functional group.  
Potential ligands 
Currently, many biocompatible polycationic polymers are used in microcapsule 
fabrication. Examples include polysaccharides such as chitosan and dextran-spermine 
conjugate, (Azzam et al., 2002) and polypeptides such as poly-l-arginine and poly-l-
glutamic acid and poly-l-lysine. For a stronger electrostatic affinity, poly-allylamine 
hydrochloride or Polydiallyldimethylammonium chloride (PDADMAC) could be used, 
as these polymers have been characterised with zeta potentials of +20 mV and +35 mV 
respectively, on planar surfaces (Michel et al., 2012) (Decher and Schlenoff, 2012). 
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However, these polymers are non-biodegradable and therefore would not be as efficient 
in terms of drug release, as shown in chapters 2 and 3. 
 
Instead of tackling the problem from an electrostatic approach, it may be beneficial if a 
more specific approach was used. As explained earlier, there are many proteins on the 
surface of the cell membrane. Each of these proteins may be targeted by functionalising 
the microcapsules with specific antibodies, however, this would be costly. Furthermore, 
surface of the cells are not entirely covered with these surface bound proteins. Instead it 
would be more beneficial to target a structure that surrounds the entire exposed area of 
the cell membrane i.e. the glycocalyx. 
 
Integrins are transmembrane proteins that are involved in interactions between cells and 
the extracellular matrix. A group of integrins including αV and 2 β1 integrins (α5 and α8) 
have the ability to interact with a specific tripeptide group found within protein 
structures, namely the RGD (Arginine-Glycine-Aspartic acid) sequence (Xiong et al., 
2002). To mimic the adhesive function of these cell-binding proteins, short peptides 
containing the RGD sequence can be synthetically manufactured. These peptides are 
often coated on cell substrate surface in order to promote cell adhesion. Interestingly, 
synthetic peptides containing this sequence e.g. GRGDSP derived from Fibronectin, have 
a reported affinity of up to 1000 fold less than fibronectin (Ruoslahti, 1996). 
Nevertheless, this interaction is highly specific since if the central glycine residue is 
replaced with alanine, the binding is reduced by 100 fold (Hautanen et al., 1989). 
Specificity is also demonstrated by the lack of activity when the aspartic acid residue is 
80 
 
in the D isomer conformation (Pierschbacher and Ruoslahti, 1987). Although specificity 
is a key element of cell targeting, the markedly reduced binding affinity of these peptides 
suggests that RGD peptides are not the best candidate for microcapsule functionalisation.  
 
Wheat-germ agglutinin 
Wheat germ agglutinin (WGA) is a lectin with a molecular weight of 23.5 kDa (Nagata 
and Burger, 1972). This protein specifically binds specifically to sialic acids. This 
includes N-acetyl glucosamine, a component of the hyaluronan and heparan sulfate GAG 
chains found on the proteoglycans of the glycocalyx (Salmon et al., 2012).  
 
Figure 33. Ribbon structure of wheat germ agglutinin.Adapted from (Schwefel et al., 2010). 
 
The binding of WGA to the glycocalyx arises due to the high degree of complementarity 
between the carbohydrate-binding site of WGA and N-acetyl glucosamine and its 
associated oligosaccharides (Peters et al., 1979).  As a protein, it has the potential of 
adsorbing onto the surface of polyelectrolyte microcapsules. More precisely, WGA has 
an isoelectric point of 8.7, implying that it is positively charged at pH=7 (Schaeffer et al., 
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1982). Therefore microcapsules with a negatively charged polymer should readily adsorb 
WGA, resulting in WGA-terminated microcapsules. Furthermore, WGA is a protein and 
therefore can be fluorescently labelled, thus the researcher could ascertain whether the 
WGA has been adsorbed onto the microcapsules with ease. 
 
4.3.3 Materials 
Primary pooled Human Umbilical Vein Endothelial Cells (HUVEC), were acquired from 
a commercially sourced cell-line (Lonza Cologne AG, Germany). Cell culture medium 
(cat. no. M199) and fetal bovine serum were purchased from Invitrogen, UK. Β-
endothelial cell growth factor (1 ng/ml) and penicillin (100 U/ml), Lectin from Triticum 
vulgaris (wheat) (cat. no. L4895), Poly-Lysine-FITC labelled (15-30 kDa) (cat. no. 
P3543) and neuraminidase from Clostridium perfringens (cat. no. N2876)  were 
purchased from Sigma Aldrich Co. Synthetic polyelectrolyte microcapsules were 
manufactured in the laboratory (for individual materials see section 3.2). 
 
4.3.4 Method 
Capsule preparation 
PSS and PAH polyelectrolyte layers were sequentially deposited on calcium carbonate 
cores, as described in section 3.3.2 to produce microcapsules with the structure 
[PSS/PAH]3-PSS. A WGA-FITC solution (200 μg dissolved in 2 ml PBS) was added to 
the Eppendorf tube containing the polymer-coated cores and incubated at room 
temperature for 1 hour, ensuring that the cores remained well suspended in the solution. 
Three washing cycles with PBS were administered to the sample to remove excess 
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WGA. Finally the cores were dissolved using an EDTA solution which had an adjusted 
pH of 7 in order to maintain the integrity and structure of the WGA and avoid 
denaturation of the carbohydrate-binding site. For control purposes, microcapsules 
terminated with PSS and PAH were synthesised to determine whether the WGA-
glycocalyx interaction is more potent than electrostatic interactions. For visualisation, 
these microcapsules had a single PLL-FITC polymer layer incorporated in the layer-by-
layer assembly, in a similar way as described in section 3.3.2. 
 
 
Cell preparation 
Human umbilical vascular endothelial cells were cultured on coverslips placed in a 24-
well plate at a concentration of 40 kcell/ml with cell culture medium and fetal bovine 
serum (10%) as nutrients. Cells were incubated in an incubator set at 37°C and 5% CO2. 
Cell culture medium and fetal bovine serum was replenished after 2 days. Once 
confluence had been reached, half of the wells were treated with neuraminidase, an 
enzyme that cleaves the carbohydrate components of the glycocalyx including: heparan 
sulfate, chondroitin sulfate, hyaluronic acid and sialic acid (Pahakis et al., 2007). A 1 
U/ml solution was incubated with the cells for 45 minutes in a similar fashion to previous 
studies (Barker et al., 2004). This was performed to remove the glycocalyx and 
determine whether the interaction between the WGA-terminated microcapsules and the 
cells is based on the binding of the WGA to the sialic acid component of the glycocalyx. 
The medium was then removed and replaced with WGA capsule suspension. After 
incubation at room temperature for 1 hour, the cell cultures were thoroughly washed 3 
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times to remove any unbound microcapsules. All cells were labelled with CellTracker 
Red in accordance with the relevant protocol. Cells were subsequently fixed by 
paraformaldehyde for 15 minutes. Epifluorescent images were acquired to determine 
microcapsule retention on the each sample. For consistency, the middle of each coverslip 
was analysed.  
 
4.3.5 Results 
Microcapsule adsorption 
All micrographs were taken after 3 washing cycles with PBS. The cells are stained with 
CellTracker Red. All samples analysed contained a large number of microcapsules on 
both neuraminidase-treated and untreated HUVEC cell cultures. WGA-terminated 
microcapsules experienced the largest degree of aggregation.   
 
Figure 34. FITC-labelled WGA capsules (green) on endothelial cells, stained with 
CellTracker
TM
 Red (Panel A) and neuraminidase treated cells (Panel B). 
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Figure 35. FITC-labelled PAH capsules (green) on endothelial cells, stained with 
CellTracker
TM
 Red (Panel A) and neuraminidase treated endothelial cells (Panel B). 
 
Figure 36. FITC-labelled PSS capsules (green) on endothelial cells, stained with 
CellTracker
TM
 Red (Panel A) and neuraminidase treated endothelial cells (Panel B). 
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Neuraminidase validification 
 
Figure 37. Stacked confocal image of endothelial cells (stained red by CellTracker Red. 
(Panel A) and neuraminidase treated endothelial cells (Panel B) Cells were stained with 
WGA-FITC (green) to detect the presence of the glycocalyx. 
 
WGA-FITC staining of the glycocalyx revealed an intact uniform glycocalyx on 
untreated cells, as expected for mature cells. As expected, upon neuraminidase treatment, 
it appears the glycocalyx has been degraded, as illustrated by a diminished level of green 
fluorescence in Figure 37B. 
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Capsule adsorption summary 
 
Figure 38. Capsule retention on endothelial cells treated with and without neuraminidase. 
Error bars indicate standard deviation (n = 5) 
 
Cleavage of the glycocalyx by neuraminidase treatment was confirmed by confocal 
microscopy, as shown in Figure 37. After the enzymatic treatment, the green signal 
shown in Figure 37B, corresponding to the glycocalyx (labelled with WGA-FITC), was 
markedly reduced compared to Figure 37A.  
The summary of capsule retention on endothelial cells treated with and without 
neuraminidase reveal that by terminating the microcapsules with WGA, capsule 
adsorption was marginally increased by approximately 50%. A one-tailed t-test was 
performed to determine whether the difference between results obtained with WGA 
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capsules with and without neuraminidase were statistically significant. The computed 
values for t and p were 0.043561 and 0.483671 Indicating that the difference was not 
statistically significant at the p < 0.05 level.  
 
4.3.6 Discussion 
From the data obtained, it is clear that on all occasions, the microcapsules, regardless of 
their structure, adhered to the cells quite convincingly, as expected. This is undoubtedly 
due to the non-specific electrostatic interactions between the highly charged polymers 
and the cell membrane surface. With reference to the WGA-terminated capsules, the cell 
affinity was markedly higher. At first glance, one may presume that this enhancement of 
capsule binding is indeed a result of the aforementioned glycocalyx-WGA interaction. 
However, once the glycocalyx is removed via neuraminidase treatment, the capsules are 
still equally well-retained on the cell membranes. The absence of change in capsule 
retention may have arisen due to the use of an inactive/denatured batch of neuraminidase. 
The neuraminidase was tested using confocal microscopy. By labelling the glycocalyx 
with WGA-FITC, one can determine whether the glycocalyx is present on the cell 
membrane before and after neuraminidase treatment. As seen in Figure 37 (Panel A), the 
entire surface of the cells are highlighted green confirming the presence of an intact and 
densely packed glycocalyx layer. In contrast, Figure 37 (Panel B) indicates that after 
neuraminidase treatment the green fluorescence signal is significantly weaker, suggesting 
that the glycocalyx has been considerably destroyed. This confirms that the 
neuraminidase is an adequate enzyme for glyocalyx removal. Thus it would appear that 
the binding of the WGA capsules to the cells is not purely acquired through WGA-
glycocalyx interactions. Another force must be contributing to the adhesion of WGA to 
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the cell membrane. Since WGA doesn’t significantly bind to neuraminidase treated cells, 
one must assume that the surface of the capsules is not entirely coated with WGA. 
Indeed, the polymers deposited never entirely form a continuous layer on the templates, 
hence the underlying polyelectrolytes may be exposed. However, this still would not 
account for the abnormally high level of interaction.  
 
Another factor to consider is the environment within which the capsules are incubated i.e. 
the cell culture medium. This cocktail of nutrients contains proteins from the fetal bovine 
serum component. A major constituent of fetal bovine serum is BSA, a negatively 
charged protein (Loughney et al., 2014). This BSA would have had ample time to 
electrostatically adsorb to the positively charged protein thus resulting in BSA-coated 
microcapsules. Other proteins including growth factors are also likely to contaminate the 
surface of the capsules. These proteins are involved in the promotion of cell proliferation 
and hence have a high affinity to cells (Shah, 1998). This theory could also explain why 
the negatively charged PSS-terminated microcapsules also significantly bind to the cells. 
By observation of Figure 34, it is clear that the WGA microcapsules are significantly 
more aggregated than their polylelectrolyte-terminated counterparts. This may account 
for the increase in apparent cell adsorption.  
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4.4 Collagen type IV binding pilot study 
 
4.4.1 Introduction 
In order to localise microcapsules to the site of endothelial injury, the type IV collagen-
rich basement membrane shall be targeted. A recent study led to the discovery of a type 
IV collagen-binding heptapeptide ligand (Chan et al., 2010). By functionalising 
microcapsules with this ligand, they should specifically adhere to collagen type IV and 
therefore the exposed basement membrane of a damaged vessel. The authors of this study 
successfully functionalised tailor made nano particles, aptly named nanoburrs, with 
heptapeptide ligands which have a strong affinity to collagen type IV, a highly abundant 
protein found in the basement membrane of human vasculature. This particular 
heptapeptide which boasts a two fold increase in nanoparticle retention in-vivo compared 
with a random heptapeptide library, would be an ideal ligand to functionalise the 
proposed microcapsules of this study. These ligands (KLWVLPK) were attached to the 
PEG surface of the nanoburrs via maleimide thiol conjugation chemistry. With regard to 
the polyelectrolyte microcapsules fabricated by the LbL technique, this complex 
chemistry would not be applicable. Instead, the heptapeptide ligands could be conjugated 
to the surface of the microcapsules in a similar fashion to Taublan (2006) whereby a 
short polylysine chain is attached to the ligand to serve as an electrostatic adhesive. In 
this case, it is essential to terminate the LbL process with a polyanion that will 
electrostatically bind to the polylysine chain. This proposed peptide chain can be 
manufactured by FMOC solid-phase peptide synthesis, a well-established technique 
(Stuber et al., 1989). 
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4.4.2 Materials and Methods 
In the original study, Chan et al, 2010 functionalised the PEG surface of the 
nanoparticles with the ligand via maleimide thiol conjugation chemistry. With regard to 
the polyelectrolyte microcapsules fabricated by the LbL technique, this complex 
chemistry would not be applicable. Instead, the heptapeptide ligands could be conjugated 
to the surface of the microcapsules in a similar fashion to Taublan (2006) whereby a 
short polylysine chain is attached to the ligand to serve as an electrostatic adhesive as 
shown in Figure 39. In this case, it is essential to terminate the LbL process with a 
polyanion that will electrostatically bind to the polylysine chain. This proposed peptide 
chain can be manufactured by fmoc solid-phase peptide synthesis, a well-established 
technique (Stuber et al., 1989). Once this peptide was synthesised, polyglutamic 
acid/poly-L-arginine microcapsules were synthesised as described in section 2.3. 
 
 
Figure 39. Proposed mechanism of basement membrane targeting. 
 
A solution of the above peptide was made by Cambridge Peptides Ltd. and dissolved 
with deionised water to a concentration of 2mg/ml. The polyglutamic acid-terminated 
microcapsules were then suspended in this solution. After 30 minutes of vigorous 
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shaking, the suspension was centrifuged and microcapsules were washed three times. 
After washing the capsules were tested for their affinity for collagen type IV by 
introducing them to a collagen type IV-coated glass slide. This substrate was prepared by 
immersing a glass slide in a 1 mg/ml solution of collagen type IV (prepared in PBS). 
After incubating at room temperature for 1 hour, the slide was washed with PBS to 
remove any non-adsorbed collagen. 200μl of functionalised capsule solution was then 
pipetted onto a marked out volume on the glass slide. For control, polylysine-terminated 
microcapsules were tested against collagen type IV. After 24 hours, the samples were 
washed three times using deionised water and the slides were viewed under an optical 
microscope to assess capsule retention. Initial results were negative as shown in the 
micrographs below. 
 
4.4.3 Results and Discussion 
 
 
Figure 40. Micrographs showing the retention of Microcapsules with heptapeptide ligand 
(Panel A) and control microcapsules terminated with Poly-L-lysine (Panel B) on collagen 
type IV-coated glass. 
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Evidently, the control microcapsules displayed a higher affinity to collagen type IV than 
the specifically functionalised microcapsules. The high binding rate noticed in the control 
sample could be explained to an insufficiently coated glass slide. Therefore in reality, 
what is being observed is the electrostatic attraction between the positively charged 
microcapsules with the negatively charged glass. To verify this explanation, a collagen 
type IV-coated 8 well slide was acquired from Ibidi GmbH. The same procedures were 
carried out on this reliable substrate, however, the results were similar. The 
functionalised microcapsules may not have been sufficiently coated with the 
heptapeptide in order to have a noticeable effect on microcapsule retention. In normal 
practice, large polymers are used to coat the surface of microcapsules. In the presence of 
an ionic solution e.g. NaCl, the large size of high molecular weight polymers contribute 
to a thicker, denser layer. It is likely that the underlying robust polyglutamic acid layer 
was in fact interacting with the collagen type IV. Unfortunately the production of custom 
made high molecular weight polypeptides is very costly and due to lack of funding and 
not enough scientific evidence to justify such purchase, this idea was terminated. 
On reflection, 2 major requirements were necessary for a ligand to be a viable candidate 
in the proposed polyelectrolyte microcapsule system: 
- The ligand must have a high molecular weight (>10kDa) in order for sufficient 
coating of microcapsules 
- The ligand must be easily attached to the surface of microcapsules e.g. could have 
an electrostatic charge. 
-  
In addition to collagen type IV, the basement membrane contains proteoglycans such as 
perlecan which is high in heparan sulfate, a glycosaminoglycan. These biomolecules bind 
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in-vivo as depicted in Figure 19. Furthermore, research has also shown that they also bind 
in-vitro. Unfortunately, this proteoglycan is extremely expensive. Instead, the use of a 
cheaper alternative, namely heparin, was investigated. Heparin is very similar to heparan 
sulfate. The glycosaminoglycan features similar disaccharide units to heparan sulfate. 
Due to these similarities, heparin also possesses the ability to bind to collagen type IV, as 
shown in previous studies (Koliakos et al., 1989). It is believed to bind to three major 
sites, the site with the highest affinity being the NC1 domain. Other biopolymers capable 
of binding to this site include chondroitin sulfate and dermatan sulfate. These 
glycosaminoglycans do not possess the ability to bind to the other two heparin binding 
sites which are located 100nm and 300nm from the NC1 domain. For this reason, heparin 
would be the most ideal polymer to use in a type IV collagen binding study. Another 
advantage of using heparin as a ligand is that it is extremely negatively charged. This will 
easily allow it to attract to a positively charged polyelectrolyte used in microcapsules, 
thus satisfying the 2
nd
 criterion. Furthermore, heparin has a large molecular weight 
(>12kDa), therefore it should adequately coat the surface of the capsule membrane.  
 
4.5 Heparin study 
Since the main aim of this study was to develop microcapsules which have the ability to 
bind to collagen type IV, the biodegradable polymers were substituted for cheaper, more 
traditional synthetic polymers (PAH/PSS) in the layer by layer process. 2 samples of 8 
layer microcapsules were manufactured. One sample was terminated with heparin by 
suspending 7 layer microcapsules (PAH terminated) in a 2mg/ml heparin solution. As a 
control, the other sample was terminated with the negatively charged PSS 
polyelectrolyte. All samples were labelled with tetramethylrhodamine isothiocyanate 
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(TRITC) by incorporating a singleTRITC-labelled PAH layer within the layer-by-layer 
assembly (layer 3). 300μl of each sample was introduced to 2 wells on a collagen type IV 
8 well slide and left for 48 hrs. This would allow the capsules to sink to the bottom and 
contact the collagen type IV. 
 
Results:- 
 
Figure 41. Confocal images of heparin-terminated microcapsules labelled with TRITC on 
collagen type IV glass slide before and after washing (Scale bar: 50 μm). 
 
 
Clearly after 3 wash cycles, the majority of capsules were washed away, indicating that 
the manufactured microcapsules do not bind to collagen type IV. This did not bode well 
with previous studies that claim that heparin does indeed bind with type IV collagen 
(Koliakos et al., 1989). An explanation for this negative result could be that the size of 
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the heparin isn’t large enough to create a thick substantial heparin layer. This led to 
research into creating a denser layer by applying the concept of heat-shrinking. 
 
Heat shrinking 
Microcapsules fabricated by specific polymers have been shown to undergo an 
irreversible shrinking process upon heat treatment. Studies have proved that the density 
of the materials used doesn’t reduce therefore suggesting that material has not been lost 
during the annealing process. It has been proposed that the increase in temperature causes 
the ionic bonds to temporarily break. This softens the capsule shell which allows for the 
reformation of the polyelectrolyte layers into a more preferred structure (Song et al., 
2009a). The polymers assume a more uniformly coiled structure due to this formation 
possessing a higher entropy. The ionic bonds are reformed once the structural changes 
are made, as shown in Figure 42. 
 
 
Figure 42. Schematic showing the structural changes of PAH/PSS microcapsules upon 
annealing. Adapted from (Leporatti et al., 2001). 
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Microcapsules have been reported to shrink by up to 30%. It has also been reported that 
microcapsules terminated with a negative polyelectrolyte tend to shrink less than those 
terminated with a positive polyelectrolyte. Although the microcapsules under 
investigation in this study are terminated with a negative polymer, the annealing process 
was trialled in order to create a thicker outer coating. After fabricating microcapsules in 
the same way as previously described, they were placed in a dryer at 70°C for 2 hours. 
After this period, SEM images were taken, as shown in Figure 43. 
 
 
Figure 43. SEM images taken before (left) and after (right) heat-shrinking treatment with 
diameters displayed. Diameter range before shrinkage: 5.35 – 6.66 μm. Diameter range 
after shrinkage: 3.33 – 4.41 μm. 
 
After heat-shrinking treatment, the microcapsules shrunk by an average of 35.5% by 
diameter. This was not as significant as predicted. Nevertheless, these microcapsules 
were introduced to a collagen type IV well slide and left for 48 hours. As a control PSS 
terminated microcapsules were subjected to the same annealing process and placed in an 
identical collagen type IV well slide at an identical microcapsule concentration (10
6
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capsules/ml). After 48 hours, both slides were visualised using a fluorescent microscope, 
washed three times, then visualised again to quantify microcapsule retention. The results, 
as seen below, differ vastly from the untreated microcapsules. 
 
 
Figure 44. PSS terminated capsules (left) and heparin terminated capsules (right) on 
collagen type IV slide after 3 washing cycles. 
 
The notion that PSS is a relatively strong polyanion, leads one to believe that the 
interaction between heparin (a strong polyanion) and type IV collagen cannot be based 
purely on electrostatic attraction since the PSS terminated microcapsules did not adhere 
to the collagen type IV. Indeed, type IV collagen is weakly positive at a neutral pH. This 
evidence proves that there is indeed a more specific interaction between heparin and type 
IV collagen. Literature suggests that heparin-collagen type IV interactions are at least 
partially dependent on electrostatic attraction (Tsilibary et al., 1988). The result shown in 
Figure 44 appear to be in agreement with the literature since the fluorescent 
microphotographs  clearly show that annealed heparin-functionalised microcapsules have 
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the ability to adhere to type IV collagen. Unfortunately, this experimental procedure was 
repeated 5 times and all other occasions revealed negligible binding of heparin-
terminated microcapsules.  
 
4.6 Cell culture study 
In order to verify that the heparin-terminated microcapsules do not bind to intact 
endothelium, a simple in-vitro study was conducted involving human umbilical vein 
endothelial cells (HUVECs). It is important to mention that the capsules were not 
synthesised under sterile conditions and were therefore sterilised prior to introducing 
them to the cells. UV sterilisation was used as oppose to autolclave sterilisation since the 
high temperatures involved in the autoclave process would most likely denature the 
microcapsules. Microcapsules were exposed to the ultraviolet light for 1hr. To determine 
whether UV irradiation had an effect on the adsorption of microcapsules, untreated 
microcapsules were introduced to cell cultures. These capsules were fabricated under 
sterile conditions under the cell culture hood. Microcapsules with the following structure 
were synthesised: 
[PAH/PSS]3[PAH/Heparin] 
[PDADMAC/PSS]3[PDADMAC/Heparin] 
Polydiallyldimethylammonium chloride is a strong cationic polymer. It was selected to 
determine whether a stronger polyelectrolyte would lead to a denser terminal layer of 
heparin and ultimately a higher retention of capsules on collagen type IV. 
 The cells were cultured on a 40 mm petri dish (10% Fetal bovine serum, 90% cell 
culture medium). When fully confluent, 100µL of heparin terminated microcapsule 
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suspension was added to the cell culture. The capsules and cells were incubated for 24 
hours to allow the microcapsules to sink to the bottom of the petri dish and allow them to 
contact the cells. After 24 hours, images were taken using an optical microscope. The 
cells were washed three times with phosphate buffered saline solution to remove the 
capsules. Images were taken after this was done to see if the capsules were successfully 
washed away. To determine the biocompatibility, capsules and cells were incubated for 3 
days. For control purposes, the following microcapsules were fabricated: 
[PSS/PAH]4 
[PSS/PDADMAC]4 
 
Results 
 
Figure 45. (PAH/PSS)3-PAH/Heparin microcapsules on HUVECs before (left) and after 
(right) washing. 
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Figure 46. (PDADMAC/PSS)3-PDADMAC/Hep microcapsules on HUVECs (UV treated) 
before (left) and after (right) washing. 
 
Figure 47. (PDADMAC/PSS)3-PDADMAC/Hep microcapsules on HUVECs (no UV)  
before (left) and after (right) washing. 
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Figure 48. The effect of the terminal layer on microcapsule retention on collagen type IV 
substrates. Microcapsules were counted after washing sample three times. Heparin 
terminated capsules were fabricated with 3 PDADMAC/PSS bilayers (n=5). 
 
 
Figure 49. The effect of the terminal layer on microcapsule retention on a confluent 
HUVEC cell culture. Microcapsules were counted after washing sample three times. . 
Heparin terminated capsules were fabricated with 3 PDADMAC/PSS bilayers (n=5). 
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4.7 Discussion 
 
After 3 days of incubation with a complete monolayer of capsules, the endothelial cells 
remained viable and an endothelial monolayer was maintained. It is clear that for all 
samples, non-specific adhesion was noticed after washing. This was only apparent on a 
fraction of cells within each culture. The attraction was more noticeable in the capsules 
fabricated from PAH and PDADMAC which showed capsule retentions of 64.2% and 
75.2%, respectively. This was expected since both of these polyelectrolytes are positively 
charge, resulting in electrostatic attraction to the anionic cell surface. The degree of 
retention is consistent with the strengths of  PDADMAC and PAH (Smith et al., 2004). 
Furthermore, heparin-terminated microcapsules were also retained on HUVECs, albeit at 
lower levels. This is particularly undesirable since ideally the capsules should refrain 
from binding to cells and specifically bind to the basement membrane, represented by 
collagen type IV in these experiments. Figure 48 and Figure 49 clearly show that there is 
no significant difference between results measured for UV-treated and untreated samples, 
indicating that the capsules are not sensitive to ultraviolet light. Moreover, the cells 
survived the 24 hour incubation period with unsterilised microcapsules, with no sign of 
elevated levels of cell death. 
 
Type IV collagen binding studies were performed using these modified microcapsules. 
Ideally, the incorporation of a stronger polycation should serve to improve the integrity 
of the layer-by-layer formation, thus resulting in a more substantial terminal layer. The 
respective micrographs reveal that the microcapsules terminated with heparin on collagen 
type IV substrates appear to have in fact lost their adhesive properties, with a mean 
retention of 6.1% compared with 17.1% and 13% capsule retention for PAH and 
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PDADMAC, respectively. This leads one to believe that the heparin layer is not the main 
contributor to collagen type IV adhesion, and that the PAH polymer played a significant 
role in this adhesion. A reason for this lack of adhesion could be that the molecular 
weight of the heparin (unknown) could be too low. Moreover, cell culture grade heparin 
was not used, rendering the sample used impure. This could also have an effect on layer 
integrity.  
 
4.8 Conclusion 
Despite many attempts of functionalising microcapsules with ligands that recognise 
collagen type IV, a suitable candidate for exclusive binding to the basement membrane 
protein has not been determined. One of the major limitations of all experiments carried 
out in this chapter is the presence of unspecific binding. Without its suppression, 
exclusive binding simply cannot be achieved. A more intricate solution must be found 
which allows specific binding to collagen type IV surfaces whilst simultaneously 
supressing unwanted non-specific binding. 
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5. Exclusive binding of polyelectrolyte 
microcapsules to streptavidin 
 
5.1 Introduction 
Targeted drug delivery is a term used to describe the specific localisation of drugs to the 
site of where the drug is required. By achieving targeted drug delivery, one can increase 
the efficacy of the drug as well as reduce various unwanted side effects which may be 
attributed to the drug acting on normal unaffected areas of the body.  With respect to 
microcapsules, targeted drug delivery research is scarce, largely due to the fact that the 
polyelectrolyte multi-layer shell outer surface is difficult to modify in such a way that 
provides specific binding to a particular surface. Furthermore, polyelectrolyte 
microcapsules typically adsorb to protein surfaces via non-specific adsorption due to the 
presence of charged polymers (Kayitmazer et al., 2013). This is evident when using the 
well-established PAH/PSS polymer conformation (Heuberger et al., 2005b). 
Polyelectrolyte microcapsules are therefore inherently incapable of achieving specific 
adsorption without some form of surface modification. 
 
Thus far, this thesis has only focused on ways of targeting a particular protein and has not 
addressed the problem of unspecific binding. This chapter aims to initiate the exploration 
into the use of polyelectrolyte microcapsules in targeted drug delivery of specific protein 
substrates. In order to achieve specific adsorption, the microcapsules must refrain from 
adsorbing to all surfaces, other than the target surface. The work conducted in section 4.2 
has effectively demonstrated the non-fouling properties of Polyethylene glycol in terms 
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of cell resistance. This PEGylation procedure is clearly an efficient way of “shielding” 
the electrostatic effects of the polyelectrolytes. There are a number of biomolecules that 
have a high and specific affinity to various proteins e.g. antibodies and cadherins. One 
such specific interaction, is the well-established affinity of the vitamin, biotin, and 
streptavidin, a protein produced by Streptomyces avidinii. This chapter aims to produce 
biotin-functionalised microcapsules which have a highly specific affinity to streptavidin 
substrates, purely to highlight the ability to specifically target proteins with 
microcapsules. The performance of these microcapsules will be assessed by assaying 
them against 3 control proteins: collagen type IV, fibronectin and bovine serum albumin. 
 
5.1.1 Literature review on targeted drug delivery 
The incentive for studying and developing targeted drug delivery systems is twofold. 
Firstly, by localising the treatment to the site where it is required, the efficacy of the 
therapy is largely increased as a result of a higher concentration of drug at the diseased 
site. Secondly, by administering a drug at the site of the disease and retaining it within 
the confinements of the diseased area, one can circumvent the side effects associated 
with the oral/systemic route. Ultimately this improves the therapeutic index of a drug, 
which is defined as the ratio of the lethal/toxic dose divided by the therapeutic dose 
(Junutula et al., 2008).  
 
Normal drug delivery modes consist of administration via a number of pathways 
including: oral, intravenous injection, absorption through skin and inhalation. These 
traditional modes of drug delivery are not specialised for targeting diseased areas. 
Indeed, skin adsorption is an effective way of delivering drugs to the skin, however, 
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where internal diseases are concerned; this is not a viable means of drug delivery. 
Smarter drug delivery systems have subsequently been introduced into healthcare 
services worldwide. The current methods of targeted drug delivery are henceforth 
reviewed. 
 
Nanosponges 
Nanosponges are nano-sized drug carriers that are manufactured from oligomers. These 
porous structures have been used in cancer therapy and have successfully been shown to 
reduce tumour growth. Their three-dimensional scaffold-like structure gives rise to a high 
degree of porosity which, in turn, results in a high loading capacity, increasing the overall 
efficacy of drug delivery. Nanosponges are non-membrane bound with an entirely open 
structure, hence substances are freely able to move from the interior to the local 
environment and vice versa, according to the concentration gradient. Their pore size 
range from 2 to 8 nm (Farrell et al., 2008) which is significantly smaller than the pore 
size of a typical calcium carbonate microparticle (30 – 50 nm) (Sukhorukov et al., 2004) 
hence they are less efficiently loaded than their calcium carbonate counterpart. This small 
pore size also equips them with self-sterilising properties since bacteria are too large to 
diffuse through the pores (Patel and Oswal, 2012). These structures are fabricated from a 
polymer backbone e.g. polystyrene, cyclodextrin and ethyl cellulose, which is then cross-
linked by introducing the backbone to cross-linkers such as glutaraldehyde and 
dichloromethane (Yadav and Panchory, 2013).  
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Figure 50. Molecular structure of cyclodextrin-based nanosponges (Panel A). Adapted from 
(Shringirishi et al.) Panel B is an illustration of a functionalised nanosponge interacting 
with a human breast cancer cell. Adapted from (Yadav and Panchory, 2013) 
 
Nanosponges have been shown to successfully target and treat site-specific diseases, by 
functionalising the surfaces with targeting ligands, however, the modifications to 
overcome the limitations of the nanosponge system are extensively complicated. For 
instance, cyclodextrin-based nanosponges are inherently unable to form complexes with 
hydrophilic and large molecular weight species and must be chemically modified in order 
to circumvent this limitation (Trotta et al., 2012). One major limitation of the nanosponge 
system is the inability to retain larger molecular weight species e.g. the use of TIMPs for 
control of MMP activity in diseased tissue. In contrast, as previously explained, 
microcapsules are well-suited for carrying protein-sized molecules. 
 
Liposomes 
These vesicles are fabricated from a phospholipid bilayer, hence are therefore 
biodegradable, biocompatible and will not provoke an immune response i.e. they are non-
immunogenic. They can be as small as 10 nm and can hence pass through the blood-
tissue barrier (Manish and Vimukta, 2011). Their ability to transport both hydrophobic 
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and hydrophilic drugs highlights their versatility as drug vehicles (Medina et al., 2004). 
With respect to cell delivery, it is important that the liposomes are positively charged so 
it can interact with the negative cell membrane as well as negatively charged 
proteoglycans expressed on the surface of the cell. This, in turn, facilitates cell uptake 
(Wiethoff et al., 2001). By contrast, positively charged liposomes have been shown to be 
cytotoxic to cells (Lv et al., 2006).  In order to achieve targeted drug delivery, liposomes 
can be targeted with ligands including: surface proteins, peptides (Juliano et al., 2009), 
antibodies  and lectins, as shown in Figure 51 (Kelly et al., 2011). 
 
Figure 51. Schematic diagram showing the potential targeting ligands for liposome 
functionalisation Adapted from (Kelly et al., 2011). 
 
It is important to realise that although liposomes have the ability to adsorb 
immunoglobulins, hence giving them apparent specific binding properties, they also 
adsorb other serum proteins in-vivo (Patel, 1991). This renders them useless since non-
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specific adsorptions are inherently expected as a result. Furthermore, liposomes are 
impractical where controlled release is desired. These vesicles cannot be manipulated as 
easily as polyelectrolyte microcapsules to develop desired release profiles, as shown in 
chapter 2 and 3 (Barenholz, 2001). In addition, liposomes are quickly up-taken by a 
system of cells known as the reticular-endothelial system (RES). If the target for the drug 
was an extra-RES tissue, the drug is unlikely to reach its designated area as a result of 
adsorption into RES cells (Gabizon, 2001).  
 
5.1.2 Biotinylation 
 
The biotin-avidin and biotin-streptavidin complexes are widely used and well-
characterised biochemical interactions. The bonds between these structures are extremely 
strong. The binding affinities (Ka) of avidin and streptavidin to biotin have been reported 
to be as high as 10
15
 M
-1
 and 10
13
 M
-1
 respectively. In comparison, a typical protein 
ligand interaction has an affinity of 10
2
-10
4
 Ka (Boughton and Simpson, 1984). 
Furthermore, the complex is stable even under acidic and basic conditions (Boughton and 
Simpson, 1982).  Through the use of specially derived reagents, biotin is also able to 
chemically conjugate to protein, allowing proteins, such as antibodies to be 
functionalised and adsorbed to surfaces coated with streptavidin/avidin.  Biotin’s high 
affinity to both avidin and streptavidin is a direct result of their chemical architecture.  
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Biotin 
 
Figure 52. Structure of Biotin. Adapted from Patent number WO2000072802 A2(2000). 
 
Biotin, also known as coenzyme R, is a B-vitamin which is based on a cyclic urea 
structure (Boughton et al., 1984). One of the important features of biotin is that each of 
the amino groups have carbon atoms which carry a hydrogen atom each, allowing 
hydrogen bonds to be formed with other structures.  
 
Avidin, a protein isolated from egg white is composed of 4 amino acid chains made from 
approximately 128 residues each (Sochynsky et al., 1980). It is extremely thermo-stable 
with a protein-unfolding melting temperature (Tm) of 85°C. This is increased up to 
132°C when bound to biotin (Prescott et al., 1999). Within each chain, there is a ‘pocket’ 
which allows biotin to bind to the protein effectively providing 4 biotin-binding sites, as 
shown in Figure 53. This is known as the biotin-binding site. 
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Figure 53. Ribbon structure of avidin with 4 bound biotin molecules.Adapted from 
(Tetramer of Avidin Binding the Biotin Ligands, 2011). 
 
Streptavidin 
Streptavidin is a protein isolated from the bacterium Streptomyces avidinii. Similar to 
avidin, streptavidin is composed of 4 identical amino acid chains. Each chain is 159 
residues long (Aslan et al., 2007). Similarly to avidin, it has the ability to bind to 4 biotin 
molecules. These binding motifs strongly resemble the motifs found in avidin. The 
twisted barrels formed by the peptide chains are open-ended. This is where the binding of 
biotin occurs. Once bound to streptavidin, a surface loop folds over the binding site to 
effectively lock the biotin in place. This gives rise to a very low dissociation between the 
2 structures (Green, 1990).  
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Figure 54. Ribbon structure of Streptavidin-biotin complex. Adapted from (Christov and 
Karabencheva-Christova, 2012). 
 
Both proteins bind to biotin via a biotin-binding site, which has a size of 293 Å
3
. This is 
complementary to the volume of biotin (242Å
3
), allowing for a tight fit. Deep within the 
pocket resides a group of potential donors and acceptor residues including Serine, 
Threonine, Tyrosine and Asparagine, which are able to form hydrogen bonds with the 
hydrogen atoms on the polar ring of biotin. The presence of aromatic residues gives rise 
to a ‘hydrophobic box’, which aids biotin-binding. The combination of these parameters 
results in one of the strongest non-covalent bonds in the realm of biochemistry. 
Streptavidin has a slightly lower affinity to biotin than avidin, due to one less aromatic 
residue at the biotin-binding site. Furthermore, the hydrogen bonding between the 
carboxylic acid group of the pentanoic acid moiety of biotin is weaker in streptavidin 
since each oxygen is only able to form one bond with a hydrogen. Comparatively, 5 
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bonds are formed in avidin (Lindman et al., 2006). Nevertheless, the biotin-streptavidin 
complex is still an extremely strong interaction, rendering streptavidin a viable protein to 
adsorb biotinylated antibody. The control proteins must also be reviewed in order to 
justify why they were chosen. A variety of proteins were chosen, each with unique 
structural properties to prove that the binding to the target protein was specific. Their 
structures and functions are highlighted below. 
 
5.2 Target proteins 
 
5.2.1 Fibronectin 
Fibronectin is a glycoprotein which is naturally found within the extracellular matrix. It 
is comprised of 2 quasi-identical domains, each of 220 kDa in molecular weight, giving 
rise to a combined molecular weight of 440 kDa. These domains are linked together by a 
pair of disulfide bridges located near the end of the C-terminal on both domains 
(Johansson et al., 1997). This protein is multifunctional in nature, playing important roles 
in migration, differentiation, cell adhesion and wound healing. With an acidic isoelectric 
point of between 5.6 and 6.1, fibronectin possesses a net negative charge at a neutral pH 
(Boughton et al. 1984). This will therefore be an ideal protein to determine whether the 
microcapsules will adhere to negatively charged proteins, perhaps due to exposed poly-
L-arginine polymer on the surface of the capsules.  
 
5.2.2 Collagen type IV 
The structure and function of collagen type IV has been described in detail in section 
4.1.2. With a basic isolelectric point of 9.28, it is the only positively charged protein used 
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in this study. This will allow one to determine whether the PLL-PEG-Biotin is effectively 
shielding electrostatic interactions between positive surfaces and the intrinsic dextran 
sulfate component of the capsules. Furthermore, the beta pleated sheet structure is 
different to the globular structure of the other control proteins used.  
 
5.2.3 Bovine serum albumin  
Bovine serum albumin (BSA) is a commonly used and ready available serum protein. An 
important characteristic of this protein is net negative charge at a neutral pH due to the 
acidic isoelectric point of 4.7 (Ge et al., 1998). Furthermore, it would be interesting to 
investigate the adsorption properties of the microcapsules with a non-human born 
protein. 
 
5.3 Materials 
Biodegradable microcapsules (see section 3.2 for individual materials). Fluorescein 
isothiocyanate-labelled Poly-L-lysine (cat. no. P3069), Collagen from human placenta 
(Bornstein and Traub type IV) (cat. no. C5533), Bovine serum albumin (cat. no. A2153),  
Fibronectin from human plasma (F2006) and Streptavidin (cat. no. S4762) was purchased 
from Sigma Aldrich Co. Poly-L-Lysine grafted with polyethylene glycol and 
polyethylene glycol-biotin(50%) (PLL(20 kDa)-PEG(2 kDa)/PEG-biotin (50%) (3.4 
kDa)) and PLL-PEG (PLL(20 kDa) grafted with PEG(2 kDa))  was purchased from 
SuSoS AG.  
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5.4 Method 
 
5.4.1 Microcapsule Preparation 
Microcapsules were made using the previously described layer-by-layer technique. 
Briefly, dextran sulfate and Poly(L-arginine) layers were sequentially deposited on 
calcium carbonate templates until 3 bilayers were completed. At a later stage, the amount 
of adsorbed microcapsules on specific substrates would need to be quantified. For this 
reason, the 4
th
 layer (i.e. the second Poly(L-arginine) layer was replaced with Fluorescein 
isothiocyanate-labelled Poly(L-lysine) (PLL-FITC), a fluorescein-labelled cationic 
polypeptide, in order to allow fluorescent visualisation of the capsules. All polymers 
were dissolved in deionised water at 1 mg/ml and the incubation time per layer was at 
least 15 minutes in order to allow sufficient time for a coherent layer to be established. 
The resultant architecture of the produced microcapsules can be seen below: 
[DexS/Parg][DexS/PLL-FITC][DexS] 
 
 These biodegradable polymers were chosen since they are often associated with weaker 
electrostatic charges when compared with synthetic polymers such as PAH and PSS. This 
is an essential attribute to have when unspecific adsorptions must be suppressed as much 
as possible. Once the final, dextran sulfate layer was added, the capsules were deemed 
ready for PEGylation. PLL-PEG-Biotin, purchased from SuSoS AG, was reconstituted in 
PBS. This particular chemical is similar to the PLL-PEG previously described in section 
4.2, however 50% of the PEG branches have been functionalised with biotin. The 
capsules were incubated in a 1mg/ml solution of PLL-PEG-Biotin for an hour to allow 
the cationic PLL backbone to electrostatically bind to the anionic dextran sulfate surface 
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of the cores. The cores were subsequently washed to remove any unbound complexes. 
Following this step, the entire surface was PEGylated with approximately 50% of the 
surface functionalised with biotin. Hence, in theory, this process should lead to the 
suppression of unwanted non-specific adsorptions as well as the functionalisation of the 
surface to specifically target streptavidin.  Finally, the cores were dissolved using a 0.2M 
EDTA solution, using the dissolution protocol as described in section 2.3. A control 
sample, using non-functionalised PEG as the terminal layer of the microcapsules were 
prepared to demonstrate the non-fouling properties of PEG with reference to protein 
surfaces.  The microcapsules were counted in a similar fashion as described in chapter 3, 
using a haemocytometer. The microcapsule concentrations of each suspension were 
equalised by dilution to avoid the occurrence of biased data. 4 proteins were used in the 
assay to determine the affinity of the capsules to various proteins. These included the 
target protein, Streptavidin, and 3 control proteins: BSA, fibronectin and collagen type 
IV.   
 
5.4.2 Protein substrate preparation 
The protein surfaces were prepared by simple adsorption onto a planar surface. Circular 
coverslips (diameter: 18 mm) were chosen as the material to be coated. The justification 
for this choice is twofold. Firstly, the coverslips are manufactured from silica glass, a 
material that has been proven to bind to proteins very effectively via non-specific 
adsorption (Kalasin and Santore, 2009). Secondly, these coverslips fit adequately within 
the wells of a 24 well plate, which can be used as incubation chambers. Briefly, 40 μg/ml 
protein solutions were prepared by dissolving the right amount of protein in PBS. This 
concentration was determined in accordance with previous protein adsorption studies, in 
order to produce a complete monolayer on the surface (Gautrot et al., 2010). After 
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placing a coverslip in each well on the 24 well plate, 200 μl of each protein solution was 
placed into the separate wells, ensuring that the entire surface was coated. Each protein 
was deposited on 2 wells to allow affinity assays to be conducted using both PEGylated 
capsules and biotin-functionalised PEGylated capsules. After incubation at room 
temperature for 1 hour, the wells were pipette-washed 3 times with PBS, ensuring that 
the surface was kept wet at all times. This was done to maintain the integrity and 
structure of the proteins and prevent crystallisation.  
 
5.4.3 Microcapsule adsorption assay 
200 μL of microcapsule suspensions were placed in each well, as shown below in Figure 
55. This diagram clearly shows all of the experimental samples that were tested, 
including the control microcapsules and the control protein substrates. 
 
Figure 55. Schematic diagram showing the distribution of the samples in the 24-well plate. 
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The suspensions were left in the wells for 1 hour to allow the capsules within the 
suspension to sink and contact the protein substrates at the base of each well. Incubations 
were performed at room temperature. After incubation, the microcapsules were washed 
using a dilution/washing technique. This involved 3 dilution steps, where the 
microcapsule suspensions were diluted followed by the removal of approximately 50% of 
the diluted suspension, as described in a previous study (Gautrot et al., 2010). This was 
performed in order to prevent surface of the coverslip from drying out, leading to 
unspecific binding of the capsules as they dry onto the protein surface. After 3 dilutions, 
3 washes were performed, removing all solutions after each cycle. The coverslips were 
then carefully removed using tweezers to ensure that the centre of the coverslips were 
untouched. They were then mounted face down onto a glass slide with mounting 
medium.  
 
5.4.4 Epifluorescence microscopy analysis 
The mounted coverslips were analysed using a Leica DMI4000B epifluorescence 
microscope, coupled to a Leica DFC300FX digital colour camera. The excitation 
wavelength of the FITC used is 488 nm, hence a blue filter was applied to the excitation 
beam. The intensity of the mercury lamp used was kept constant at 50% throughout all 
measurements. The micrographs acquired were then processed using an intensity 
calculator tool available from the open-source software, Image J. Briefly, each image was 
loaded into the software and the entire surface was selected and measured. The software 
was used to count each microcapsule that had remained adsorbed to the protein substrate 
after washing. This would provide an indication of the affinity of the microcapsules for 
that specific surface. 
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5.5 Results 
After analysis of each sample, it became apparent that the edges of all samples were 
laden with microcapsules. Evidently, the microcapsules were not being washed 
effectively around the edges. For this reason, analysis was restricted to the centre of the 
coverslips.  
 
5.5.1 Micrographs 
The following images are examples of the micrographs obtained from different samples. 
On all occasions, where present, the microcapsules were clearly visible. They fluoresced 
green, in accordance with the emission wavelength of FITC (519 nm).  
 
Figure 56. Images showing the adsorption of PEG-biotin terminated capsules (Panel A) and 
PEGylated microcapsules (Panel B) on Streptavidin coated coverslips. 
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Figure 57. Images showing the adsorption of PEG-biotin terminated capsules (Panel A) and 
PEGylated microcapsules (Panel B) on collagen type IV coated coverslips. 
 
.  
Figure 58. Images showing the adsorption of PEG-biotin terminated capsules (Panel A) and 
PEGylated microcapsules (Panel B) on fibronectin coated coverslips. 
 
 
Figure 59. Images showing the adsorption of PEG-biotin terminated capsules (Panel A) and 
PEGylated microcapsules (Panel B) on BSA coated coverslips. 
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5.5.2 Adsorption summary 
 
Figure 60. Summary of the effects of PEGylation (cyan) and PEGylation/biotin 
functionalisation (red) of Dextran sulfate/poly-l-arginine microcapsules on adsorption to 
protein substrates. Error bars indicate standard deviation (n = 10). 
 
Results from the adsorption assay indicate that the degree of binding of the PEG-biotin 
functionalised microcapsules was 10 fold greater on the target protein (streptavidin) 
compared to the control proteins. Furthermore, computed t and p values for a one-tailed 
t-test performed on the PEG on streptavidin and PEG-biotin on streptavidin were 8.83 
and 0.000454, respectively. Hence the data is statistically significant at the p = 0.01 
confidence threshold. Furthermore, a long term study has successfully proven that PLL-
PEG-Biotin terminated microcapsules are fully functional 7 days after synthesis, as 
shown by the micrograph depicted in Figure 61. 
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Figure 61. Epifluorescence image showing 366 capsules functionalised with PLL-PEG-
biotin strongly bound to streptavidin. N.B. the capsules in this image were fabricated one 
week prior to this experiment. 
 
5.6 Discussion 
The affinity and specificity of PEGylated and biotin-functionalised microcapsules were 
tested against various proteins including the target protein, streptavidin. The micrographs 
obtained reveal that the PEG-Biotin microcapsules exhibited a high binding affinity 
towards streptavidin substrates, as shown in Figure 56A whereas a lower, in some cases 
negligible binding affinity was noticed on the remaining protein substrates. Furthermore, 
the PEGylated capsules showed insignificant binding towards streptavidin-coated 
coverslip. This statement is supported by a one-tailed t-test between the PEGylated and 
PEG-biotin microcapsules on streptavidin. The computed  p value is lower than 0.05 
(0.00366), hence the difference between the binding of the two groups are statistically 
significant.  It is important to realise that the only difference between these capsules is 
that the control capsules are not functionalised with biotin. Combined, these findings 
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suggest that the non-covalent biotin-streptavidin complex is solely responsible for the 
binding of the microcapsules to the streptavidin.  
 
The quantification method of capsule binding affinity was direct in nature. The capsules 
were simply counted with the aid of software. This should be relatively accurate, 
however, in some cases, the capsules would be found aggregated together on the surface 
of the protein substrate. This was circumvented by approximating the number of capsules 
within the agglomeration by estimating the total area covered. Since all capsule samples 
were relatively monodisperse, this was a sufficient method of estimating the total number 
of capsules within the images.  
 
Upon closer analysis of all washed coverslips, the edges were laden with microcapsules. 
This is undoubtedly not a result of protein adsorption, since most of the middle of these 
substrates were largely empty. This phenomenon has most likely occurred due to the 
washing technique. During aspiration, suspended, unbound capsules would be removed 
by pipette aspiration, however, there is always some residual suspension left in the wells, 
usually confined to the edges. This results in the apparent adsorption of capsules around 
the perimeter of the coverslips. In the interest of validity, these areas were negated from 
the analysis. 
 
Furthermore, the effects of the highly specific interaction between PLL-PEG-biotin 
microcapsules and streptavidin are still exhibited in long term assays. A sample of PLL-
PEG-biotin microcapsules were kept in the fridge for 2 weeks. The results of testing 
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these microcapsules 2 weeks after fabrication, show a high degree of binding to the 
streptavidin substrate (Figure 61). 
 
After washing all control protein samples, it was apparent that some microcapsules 
remained on the surface of these proteins despite PEGylation of all capsules. A possible 
explanation for this non-specific binding to protein surfaces could be the incomplete 
PEGylation of the surface of the microcapsules. Incomplete coverage of the underlying 
dextran sulfate layer could lead to unspecific interactions, as previously discussed. This 
non-specific adsorption may also be the result of incomplete aspiration of the 
suspensions during washing. However, the washing protocol consisted of 3 dilution and 3 
washing cycles, hence the unbound capsules should have been sufficiently removed from 
the surface.  
 
5.7 Conclusion 
A system whereby microcapsules can be functionalised to specifically and exclusively 
bind to a streptavidin substrate has been successfully established. By preventing 
unspecific adsorptions via PEGylation and functionalising the capsules with biotin, the 
ability to produce microcapsules that are able to target a specific protein has been 
achieved. Results show at least a 9-fold increase in capsule retention when in contact 
with streptavidin, compared to control proteins. Furthermore, the capsules remain fully 
functional after 2 weeks, indicating good stability which is required for long-term use 
e.g. long-term therapy. The next step in this research topic would be to add flexibility to 
the system, in order to allow specific binding to a wider variety of target proteins. 
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6. Biofunctionalisation of PEGylated micro-
capsules for exclusive binding to protein 
substrates 
 
6.1 Introduction 
One of the major challenges in modern medicine is the localisation of drugs within the 
body. Many drugs have been developed for chemotherapeutic use, however, they all 
exhibit side effects of varying degrees of severity. This is due to the fact that once a drug 
is injected into the blood stream, it becomes largely ubiquitous within the body, 
potentially affecting normal tissues and causing unwanted side effects. By generating a 
system whereby drugs can be delivered specifically to injury/carcinogenic sites in the 
body, one can significantly reduce side effects of drugs on normal tissues. Furthermore, 
site specific delivery decreases the amount of drug needed for adequate efficacy, which 
also potentially minimises costs incurred to the health service.  
 
The concept of microencapsulation in drug delivery has been extensively studied (De 
Geest et al., 2009a), however, surface functionalisation of microcapsules to achieve site 
specific adsorption has not been fully explored. A number of recent studies have 
investigated the functionalisation of micro/nanoparticles, as the surface of these particles 
are more easily modified and unspecific protein adsorptions are less common (Singh and 
Lillard Jr, 2009, Azarmi et al., 2008, Chan et al., 2010).  In contrast, microcapsules have 
higher loading capacities due to their larger size and hollow interior, which makes them 
126 
 
more suitable as carriers in drug delivery, providing that their functionalised surface 
enables site specific adsorption. 
 
As previously shown in chapters 2 and 3, when biodegradable polymers, e.g. polyamino 
acids and polysaccharides, are used, one can manufacture biodegradable capsules that are 
able to degrade over time, resulting in a controlled release of the encapsulated drug 
(Wang et al., 2007a). . Potential applications of such microcapsules include delivery of 
vascular endothelial growth factor (VEGF) to promote endothelial cell proliferation and 
migration (Wang et al., 2008) and stromal cell-derived factor 1 (SDF-1) to promote 
homing of endothelial progenitor cells to lesions with damaged endothelium. These 
processes occur over a long period of time (months to years) and therefore require a 
sustained release of drugs, which can help to inhibit the progression of these diseases 
(Horlitz et al., 2002, Pastorino et al., 2011). Furthermore, these diseases are site-specific, 
therefore capsules will need to be selectively adsorbed to the regions where endothelial 
denudation has occurred after angioplasty, i.e. where the collagen type IV-rich basement 
membrane has been exposed (Kalluri, 2003). Consequently, the aim of this study is to 
produce microcapsules that have the ability to specifically adsorb to a collagen type IV 
substrate. Additionally, the system devised should be versatile enough to be applicable to 
other diseases that require specific localisation of drugs. 
 
In order to achieve site-specific adsorption, a unique biomolecule that specifically 
recognises certain peptide sequences on the collagen molecule must be tethered to the 
microcapsule. Antibodies successfully fulfil this requirement as they specifically bind to 
the antigen that is present on their target protein. A study has demonstrated that one can 
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adsorb antibodies directly on the surface of PSS-terminated microcapsules via non-
specific protein adsorption (Cortez et al., 2006). However, it is necessary to be aware that 
achieving specific adsorption between the capsules and the target (i.e. through antibody-
antigen interactions) is not sufficient evidence to prove that the capsules have a specific 
affinity to a particular surface. One must also prove that the capsules refrain from 
adsorbing to other biological substrates. The study in question did not investigate 
whether their microcapsule adsorption would be suppressed on other biological surfaces. 
In order to determine whether the use of immunoglobulins would be a viable means of 
achieving specific adsorption of microcapsules, their structure and function should be 
fully understood. 
 
6.1.1 Immunoglobulins 
 
The use of antibodies as a means of achieving substrate-specific adhesion of 
polyelectrolyte microcapsules was investigated. In order to understand how antibodies 
achieve protein-specific adhesion, their structure must be studied. 
Antibodies are large Y-shaped proteins and are often referred to as immunoglobulin 
molecules. Below is a diagram highlighting the major constituents of an immunoglobulin 
molecule. 
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Figure 62. Antibody structure. Adapted from (Janeway, 2001). 
 
Antibodies are made up of 4 major polypeptides which are interconnected via disulphide 
bonds. Two of them are known as light chain due to their low molecular weight of 
approximately 25kDa and their larger counterparts are known as heavy chains with a 
molecular weight of 50kDa. The stems of different antibodies from the same 
immunoglobulin family are almost identical. Conversely, the arms of the y structure are 
variable. Ultimately, this is what gives antibodies their binding specificity. Each arm has 
an identical tip known as the antigen-binding site which interacts and binds with an 
antigen. Therefore one immunoglobulin has the ability to bind to two identical antigen 
molecules (Janeway et al., 2001). Although the forces involved in antibody-antigen 
interactions are weak e.g. van der Waals, ionic and hydrophobic interactions, the 
summation of the large quantity of these interactions gives rise to a relatively strong 
interaction. Furthermore, the hinge region, located between the Fc (constant fragment) 
and Fab (antigen-binding fragment)  region is flexible, giving rise to rotational and lateral 
movement, allowing the antibody to bind to epitopes that are positioned irregularly 
(Ruoslahti, 1996).  
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6.1.2 Polyclonal and monoclonal antibodies 
Antibodies come in two different forms, namely monoclonal and polyclonal antibodies. 
To decide which type is ideal for this purpose one must understand how antibodies are 
synthesised and the difference between the two types. 
 
Antibodies are formed from B lymphocytes (B-cells) in-vivo during an immune response. 
When an organism is injected with protein antigens, B-cells respond by producing 
antibodies at a single epitope of the antigen. An epitope is a specific amino acid sequence 
on the antigen, which binds to antibodies. Once an antibody has been produced, the B-
cell then divides to give multiple B-cells which produce the same antibody. Typically, B-
cells produce many different antibody clones which are able to bind to multiple epitope 
sites on the antigen. This is known as a polyclonal antibody. This type of antibody is 
particularly useful in providing a high binding affinity to the corresponding antigen, 
however, it can result in a lower specificity due to different antigens exhibiting similar 
epitopes (Anand et al., 2010). By contrast, monoclonal antibodies produced using 
hybridoma technology, are monospecific i.e. they will all bind to the same epitope of the 
antigen. Briefly, an antigen is introduced to the host which induces the production of B-
cells which produce a complementary antibody. These B-cells are subsequently isolated 
from the spleen of the organism and fused with myeloma cells via electrofusion (Karsten 
et al., 1985). The so-called hybridoma cell can be easily cloned into identical daughter 
cells, all of which will produce identical monoclonal antibodies. This technique therefore 
produces antibodies which are highly specific to a single antigen; however, should the 
epitope not be available due to the orientation of the antigen, the antibody will fail to 
bind, giving rise to a compromised binding affinity. 
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As demonstrated in the previous chapter, by grafting polyethylene glycol chains onto the 
surface of polyelectrolyte microcapsules, one can reduce the non-specific adsorption 
associated with the polyelectrolytes (Wattendorf et al., 2008, Yang et al., 2012a). The 
protein-resistant properties of PEG have been well characterised in scientific research 
(Heuberger et al., 2005a). This characteristic effectively shields the electrostatic forces 
associated with the polyelectrolyte multilayers, resulting in a significant reduction in 
non-specific protein adsorption. An ideal solution to achieve selective adsorption to 
collagen type IV would be to tether the PEG chains with anti-collagen type IV antibody. 
Furthermore, to improve binding affinity, it is essential to orientate the IgG 
immunoglobulin in a manner that exposes the Fab fragments to facilitate antigen binding.  
 
6.1.3 Interaction with Protein G and Antibodies Literature Review 
Protein G has the ability to specifically bind to IgG with high affinity. More specifically, 
the protein binds predominantly to the Fc region of the IgG molecule. This 
immunoglobulin-binding protein possesses a weak affinity to the Fab region, although 
most of the commercially available protein G has been genetically modified to virtually 
eliminate this affinity. Interactions with this region may affect the activity of the 
antibody, thus reducing its affinity to bind to its respective antigen (Saha et al., 2003). To 
this end, protein G has the ability to both isolate and orientate antibodies on a surface. 
This method of immobilisation is superior to the use of a streptavidin-biotin complex 
where the biotin attached to the antibody has the potential to compromise the activity of 
the antibody (Koutsoukos et al., 1983).  
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Protein G and Protein A are well established immunoglobulin-binding proteins, which, 
when genetically engineered, exclusively bind to the Fc fragment of IgG. Consequently, 
when antibodies are adsorbed to a protein G surface, they are automatically orientated in 
such a way that the Fab fragments are available for antigen binding (Bae et al., 2005). In 
order to understand the binding of Protein G with the Fc fragment, the structure of both 
components must be understood. 
 
Located on the heavy chain, the Fc domain is formed of two constant domains of similar 
length, namely CH
2
 (110 residues) and CH
3
 (106 residues). Protein G is made up of 600 
amino acids. Each molecule of protein G has three identical Fc-binding domains located 
near the C terminus (Ruoslahti, 1996). These chains are made up of 55 amino acids each. 
These residues are arranged in a structure that consists of a four-stranded beta sheet with 
a single alpha helix positioned diagonally across. In theory, by incorporating protein G 
into the microcapsule structure, antibodies should be able to be absorbed and orientated 
uniformly with their epitopes available for antigen-binding. Furthermore, this method 
will selectively filter any stabilising proteins that may be present in the antibody solution, 
as it will only bind immunoglobulins. The end result should be a pure coating of antibody 
on the surface of the microcapsules. 
 
Protein G has been reported to have a higher affinity to the IgG isotype than protein A 
(Saha et al., 2003). For this reason, protein G shall be used in this study.  This 
PEG/antibody assembly will be applied to biodegradable microcapsules, made from 
dextran sulfate and poly-L-arginine, since these polymers are biocompatible and have 
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been previously used to create degradable microcapsules successfully (De Koker et al., 
2010, Santos et al., 2012). 
 
Protein G can be easily grafted to PEG via the use of the biotin/streptavidin or 
biotin/avidin complex, providing that both protein G and PEG are biotinylated. The 
interaction between biotin and streptavidin is believed to be one of the strongest non-
covalent interactions in biology (González et al., 1997). Furthermore, streptavidin has a 
more neutral isoelectric point (5-6) compared to avidin (10.5), rendering the protein less 
susceptible to non-specific adsorptions (Darzynkiewicz et al., 2009, Wilson et al., 2000). 
Since one of the functions of the proposed microcapsules is to reduce non-specific 
protein adsorption, it was decided that the streptavidin/biotin complexation was a reliable 
means of tethering protein G to PEG chains. The biotinylation process allows one to 
functionalise proteins with biotin. This must be performed in order to take advantage of 
the streptavidin/biotin linking mechanism. 
 
6.1.4 Functionalising proteins with biotin - Biotinylation 
Referring back to the structure of biotin, it has a pentanoic acid branch with its 
characteristic carboxylic acid group. This group can be easily derivatised to make 
reagents that can label protein. The so-called Biotinylation of proteins is often achieved 
through the use of NHS ester derivatives. The NHS- biotin derivative provides a good 
leaving group and is therefore easily substituted for an amine group on an 
immunoglobulin molecule. 
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Most commercially available antibodies are shipped in ascites fluid since a higher 
concentration of antibody is found in ascites fluid compared to cell culture supernatant. 
The disadvantage of this is that ascites fluid is comprised of many other proteins. 
Ordinarily this would not be a problem for common experiments such as ELISA and 
other immunoassays, however for biotinylation, this is not ideal since the NHS ester 
group on the biotinylation reagent reacts with any chemical or biomolecule with an 
amine group, giving these proteins potential to bind to the streptavidin surface of the 
microcapsules. Ultimately this will contaminate the surface and may reduce the binding 
affinity of the microcapsules to the collagen type IV antigen. Using this linking 
technique, the study aims to fabricate antibody-functionalised microcapsules for specific 
protein adsorption. Their performance will be tested on a micro-patterned platform. 
 
To further illustrate the specific adsorption of the functionalised microcapsules, micro-
patterned substrates were used. These patterns are relatively easy to synthesise and come 
in a wide range of shapes and sizes, ranging from tens to hundreds of microns across. 
Micro-patterns offer great flexibility in creating defined areas for interrogation. There 
have been a number of reports of microcapsule adsorption onto micro-patterns (Antipina 
et al., 2009, Nolte and Fery, 2004). These studies rely solely on either the physical 
entrapment of microcapsules on embossed patterns or electrostatic interactions between 
microcapsules and patterned polyelectrolytes. 
 
 
Micropatterning of proteins on a planar substrate is achieved through the use of protein 
resistant polymers. In essence, these polymers are printed onto the substrate, creating a 
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negative of the desired micropattern. The substrate, usually glass or ultra-thin gold-
coated glass, is then incubated in a protein solution, allowing the protein to be adsorbed 
onto the unprotected areas, resulting in a micropatterned protein surface (Gautrot et al., 
2010). The most commonly used protein resistant polymer is polyethylene glycol (PEG).  
These micropatterned substates would be excellent candidates for testing the 
biofuctionalised microcapsules since it provide a distinct visual representation of the 
specificity of the microcapsules. 
 
 This study aims to create a micro-patterned protein substrate using a technique involving 
micro-contact printing and controlled atom-transfer radical-polymerisation (ATRP) as 
previously described (Gautrot et al., 2010). The biofunctionalised microcapsules will 
then be introduced to the various protein micro-patterns, whereby retention will be 
quantified using fluorescence microscopy. Zeta potential and surface plasmon resonance 
(SPR) was performed on the layer-by-layer assembly to verify the construction of the 
microcapsules. SEM was performed to monitor the surface morphology of the 
microcapsules. 
 
6.2 Materials 
Materials for microcapsules. Calcium chloride dihydrate (CaCl2.2H2O), sodium 
carbonate (Na2CO3), Ethylenediaminetetraacetic acid disodium salt dihydrate 
(C10H14N2Na2O8.2H2O), dextran sulfate sodium salt (Mol. Wt. ~40kDa), Poly-L-
Arginine Hydrochloride (Mol. Wt. 15-70kDa), Streptavidin (from Streptomyces 
Avidinii), Protein G’ (from Streptococcus Sp), Monoclonal Anti-Collagen Type IV 
antibody (produced in mouse), Monoclonal Anti-Fibronectin antibody (produced in 
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mouse), and Mix-n-Stain™ CF™ 555 Antibody Labeling Kit were purchased from 
Sigma-Aldrich Co. Poly-L-Lysine grafted with polyethylene glycol and polyethylene 
glycol-biotin(50%) (PLL(20 kDa)-PEG(2 kDa)/PEG-biotin (50%) (3.4 kDa)) was 
purchased from SuSoS AG. EZ-Link
TM
. Sulfo-N-Hydroxysulfosuccinimide-6-
aminocaproic acid-6-aminocaproic acid-Biotin (Sulfo-NHS-LC-LC-Biotin) was 
purchased from Thermo Fisher Scientific, Inc. 
  
Materials for Micro-patterning. Collagen from human placenta (Bornstein and Traub 
type IV), Bovine serum albumin (BSA), Fibronectin from human plasma, oligo(ethylene 
glycol methyl ether methacrylate) (OEGMA, mol wt. 300 Da), CuCl, CuBr2, 2,2’-
dipyridyl (bpy) were purchased from Sigma-Aldrich Co. Fibronectin antibody (anti-
human), rabbit polyclonal, was purchased from Abcam . Alexa Fluor® 594 Donkey Anti-
Rabbit IgG (H+L) Antibody was purchased from Invitrogen. Antibodies were used at 
recommended dilutions. ω-Mercaptoundecyl Bromoisobutyrate was synthesised 
according to the literature (Jones et al., 2002). 
 
6.3 Method 
6.3.1 Fabrication of microcapsules 
Microcapsules were fabricated using the LbL technique. Briefly, calcium carbonate cores 
(4-6μm) were formed by mixing equal volumes of 0.33M CaCl2 with 0.33M Na2CO3. 
The mixture was incubated for 5 minutes to allow the formation of the cores. After 
washing with deionised water (18.2 MΩ·cm), dextran sulfate was adsorbed to the surface 
of the cores by immersing them in a 1 mg/ml solution of the polymer dissolved in 
136 
 
deionised water. The sample was incubated on a vortex mixer for 15 minutes, after which 
the cores were washed 3 times by centrifuging at 1,500 rpm and redispersing the capsules 
in fresh deionised water. Layers of oppositely charged polymers were sequentially 
deposited in this manner until 2 [Dex.S/PArg] bilayers were adsorbed to the cores. The 
second polyarginine layer was fluorescently labelled with rhodamine B to allow the 
microcapsules to be detected and quantified. A final dextran sulfate layer was then 
adsorbed. For protein resistance, the polymer-coated cores were immersed in PLL-
PEG/PLL-PEG-biotin solution (100 μg). Cores were subsequently dissolved in 0.2M 
EDTA for 10 minutes and excess calcium ions were washed using fresh EDTA. Finally, 
the capsules were washed 3 times with PBS. 
 
6.3.2 Biofunctionalistion of microcapsules 
A sulfo-NHS derivative of biotin, complete with spacer arm to allow adequate room for a 
streptavidin molecule to bind, was reconstituted in ultrapure Milli-Q water (18.2 
MΩ·cm). Immediately after dissolution, the reagent was added to a protein G solution 
(reconstituted in PBS) and incubated for half an hour. The resulting biotinylated protein 
G was dialysed against a regularly replenished PBS solution for 48hrs to remove any 
unconjugated biotin. Streptavidin (100 μg) was then adsorbed onto the aforementioned 
PLL-PEG/ PLL-PEG-biotin (50%) terminated microcapsules before adsorption of 
biotinylated protein G (100 μg). Finally, 100 μg monoclonal anti-collagen type IV was 
specifically adsorbed to the protein G present on the microcapsules. This resulted in the 
formation of PEGylated microcapsules with approximately 50% of the surface of each 
capsule functionalised with anti-collagen type IV (Figure 63).  
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Figure 63. Reaction scheme for the synthesis of anti-collagen biofunctionalised 
microcapsules. 
 
After washing off excess antibody with PBS solution, the microcapsules were stored in 
PBS at 4˚C. To test the versatility of the model, anti-fibronectin functionalised 
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microcapsules were prepared in a similar fashion. Quantities of polymer/protein required 
for complete adsorption were calculated by using the following estimation.  
Total surface area of microcapsules in one sample is: 
        
where N is the total number of microcapsules per sample, which is approximately 5.0 × 
10
7
 (estimated using haemocytometry) and r is the radius of the microcapsules estimated 
at 3µm. Thus the estimated total surface area is 0.0057 m
2
. Given that 1 m
2
 can be coated 
by approximately 1 mg, 0.0057 mg of polymer is required to coat the surface. Hence the 
mass of 0.1 mg of polymer was assumed to be sufficient. 
 
6.3.3 Micro-patterning of protein 
Preparation of the substrate with gold circular islands surrounded by protein resistant 
poly(oligo(ethylene glycol methyl ether methacrylate)) (POEGMA) brushes was 
achieved using a protocol as described in a previous study (Gautrot et al., 2010). The 
procedure is illustrated in Figure 64. 
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Figure 64. Protocol for micro-patterning of Protein using ATRP. Adapted from (Gautrot et 
el., 2010). 
 
 Briefly, a PDMS stamp to print negatives of the micro-pattern was copiously inked with 
ω-Mercaptoundecyl Bromoisobutyrate initiator. After 10 seconds, excess initiator was 
washed off with ethanol and the stamp was dried under a nitrogen stream. The stamp was 
then gently placed on the gold coated slide to transfer the initiator to the surface. After a 
further 10 seconds, the stamp was removed. Multiple substrates were prepared and 
placed into a glass slide chamber. A POEGMA solution, previously prepared via ATRP, 
was added to the chamber and the slides were left to incubate under a nitrogenous 
environment for 1 hour. During this time, the POEGMA selectively bound to the areas 
coated with ω-Mercaptoundecyl Bromoisobutyrate initiator, resulting in a pattern 
consisting of  400μm circular gold islands surrounded by POEGMA brushes 
approximately 20nm thick. The micro-patterned substrates were thoroughly washed with 
ethanol and dried under a nitrogen stream. The wafer was then cut into 1 cm
2
 chips and 
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placed in wells on a 24-well plate. A collagen type IV protein solution (10 μg/ml) was 
applied to a 1 cm
2
 micro-patterned chip in a 24-well plate and incubated for 1 hour at 
room temperature to allow the protein to bind to the gold islands. Excess collagen was 
diluted and washed off with PBS solution, resulting in a micro-patterned protein surface 
consisting of 400 μm collagen-coated circles. As a control, fibronectin and bovine serum 
albumin were micro-patterned using the same procedure. 
 
6.3.4 Biofunctionalised microcapsule protein adsorption assay 
Equal volumes of biofunctionalised microcapsule suspensions were added to each well 
with the protein-micro-patterned chips and left for 1 hour to allow the capsules to sink 
and make contact with the substrate. After 3 dilution and 3 washing steps with PBS 
solution, microcapsule retention was analysed using epifluorescence microscopy. 
Fluorescence intensity of each island was computed using Image J software and values of 
relative fluorescence measured in arbitrary relative fluorescence units (RFU). The 
fluorescence intensity was corrected by subtracting background readings to give a 
corrected relative fluorescence intensity (RFI) reading using the following equation: 
             ̅̅ ̅̅   
where FI is the total fluorescence intensity within the island, Ai is the area of the island 
and    ̅̅ ̅̅  is the mean background fluorescence calculated from three readings. Control 
(dextran sulfate terminated), anti-collagen IV terminated, and anti-fibronectin terminated 
microcapsules were tested against each of the three protein substrates: collagen type IV, 
fibronectin and bovine serum albumin.  5 islands were randomly chosen for analysis for 
each scenario and the experiment was repeated 5 times for each protein.  T-tests (2 tailed) 
141 
 
were performed on each sample to assess the significance between the experimental and 
each of the control groups (n=25).  
 
6.3.5 Immuno-staining and microscopy 
To prove that protein was successfully being adsorbed onto the patterned gold substrates, 
immuno-staining was conducted on a fibronectin-coated sample. Initially, the fibronectin 
was blocked using a blocking buffer (10% FBS, 0.25% gelatin). Monoclonal anti-
fibronectin, diluted with blocking buffer was then applied to the substrate and left for 1 
hour at room temperature, after which the sample was thoroughly washed. Finally, the 
substrate was incubated in Alexa Fluor® 594 Donkey Anti-Rabbit IgG secondary 
antibody for 1 hour at room temperature. Images were taken after thoroughly washing the 
micro-pattern 3 times using a pipette.  
 
6.3.6 Zeta potential analysis 
Zeta potential is commonly used to monitor the layer-by-layer polymer depositions on 
colloidal particles in order to ensure the successful synthesis of polyelectrolyte 
microcapsules (Peyratout and Dähne, 2004). In order to apply this technique to this 
research, one must fully understand the concept of zeta potential and how it can be 
measured experimentally. 
 
Zeta potential (ζ – potential) is a parameter used to measure the average surface charge of 
colloidal particles suspended in a dispersion medium. It can be defined as the potential 
difference between the static layer of fluid adjacent to the particles and the surrounding 
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medium. Although it cannot be measured directly, it can be experimentally quantified 
using a Zeta Sizer machine, via electrophoresis. Briefly, a sample of the suspension is 
injected into a special cuvette with external electrodes. After loading the cuvette into the 
Zeta Sizer, an electric current is applied across the suspension. Naturally, particles with a 
positive zeta potential will migrate towards the cathode and vice versa. Furthermore, the 
velocity at which the particles travel is proportional to the magnitude of the charge. 
 
This electrokinetic phenomena is measured using a Laser Doppler Anemometer. This 
velocity can then be inserted into an equation that corresponds to the Smoluchowski 
theory: 
         
 
   
       
 
where μ is viscosity of the solution, r is the radius of the colloidal particles,   is the 
Debye-Hückel parameter, ε0 and εr are the relative dielectric constants (Sze et al., 2003). 
 
Zeta potential analysis was performed using a Zetasizer Nano ZS system from Malvern 
Instruments Ltd. Calcium carbonate cores were intact during the measurements. 
Recordings were made after each layer was deposited on the cores. Concentrations of 
polymer/protein used are identical to the concentrations used in the aforementioned 
microcapsule fabrication methodology. All measurements were conducted in deionised 
water. Measurements were performed in triplicate. 
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6.3.7 Surface plasmon resonance (SPR) analysis 
A Surface plasmon resonance (SPR) machine has the ability to detect interactions 
between two different molecules via optical methods. The sensor platform is made up of 
the sensor chip and a conductive material (usually a thin gold film approximately 50nm 
in thickness). Polarised light from an inclined light source hits the base of the chip. An 
electromagnetic component of this light is leaked through the gold chip, into the adjacent 
buffer/sample. This is known as an evanescent wave. At a particular angle of incident 
light, electrons within the gold film become excited by the evanescent wave. This 
stimulation of electrons results in electron charge density waves otherwise known as a 
surface plasmon. As a result of surface plasmon generation, the intensity of the reflective 
light is markedly reduced.  
 
When a mass/substance is deposited on the film, the angle of incident light at which the 
surface plasmon resonance takes place changes. This is due to a change in refractive 
index near the surface of the sensor chip. The detector of an SPR system has the ability to 
monitor these angular displacements, which is measured in resonance units (RU) where 
1RU = 0.0001°= 1pg.mm
-2 
of deposited material. 
 
SPR is hugely advantageous with regard to the accuracy of binding events. Unlike many 
other techniques that measure quantities of adsorbed polymers/chemicals, SPR doesn’t 
require labelling of the analyte. Labelling of analytes can lead to many inaccuracies. For 
example, the labelling yield of the analyte may not be 100% leading to an 
underestimation of the adsorbed mass. Furthermore, the labelling molecules may occupy 
the binding sites of the analyte leading to a lower binding affinity. SPR also enables the 
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user to monitor binding kinetics between a surface and an analyte allowing one to 
determine the binding and dissociation constants, Ka and Kd. SPR would be ideal to use 
for monitoring polymer and protein deposition during the layer-by-layer process and 
ensuring that all layers within the biofunctionalised microcapsule membrane are tethered 
to each other sufficiently. It will also give an indication whether there are regions 
terminated with just PLL-PEG since this is a vital part of the design. It’s estimated that 
approximately 50% of the surface will be coated with only PLL-PEG and the remaining 
50% of the PEG will be biotinylated and functionalised with antibody via streptavidin-
biotin and protein G linkages. 
 
SPR analysis was performed to characterise the last 5 steps of the biofunctionalised 
microcapsule construction, namely, dextran sulfate, PLL-PEG-biotin, streptavidin, 
protein G-biotin and anti-collagen type IV. This was performed to monitor the growth of 
each layer and ensure that each LbL assembly step was performed successfully. 
Measurements were taken using a Biacore X system. Gold coated chips (Ssens) were 
functionalised with cysteamine (5mmol in ethanol) and thoroughly washed after 
incubation for 24 hours. After mounting, the cysteamine chips were docked and primed 
with PBS buffer. A sensogram was performed for 30 minutes at 10 µL/min to equilibrate 
and gain a stable baseline. Once a stable baseline had been achieved, a sensogram was 
performed at 10µL/min using PBS. A 100 µL sample of dextran sulfate (1 mg/ml) was 
injected into the stream at 10 µL/min. After 10 minutes of injection, PBS was re-
introduced to the sensor surface in order to wash off any non-adsorbed polymer. The 
system was left for at least 5 minutes or until a stable baseline was re-established. This 
was repeated for each consecutive layer. A concentration of 1 mg/ml of polymer/protein 
solution was used for each step. The Biacore X system requires the user to inject each 
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sample manually. Occasionally, bubbles would be unintentionally introduced into the 
microfluidic chamber resulting in a concomitant spike in resonance signal. This was 
manually removed during post-processing of the data.   
 
6.3.8 SEM analysis of microcapsules 
SEM analysis was performed using a FEI Inspect-F™ scanning electron microscope. 
Samples were coated in gold and were subsequently analysed using a 10kV electron 
beam (spot size 3.5). SEM images after each significant layer were acquired (outermost 
dextran sulfate, PLL-PEG-biotin, streptavidin, protein G-biotin and anti-collagen type 
IV). 
 
6.4 Results 
6.4.1 Micro-pattern immunostaining 
The fluorescence detected after immunostaining of the patterned fibronectin confirms a 
high fidelity protein pattern. A high fluorescence signal can be seen within the island, 
indicating the presence of fibronectin, whereas no fluorescence is detected on the area 
surrounding the island i.e. the POEGMA brushes, as seen in Figure 65A. The sharp 
increase in the fluorescence intensity profile which is illustrated in Figure 65B taken 
along the centre of the island, further confirms this high contrast in fluorescence between 
the island and the brushes, consistent with the high protein resistance of POEGMA 
brushes (Gautrot et al., 2010). 
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Figure 65. Immunostained fibronectin-coated island (Panel A). Fluorescence intensity 
profile taken from the yellow dotted line (Panel B). 
 
6.4.2 Fluorescent tracking of antibody on modified PEG microcapsules  
Figure 66 shows a collagen type IV island with adsorbed anti-collagen IV functionalised 
microcapsules.  Fluorescence exhibited in this image is produced by CF-555 labelled 
anti-collagen type IV. This strong signal is indicative of successful binding of antibodies 
to the PEG-Streptavidin-Protein G complex. This result also shows that these 
microcapsules are able to be adsorbed onto collagen type IV surfaces. 
 
 
Figure 66. A single collagen type IV-coated island with adsorbed anti-collagen type IV 
functionalised microcapsules. This image was taken after three dilution and three washing 
steps. N.B. Fluorescence in this picture is produced by CF-555 labelled anti-collagen type 
IV. This signal is indicative of successful binding of antibody to the PEG-Streptavidin-
Protein G complex. 
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6.4.3 Surface plasmon resonance analysis 
The polyelectrolytes and proteins were sequentially injected through the microfluidic 
channels for 10 minutes each at 10 µL/min to allow the polyelectrolyte/protein to adsorb 
to the sensor surface.  The channels were then flushed with PBS for at least 5 minutes at 
10 μL/min (indicated as ‘W’ in Figure 67) to wash off excess polymer or protein. The 
next polymer was introduced once a stable baseline was achieved.  
 
As expected, an increase of resonance signal was recorded after each deposition/washing 
cycle. Since the SPR response is related to the mass of adsorbed material, this data 
strongly suggests that the LbL assembly has been successfully created (Liedberg et al., 
1993). A notable feature of the SPR data can be seen at the end of the graph, where the 
adsorbed mass increases by 236 ng/cm
2
 after the deposition and washing of anti-collagen 
type IV. Increase in resonance units (RU) and corresponding mass adsorption for each 
step is shown in Table 1 (1RU = 0.1 ng/cm
2
). 
 
Table 4. SPR signal after each step of the LbL assembly. 
Layer SPR signal increase (RU) Mass density (ng/cm
2
) 
Dextran sulfate 416.6 41 
PLL-PEG-biotin 1559 155 
Streptavidin 463.7 46 
Protein G-Biotin 182.8 18 
Anti-collagen type IV 2363.1 236 
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Values shown represent average signal/mass density recorded after washing excess 
polymer/protein (n=3).  
 
 
Figure 67. SPR analysis of the last 5 layers of the biofunctionalised microcapsule structure. 
‘W’ indicates the end of the injection period and the beginning of washing for each layer. 
 
6.4.4 SEM Analysis 
SEM images reveal a significant level of aggregation once proteins were tethered to the 
microcapsules, as shown in Figure 68 (Panel C-E). The dextran sulfate and PLL-PEG-
biotin terminated microcapsules were more well dispersed as expected (Panel A and B). 
Negligible differences in surface morphology were observed between the different layers 
(Panel F-J) with the final image, depicting the fully constructed bio-functionalised 
microcapsule, showing a slightly increased thickness, as shown in Panel J. 
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Figure 68. SEM images of a single capsule following consecutive LbL deposition: (A) 
outermost dextran sulfate layer, (B) PLL−PEG−biotin, (C), streptavidin, (D) protein G-
biotin, and (E) monoclonal anticollagen type IV. (F−J) Zoomed in images showing single 
microcapsules taken from their respective samples above. 
 
6.4.5 Zeta potential analysis 
As expected, the first 5 layers of oppositely charged polyelectrolytes produced 
alternating zeta potentials, as shown in Figure 69. Values of -20.3mV, -21.9mV and -
26.8mV were measured from the dextran sulfate layers. The zeta potential of the poly-l-
arginine layers were 32.1mV and 39.4mV. As the consecutive layers are deposited, the 
absolute values of the zeta potentials for both anionic and cationic polymers increase, 
suggesting that the layers are becoming progressively more uniform. Introduction of the 
PEGylated layer produced a more neutral reading of -8.06mV. Further protein deposition 
showed minor fluctuations in zeta potential. 
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Figure 69. ζ-potential after each layer deposition. Error bars indicate the standard 
deviation (n = 30). All samples were measured in de-ionised water. Concentrations of 
polymer solutions: dextran sulfate and poly-L-arginine - 1 mg/ml, PLL-PEG-Biotin - 100 
μg/ml, streptavidin – 100 μg/ml, protein G – 100 μg/ml, anti-collagen type IV – 100 μg/ml. 
 
 
6.4.6 Biofunctionalised microcapsule protein adsorption assay 
For control, microcapsules terminated with a dextran sulfate layer were introduced to 3 
types of protein patterns. Results indicate that a high degree of non-specific binding of 
dextran sulfate-terminated microcapsules were present on all protein micro-patterns, as 
shown in Figure 70. The highest level of adsorption was noticed on the collagen type IV 
islands with an average RFI of 1572 RFU per island. Lower values of 232 RFU and 564 
RFU were recorded from BSA and fibronectin islands respectively. When PEGylated and 
biofunctionalised with anti-collagen type IV, the microcapsules show preferential 
adsorption to the target protein, collagen type IV (652 RFU per island) and negligible 
binding to the control proteins (7 and 9 RFU for BSA and fibronectin respectively). 
Similar results can be seen when the microcapsules are functionalised with anti-
fibronectin. Computed p values from the two-tailed t-tests for the anti-collagen type IV 
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functionalised microcapsules were 4.36×10
-16 
and 4.93×10
-16 
for collagen-BSA and 
collagen-fibronectin comparisons, respectively. Computed p values from t-tests 
performed on the anti-fibronectin functionalised microcapsules were 5.74×10
-50
 and 
1.02×10
-50
 for tests between fibronectin and collagen type IV and fibronectin and BSA, 
respectively. 
 
 
Figure 70. Typical images control microcapsules (terminated with dextran sulphate) on 
various protein coated islands: collagen type IV (Panel A), Bovine serum albumin (Panel B), 
fibronectin (Panel C). Images were taken after 3 dilution and three washing steps with PBS 
to remove non -adsorbed microcapsules. Panel D shows the relative fluorescence intensities 
recorded on each protein micropattern (n=25). 
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Figure 71. Typical images of Anti-collagen type IV terminated microcapsules on various 
protein coated islands: collagen type IV (Panel A),Bovine serum albumin (Panel B), 
fibronectin (Panel C). Images were taken after 3 dilution and three washing steps with PBS 
to remove non-adsorbed microcapsules. Panel D shows the relative fluorescence intensities 
recorded on each protein micropattern (n=25). 
 
 
Figure 72. Typical images of Anti-fibronectin terminated microcapsules on various protein 
coated islands: collagen type IV (Panel A), Bovine serum albumin (Panel B), fibronectin 
(Panel C). Images were taken after 3 dilution and three washing steps with PBS to remove 
non-adsorbed microcapsules. Panel D shows the relative fluorescence intensities recorded 
on each protein micropattern (n=25). 
153 
 
6.5 Discussion 
We hypothesise that by functionalising capsules with correctly orientated anti-collagen 
type IV, the capsules should display high binding affinity to collagen type IV surfaces, 
and furthermore, by incorporating a PEG layer on the periphery of the capsules, it should 
supress any form of unspecific binding to other proteins, giving rise to exclusive binding 
to the target protein. This hypothesis was tested in our study by applying these 
biofunctionalised microcapsules to micro-patterned substrates of collagen type IV, 
bovine serum albumin and fibronectin. The fluorescence recorded in Figure 66 illustrates 
the successful binding of CF 555-labelled anti-collagen IV onto the PEGylated/protein 
G-coated microcapsules, which suggests that the streptavidin-biotin complex is a viable 
means of conjugating protein G to the PEGylated surface of the microcapsules.  
 
To complement this, zeta potential analysis was performed on the polymer coated 
calcium carbonate cores after each layer. It was necessary to keep the cores intact during 
analysis since the zeta potential technique is an optical technique which can only measure 
particles in suspension. As expected, the polyanionic and polycationic layers produced 
negative and positive zeta potential values, respectively. The average zeta potential of the 
PLL-PEG-biotin was -8.06mV. According to previously published data, this value should 
be approximately 0mV (Wattendorf et al., 2006, Wattendorf et al., 2008). Furthermore, 
the zeta potential is seldom recorded as a negative value, due to the positively charged 
grafted PLL. A possible reason for this could be the incomplete coverage of the 
underlying dextran sulfate. Regardless, the value is significantly increased from the zeta 
potential of the previous layer of dextran sulfate (-26.8mV), indicating that a significant 
quantity of PEG had been adsorbed to the surface. The remaining protein layers all 
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produced slightly negative zeta potential measurements, consistent with their respective 
isoelectric points (Aslan et al., 2007, Lindman et al., 2006). Collectively, this evidence 
strongly suggests that the layers were successfully tethered.  
 
It is difficult to decipher from the SEM images whether there is a difference in the 
thickness or surface morphology of the microcapsules as the layers are added to the 
surface. Previous studies have shown a significant difference between substrates with 4 
and 8 polyelectrolyte layers (Guo et al., 2009). With this in mind, one would expect to 
see a vast difference between the surface of capsules shown in Figure 68F and J since 
they are comprised of 5 and 9 layers respectively, most of which consist of large proteins. 
However, it is important to realise that in theory, only half of the surface is coated due to 
the surface being functionalised with 50% PEG and 50% PEG-biotin. This may have 
potentially led to the generation of a less coherent membrane. Upon observation, it 
appears that the surface of the microcapsules after the addition of antibody, is slightly 
thicker than the others samples, in particular, the dextran sulfate terminated sample 
Figure 68F, which only comprises of 5 polyelectrolyte layers.   
 
The asymmetric increase in thickness between the first two polymers, as shown by the 
SPR data, is consistent with previous reports for polyelectrolyte mulitlayers (Ghostine et 
al., 2013). The level of streptavidin adsorption to the PLL-PEG-biotin was lower (46 
ng/cm
2
) than expected for monolayers. However, taking into consideration that only 50% 
of the PEG chains are biotinylated, sub-monolayers of streptavidin are expected to form. 
Indeed, previous reports have demonstrated that a densely packed monolayer of 
streptavidin has a much higher mass density of approximately 250 ng/cm
2
 (Trmcic-
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Cvitas et al., 2009).  This result reflects the balance between binding to biotin molecules 
and repulsion from the protein resistant PEG side-chains. Protein G-biotin was adsorbed 
at a density of 18 ng/cm
2
. The ratio of molecular weights between streptavidin and 
Protein G-biotin is 2.44. Hence the level of protein G immobilisation, being 2.5 times 
lower than that measured for streptavidin, implies a binding of one protein G molecule 
per streptavidin molecule, on average. Although streptavidin has 4 binding pockets for 
biotin, the 1:1 binding ratio observed could imply that other binding pockets are saturated 
by other biotin molecules in the PLL-PEG layer, or that the first bound protein G masks 
other binding pockets and prevents subsequent binding. The bound protein G is stably 
immobilised though, indicated by a negligible decrease after 5 min washing with buffer 
(<5 ng/cm
2
).  
 
A remarkable feature of the SPR graph, shown in Figure 67 is the high increase in signal 
corresponding to the anti-collagen type IV step. This large increase of 236 ng/cm
2
 (after 
washing) can be explained by the high molecular weight of this antibody (170 kDa). 
Quartz crystal microbalance/dissipation methods have reported an IgG adsorption of 
approximately 700 ng/cm
2
 for a similar antibody concentration to the one used in the 
present study (Zhou et al., 2004). Hence the adsorption that we report is in line with 
previous studies, the difference perhaps stemming from the sub-monolayer deposition 
that is achieved for protein G using PLL-PEG-biotin.  
 
Micro-patterned substrates were chosen as they provide a surface containing many 
protein-coated islands with distinct boundaries. In addition to offering a clear visual 
representation, it allows many areas to be analysed on one sample, providing an efficient 
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way of collecting the data. All microcapsules were labelled by incorporating a single 
rhodamine B-poly-L-arginine layer within the LbL assembly. This allowed the retention 
to be quantified by measuring the total integrated fluorescence per protein island. 
Measurements were computed using Image J. This method provides an efficient way to 
calculate the microcapsule retention with sufficient accuracy.   
 
To test the versatility of this model, anti-fibronectin was also tethered to the PEGylated 
microcapsules in a similar fashion. Analysis of the binding assay between the 
microcapsules functionalised with anti-collagen type IV and the collagen type IV protein 
pattern indicates that on all occasions, strong binding was present (Figure 71).  More 
interestingly, these capsules refrain from adsorbing to the other proteins, suggesting that 
unspecific adsorption is supressed. All p values computed from the t-tests between the 
control and experimental groups of both types of biofunctionalised microcapsules are 
well below the p≤0.001 confidence threshold, indicating that the differences recorded 
between the groups are statistically very significant. As a reference, dextran sulfate-
terminated microcapsules were tested against the 3 protein micro-patterns. As expected, 
unspecific adsorption was recorded in all cases, particularly with collagen type IV 
(Figure 70). On the other hand, fibronectin exhibited a much lower fluorescence intensity 
value, demonstrating a significantly lower adsorption of microcapsules to this protein. 
The isoelectric point of fibronectin has been reported to lie within 5.6-6.1 (Boughton and 
Simpson, 1984). Experiments were carried out at a pH≈7.4, therefore the protein is likely 
to have a negative net-charge, possibly leading to a repulsive force between itself and the 
microcapsules, thus explaining this decrease in microcapsule adsorption. A similar 
finding was made in a previous study which showed that microcapsules adsorb less 
readily to micro-patterned surfaces of a similar charge (Nolte and Fery, 2004). Despite 
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this, a 60 fold decrease in fluorescence intensity was recorded on the fibronectin patterns 
with biofuctionalised PEG microcapsules, suggesting that PEG is supressing this 
unspecific binding to a high degree.  When comparing the collagen-coated islands shown 
in Figure 70 and Figure 71, it is clear that despite being functionalised to specifically 
adhere to collagen type IV, a reduction in microcapsule adsorption was noticed when 
compared to the control microcapsules, terminated with dextran sulfate (58.5% 
reduction). This could be attributed to the presence of PEG in the biofunctionalised 
microcapsules. Regardless, there is a significant difference when comparing the data 
from the target protein and the control proteins. 
 
Anti-fibronectin microcapsules exclusively adhered to fibronectin micro-patterns, with 
minimal unspecific adsorption recorded on the control samples, as depicted in Figure 72. 
A limitation of this model is that the antibodies used may be prone to cross-reactivity 
with other proteins that possess similar antigen sequences (Arevalo et al., 1993). Another 
limitation of the current study is on the circulation time of these capsules in-vivo. We 
plan to carry out ex-vivo studies followed by in-vivo studies in the near future to address 
this issue. 
 
It is believed that this biofunctionalisation protocol may be applied to both pre-loaded 
microcapsules (She et al., 2010b) and encapsulated drug particles (Pargaonkar et al., 
2005), to provide site-specific controlled drug release.  A study using microcapsules 
constructed of ten BSA protein layers, has shown that the microcapsules are still 
permeable to molecules of a lower molecular weight (Tong et al., 2008). The 
microcapsules used in this study comprise of 6 polymer layers and 3 protein layers and 
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hence should therefore provide an adequate release profile for low molecular weight drug 
molecules. The biofunctionalisation process is also unlikely to have an impact on the 
encapsulation efficiency due to the increase in sealing of microcapsules as more 
polymer/protein layers are applied (De Temmerman et al., 2011). 
 
6.6 Conclusion 
Polyelectrolyte microcapsules that incorporate a protein-resistant polymer (PEG), with 
approximately 50% of the surface functionalized with antibodies, have been successfully 
manufactured. By applying the microcapsules to various protein micropatterns, one has 
demonstrated that these microcapsules specifically and exclusively bind to their 
complementary target area. Furthermore, the model that has been developed for this 
study is versatile since similar results were noticed when a different antibody was used. 
This study allows for further research involving in vitro and in vivo experiments to 
analyze whether microcapsules can be used as targeted drug carriers. 
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7. Ex-vivo site-specific targeting of polyelectrolyte 
microcapsules 
7.1 Introduction 
 
The previous chapter clearly demonstrates that, with appropriate functionalisation, 
exclusive binding of polyelectrolytes can be achieved. Admittedly, the testing 
environment was artificial in nature, with the use of well-defined protein patterns. These 
capsules must be tested under more clinically relevant scenarios. Ex-vivo experiments 
allow the researcher to conduct experiments on tissues that have been removed from the 
body of an organism. This offers a more reliable and accurate model for experimental 
analysis, without the risk and ethical complications associated with in-vivo studies. This 
will provide an insight into how the specially designed biofunctionalised microcapsules 
will interact with the irregularities associated with biological tissues. The following pilot-
study shall aim to accomplish this by means of epifluorescence microscopy of ex-vivo 
tissues. 
 
Referring back to the arterial endothelial injury discussed in chapter one, we require a 
blood vessel that exhibits patches of endothelial denudation, where the basement 
membrane is exposed, as found in arteries that have undergone angioplasty procedures. 
Ex-vivo testing provides a platform by which one can test the effectiveness of the 
microcapsules within a biological setting, without encountering the risks associated with 
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in-vivo clinical trials.  Various ex-vivo tests have been conducted using polyelectrolyte 
microcapsules.   
 
A number of studies have reported techniques of achieving this type of wound ex-vivo 
with varying degrees of success. Ex-vivo wounds are typically inflicted while the vessel 
is either intact or open. Some studies have reported success simply by surgically 
scratching the luminal side on an open vessel with a scalpel blade (Darsaut et al., 2007). 
Another study achieved endothelial denudation by inserting a wire with a diameter of 70 
microns which is slightly bigger than the mouse tail artery used (Bailey et al., 2007). The 
wire was passed in a retrograde proximal direction for a distance of up to 10mm and then 
was removed. Although successful endothelial denudation was achieved, the study does 
not comment on the integrity of the type IV collagen after the wire treatment. 
 
 Another study, that predates this one by more than 20 years, used an entirely different 
technique to achieve endothelial denudation. 30 years ago, a technique was established 
by which endothelial denudation was achieved without applying direct mechanical force 
to the endothelium (Guyton et al., 1984). The researchers had succeeded in removing the 
endothelium using a micro-bubble technique. Briefly, a passage of nitrogen bubbles was 
introduced into the lumen of an intact carotid artery. 2000 bubbles were declared 
sufficient for complete endothelial denudation. This method is significantly less 
mechanically invasive than the wire technique used in the aforementioned study. Indeed, 
it was reported that the basement membrane was not damaged after the technique was 
applied. The bubbles were generated by a pressurised tilting chamber and catheter. This 
method would be more favourable than physical scraping of the endothelium since it is 
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less mechanically invasive and less likely to damage the underlying basement membrane. 
Due to limited resources, this is not a viable means of endothelial denudation in the 
present study. Current research into the use of microcapsules in an ex-vivo scenario is 
scarce. The methodology of this study must address the important aspect of visualising 
the microcapsules once they have adhered to the sample. The best way to visualise what 
has adhered to the luminal surface is to make a longitudinal cut and open up the vessel to 
expose the endothelium. This involves a lot of delicate manipulation, and therefore can 
only be applied to larger blood vessels. For this reason, aortic sections shall be used in 
this study.  
 
A limitation of this technique is that it is not fully reproducible and requires the 
technician to apply the same force to the sample each time the experiment is completed, 
which is virtually impossible. Injury to smaller blood vessels, such as the mouse femoral 
artery have been well-established by inserting an angioplasty guidewire into the lumen 
and physically shearing the endothelium, stripping the cells from the basement 
membrane (Roque et al., 2000). However, these vessels are simply too small (outer 
diameter approximately 250 μm) and delicate to handle and mount using conventional 
forceps. A number of trials were conducted on aortic samples that had been opened 
longitudinally in order to determine whether the reproducibility was sufficient enough. 
The main concern faced with this wound infliction technique is whether the wound 
would extend into the basement membrane and thus damage the collagen type IV, 
rendering the microcapsules dysfunctional. In order to assess whether the collagen was 
intact after the injury was inflicted, immunostaining was performed using an anti-
collagen type IV primary antibody.  
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7.2 Materials 
C57BL/6 mice (2-4 months old) were acquired from the James Black Centre at King’s 
College London. Collagen type IV-functionalised microcapsules were prepared as 
described in chapter 6 (see chapter  6 for individual materials). Polyclonal Anti-Collagen 
IV antibody, produced in rabbit (cat. no. ab6586) was purchased from Abcam®. 
Monoclonal Anti-VE Cadherin antibody produced in rat was purchased from Abcam® 
(cat. no.ab91064). Alexa Fluor® 488 Goat Anti-Rat IgG (H+L) Antibody (cat. no. A-
11006), Alexa Fluor® 594 Goat Anti-Rabbit IgG (H+L) Antibody (cat. no. A11012)  
and Alexa Fluor® 488 Goat Anti-Rabbit IgG (H+L) Antibody (cat. no. A11008) was 
purchased from Thermo Fisher Scientific Inc.VE-cadherin Antibody was (cat. no. sc-
6458), Normal swine serum (diluted by 1:20 with PBS) (cat. no sc-2486).  and Anti 
collagen IV antibody produced in rabbit (cat. no. sc-70246), goat anti-rabbit IgG-HRP 
(cat. no. sc-2030)    was purchased from Santa Cruz Biotechnology Inc.  
 
7.3 Method 
Ex-vivo sample preparation 
Mouse aortas were harvested from mice at Kings College London with help from 
experienced technicians. The aorta was carefully detached from the mouse body and all 
branches were severed. Excess fat surrounding the vessel was removed using forceps. 
This was to ensure that the samples would remain as flat as possible once mounted onto 
glass slides. At this stage, some samples were injured by squeezing the blood vessel 
gently to attempt to kill the endothelial cells and allow them to detach and be washed 
away.  
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Forceps clamp 
 
Figure 73. Schematic diagram depicting the forceps injury method, where the forceps were 
gently squeezed. 
 
Before the longitudinal incision was made to open the vessel, a section (roughly around 
2mm) of the aorta was compressed using forceps. The mechanical compression would 
serve to physically disrupt the endothelial cell membrane and cause cell death.  
 
The aorta was then cut into sections (about 4mm in length) to provide multiple samples. 
Half of the samples were then cut open longitudinally and pinned down onto silicone 
rubber mounts with the endothelium facing upwards as illustrated by the schematic 
shown in Figure 74. The other half were put into Eppendorf tubes and washed inside the 
tube. For these samples, all procedures would take place inside the tubes. This was to 
determine whether results could also be obtained using a less time consuming method.  
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The remaining uninjured samples were then injured using the following techniques: 
 
Needle scratch 
 
Figure 74. Schematic diagram depicting the needle scratch method. 
 
A needle was gently scraped against the endothelial surface in a direction parallel to the 
long axis of the needle. It was hoped that this will provide a distinct region where the 
endothelial cells would be scraped off of the basement membrane. 
 
Scalpel scrape 
 
 
Figure 75. Schematic diagram depicting the scalpel scrape method. 
 
A scalpel was scraped gingerly in a direction perpendicular to the long axis of the scalpel 
with the intention of removing a larger area of endothelium.  
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Once the samples were injured, they were washed thoroughly with PBS to remove any 
detached endothelial cells from the surface. Samples were subsequently fixed with 
formaldehyde for 15 minutes to preserve the sample during the adsorption assay. 
Previously prepared anti-collagen type IV biofunctionalised microcapsules (with a single 
PLL-FITC layer incorporated in the lbl structure) were then incubated onto the surface of 
the ex-vivo sections for 12 hours in a cold room at 4°C to preserve the integrity of the 
samples. Non-adsorbed microcapsules were subsequently washed by administering 3 
dilution and 3 washing cycles, as described in section 6.3.4. 
 
Endothelial cell verification 
In order to differentiate between smooth muscle cells and endothelial cells, cell wall 
junctions were immunostained by using an appropriate anti-Vascular endothelial (VE) 
cadherin antibody. VE cadherins are calcium dependent cell adhesion proteins with many 
functional roles. Primarily, they serve as an intermolecular glue and therefore are located 
at the cell-cell junctions (Dejana et al., 1999). To highlight these junctions, samples were 
incubated with anti- vascular endothelial cadherin (CD144) antibody at a concentration 
of 1:200 PBS. After thoroughly washing, the ex-vivo sample was ready for secondary 
antibody labelling in order to detect the cell wall junction under fluorescence. Alexa 
Fluor 488-conjugated donkey anti-goat antibody was diluted from stock by a factor of 
1:500, as indicated by the datasheet, and was applied to the sample and left for 45 
minutes at room temperature. In order to determine the validity of the injury model and 
determine whether the collagen type IV was intact, anti-collagen type IV antibody, 
produced in rabbit, was incubated for 1 hour at room temperature at a dilution factor of 
1:50. After thorough washing, a donkey anti-rabbit secondary antibody (conjugated with 
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Alexa Fluor 594 was incubated for 45 minutes at a dilution of 1:1000. Cell nuclei were 
stained with DAPI by incubating in DAPI solution for 5 minutes. 
 
Immunohistochemistry verification of anti-collagen type IV antibody activity 
In order to work out the optimal working dilution for the antibody, and to determine 
whether the antibody is able to bind successfully to the antigen present on the ex-vivo 
samples, cross sections of a mouse liver were prepared using a Microm HM 560 
microtome-cryostat. Instead of using a conventional microtome, it was decided that a 
cryostat machine would be used instead since the traditional technique requires antigen 
retrieval treatment prior to the incubation of antibodies. Furthermore, the frozen sections 
can be kept at -20°C for long term storage.  
 
The sample was fixed onto the specimen platform with embedding compound and the 
entire frozen liver sample was covered in embedding compound and placed on the 
freezing plate. Once frozen, the specimen was transferred to the specimen holder. The 
knife temperature was set to -21°C and the specimen temperature was set to -23°C. 
Colder temperatures were avoided to prevent the occurrence of cracks within the sample. 
8μm thick cross sections were cut by rotating the handle and each section was transferred 
to a glass slide. After leaving the samples to air-dry for 20 minutes, they were stored at -
20°C. 
 
N.B. Prior to all primary antibody incubations, samples were blocked with goat normal 
serum at a recommended dilution (1:20). Furthermore, All dilutions were performed with 
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PBS. Dilution of the primary antibody with normal serum was considered, however, after 
previous testing, PBS was shown to deliver results which yielded minimal background 
signal.  
 
Cross sections of an aorta from mice liver samples were then stained using 
immunofluorescence and immunohistochemistry techniques to determine whether the 
anti-collagen type IV has the ability to bind to collagen type IV in an ex-vivo 
environment (e.g. the basement membrane of the blood vessels in each cross section). 
Samples were allowed to dry for 5 minutes before fixing with ice-cold acetone for 8 
minutes. The samples were thoroughly washed with PBS to remove the acetone.  
Immunofluorescence was performed as described in section 6.3.5, using polyclonal Anti-
Collagen IV antibody, produced in rabbit primary antibody with  Alexa Fluor® 488 Goat 
Anti-Rabbit IgG secondary antibody. The commonly implemented antigen retrieval step 
was not needed since the method of fixation with acetone increases tissue porosity and 
doesn’t produce cross-links which would otherwise prevent the antibodies from 
interacting with the antigen (Pileri et al., 1997). 
 
Immunohistochemistry was performed using a HRP-DAB kit. This technique differs 
from immunofluorescence in the sense that the secondary antibody is now conjugated 
with Horse radish peroxidase enzyme instead of a fluorophore. A substrate, cleavable by 
the HRP (DAB) is then applied to the sample, and areas, where the HRP has been 
tethered are stained brown due to the change in colour produced by the cleaved DAB. 
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Method: The frozen section was taken out of the freezer and left to dry for 5 minutes, 
before fixation via methanol. After 10 minutes of incubation, the methanol was 
thoroughly washed with PBS. The sample was then treated with 3% H2o2
 
for 15 minutes 
to destroy any endogenous enzymes that may cleave the DAB which would otherwise 
produce false staining. The sample was then blocked with normal swine serum for 45 
minutes and subsequently incubated in primary antibody, which had been diluted in 
normal swine serum. After 24 hours at 4°C, the sample was washed 3 times, leaving the 
slides submerged in PBS for 5 minutes each time. The secondary antibody, conjugated 
with HRP was then diluted to the recommended dilution (1:50) and applied to the glass 
slides. After 1 hour of incubation at room temperature, excess secondary antibody was 
removed in a similar fashion to the primary antibody wash step. Finally, the DAB was 
applied to the sample and left for 2 minutes to allow the HRP to cleave the substrate and 
generate the stain. Excess DAB was washed off with PBS. Finally, counterstaining of the 
nucleus was achieved by hematoxylin treatment for 5 minutes. The excess dye was 
washed away with water and xylene before mounting.   
 
Figure 76. Photographs showing the frozen liver sample on the specimen platform (Panel A) 
and the specimen being sectioned (Panel B). 
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7.4 Results 
 
 
Figure 77. Fluorescent micrographs showing the retained microcapsules on the mouse aorta 
samples using different injury and incubation methods. Anti-collagen IV functionalised 
microcapsules are labelled with FITC (green fluorescence) and cell nuclei are labelled with 
DAPI (blue fluorescence). 
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Figure 78. Control capsules (dextran sulfate-terminated) retained on an ex-vivo mouse 
aorta sample. Image shows a large degree of capsule adsorption (FITC labelled) due to the 
absence of PEG. Cell nuclei was stained with DAPI. 
 
 
Figure 79. Confocal image of sample injured by scalpel scrape method. Collagen type IV 
was immunostained with Alexa Fluor 594-conjugated antibody (red fluorescence). Nuclei 
were stained with DAPI (blue). Endothelial cell-cell junctions were stained with anti-VE 
cadherin and a complementary FITC-labelled secondary antibody (green). 
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Figure 80. Epifluorescence image of sample injured by needle scratch method. Collagen 
type IV was immunostained with Fluor 594 conjugated antibody (red fluorescence). Nuclei 
were stained with DAPI (blue). Endothelial cell-cell junctions were stained with anti-VE 
cadherin and a complementary FITC-labelled secondary antibody (green). 
 
 
 
Figure 81. Epifluorescence image of sample injured by scalpel scrape method. Collagen 
type IV was immunostained with Alexa Fluor 594-conjugated antibody (red fluorescence). 
Nuclei were stained with DAPI (blue). 
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Figure 82. Epifluoresence image of an arteriole branch entrance. Sample was 
immunostained for collagen type IV (red). Cell Nuclei was stained with DAPI (blue). 
 
7.5 Discussion 
At first glance, the figures indicate that regions where the endothelium has been denuded 
are laden with biofunctionalised microcapsules, indicating that the microcapsules have 
successfully been adsorbed to the damage site. However, closer examination reveals that 
this is not the case. It is important to realise that the aorta is a branched vessel. For planar 
mounting of this vessel, the branches need to be severed. This leaves behind an orifice, 
which is noticeable, even to the naked eye. In reality, the region which is devoid of cells 
and covered with microcapsules, is one of these orifices as shown in Figure 77A and 
Figure 77C. It appears that the microcapsules have become physically entrapped and 
aggregated in this gap. More positively, the microcapsules refrain from adhering to the 
intact endothelial cells, indicating that the PEG is still exhibiting non-fouling properties, 
despite being functionalised indirectly with anti-collagen type IV. Further confirmation 
of the non-fouling properties can be seen from the incubation of the control capsules on 
the ex-vivo aorta specimens. These dextran sulfate-terminated capsules are non-
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PEGylated and non-functionalised. Figure 78 clearly indicates that upon incubation for 
24 hrs, followed by washing with PBS solution, many capsules remain adsorbed to the 
endothelium. This conclusively highlights the potency of the PEG functionalisation.  
 
It is highly likely, that due to the nature of the injury methods used, the collagen type IV-
rich basement membrane was likely to have been damaged during infliction. In order to 
test the integrity of the collagen type IV after injury, immunofluorescent staining was 
performed. As seen in Figure 81 there is a weak red signal, corresponding to the Alexa 
Fluor® 594 Goat Anti-Rabbit IgG secondary antibody. These signals were achieved 
using a relatively long exposure time of 2 seconds. It is likely that these were background 
signals from non-specifically adsorbed secondary antibody. This signal is also believed 
to have arisen due to the autofluorescence of vessel elastin, a protein which is found in 
abundance at this anatomical region. This uncertainty warranted an investigation into the 
reactivity of the rabbit anti-mouse collagen type IV primary antibody with the ex-vivo 
specimens. Intact mouse collagen type IV, believed to be present on a cross section of a 
proximal region of a mouse aorta was immunostained in a similar fashion.  
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Figure 83. IHC analysis of cross section of a mouse aorta. Panel A shows the control sample 
without primary anti-collagen type IV and panel B shows a mouse aorta immunostained 
with anti-collagen type IV from Abcam (new sample). 
 
 
Figure 84. IHC analysis of cross section of a mouse aorta. Panel A shows the new abcam 
antibody and panel B shows a mouse aorta immunostained with anti-collagen type IV from 
Santa Cruz. 
 
 
Figure 85. IHC analysis of cross section of a mouse arota Panel A shows the control sample 
without primary anti-collagen type IV and panel B shows a mouse aorta immunostained 
with fresh Abcam anti-collagen type IV. 
 
175 
 
 
Figure 86. Epifluorescence analysis of cross section of a mouse aorta. Panel A shows the 
control sample without primary anti-collagen type IV and panel B shows a mouse aorta 
immunostained with fresh anti-collagen type IV from Abcam. 
 
Results, as shown in Figure 86B indicate that no significant staining was present on all 
samples tested (n=6). Control samples (where no primary antibody was used) look 
virtually identical to samples that underwent full immunostaining, with one noticeable 
difference being a higher intensity of fluorescence on the control samples. It is important 
to realise that the images taken in Figure 86, are long exposure images of the green 
channel (1.7s). Despite this long exposure, the signals are still weak, further confirming 
that this is indeed a background signal, or potentially autofluorescence from elastin. The 
laser scanning confocal microscopy image shown in Figure 79 provides precise focus on 
the intimal region of the ex-vivo sample. This particular image shows the site of damage 
via the needle technique. The positive green staining at the cell-cell junctions 
corresponds to the Alexa Fluor® 488 Goat Anti-Rat IgG secondary antibody, which in 
turn, corresponds to the endothelial cell marker, anti-CD144 antibody, thus confirming 
the identity of these cells as endothelial cells.  
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Interestingly, immunohistochemistry anaylsis, performed on a mouse liver cross section 
containing three blood vessels, showed, significant background staining. It is important 
to realise that this background staining is different from the background staining noticed 
in the immunofluorescence images. Firstly, this technique is not prone to 
autofluoresence, so a pigment will only be present where secondary antibody, and 
consequently primary antibody has been tethered. Secondly, the intensity of the 
pigmented sections outside the blood vessel wall is relatively high. It was found that the 
intensity decreased with more washing cycles, however, the stain was never completely 
eliminated. This shows a significant degree of unspecific adsorption. In addition to the 
background staining, the entire blood vessel wall had been stained as oppose to 
exclusively staining the collagen type IV basement membrane. It may be the case that the 
antibody is cross reacting with other proteins on the sample. This is unlikely, since the 
samples were previously blocked with normal serum, in theory, eliminating cross-
reactivity between non-target antigens and the antibody. To see if a more convincing 
result could be achieved, the experiment was repeated with a different anti-col IV 
antibody (Santa Cruz). Results indicated that no staining was present on the blood vessel 
wall and a weak background signal was present on all samples (n=6).  
 
The immunostaining results of the cross section offers some evidence to suggest that the 
anti-collagen type IV antibody purchased from Abcam was able to adsorb to intact 
collagen type IV, but not exclusively. Taking this into consideration, it can be concluded 
that the anti-collagen type IV was unable to bind to the exposed collagen type IV of the 
basement membrane due to the fact that the collagen type IV was no longer intact. The 
shear force inflicted on the surface of the ex-vivo samples is likely to have mechanically 
damaged the collagen type IV, denaturing the antigen of the protein. This highlights the 
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main weakness of the antibody-functionalised microcapsules. That is, the system relies 
on the presence of an intact, non-denatured target protein. 
 
A major limitation of this work, is the absence of a reliable and repeatable method of 
achieving endothelial denudation, while simultaneously protecting the underlying 
collagen type IV-rich basement membrane from mechanical damage. By applying the 
angioplasty guidewire technique and using a different sized diameter wire, this may have 
been feasible. This is not well-established and due to resource limitations, a larger 
angioplasty guidewire could not be acquired for this procedure.  
 
Another potential method for endothelial denudation would be to freeze-thaw the luminal 
surface of an longitudinally opened aorta. Also known, as cryotherapy, this technique has 
been investigated as a potential method for tumor control. More recently, this method has 
been commercialised, highlighting the efficacy of this technique (Li et al., 2010). In 
essence, the subzero temperatures induce the formation of both intra and extracellular ice 
crystals, causing the cell membrane and organelles to rupture mechanically, ultimately 
leading to necrotic death (Mazur, 1963). In particular, when gradual freezing is applied to 
cells, the formation of extracellular ice leads to an increase in potential difference across 
the cell membrane. This causes water to be expelled from the cells leading to cell 
dehydration and ultimately cell death (Mazur et al., 1972).   There has also been evidence 
that freezing can cause apoptosis (gene associated cell death) near the ice/cell interface 
(Baust and Gage, 2005).  
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A more recent study focused on the specific analysis of the mechanism by which ice 
crystals form intracellularly on human umbilical vein endothelial cells (Yang et al., 
2009). In order to control the freezing and thawing rate, the cells were seeded on a 
coverslip and placed on a cryostage (freezing platform). The freezing of the cells were 
recorded via a CMOS high speed camera coupled to a microscope. In all cases, 
intracellular ice formation was initiated at the cell membrane closest to the nucleus. This 
is believed to occur due to the presence of a perpendicularly orientated area of water 
molecules adjacent to the phosphate lipid bilayer. This well-organised layer ultimately 
requires less energy for crystal nucleation, hence this region will always be the site of 
intracellular ice formation. After this initial ice crystal is formed, the ice dendrite then 
propagates into the nucleus itself, where the entire nucleus is frozen thereafter. Further 
freezing and thawing results in the rupture of these membrane and other membrane-
bound organelles. Extracellular ice formation was reported to occur at -2.5°C, whereas 
intracellular ice formation initiates at -17.6°C. This study offers a vast amount of 
information regarding the mechanism behind endothelial cell cryotherapy, however, it 
only considers a monolayer of cells in an in-vivo environment rather than a three 
dimensional ex-vivo sample.  It is unclear whether the underlying basement membrane 
will survive this treatment. It is a well-known fact that proteins are able to withstand a 
freeze/thaw cycle. However multiple freeze/thaw samples are known to denature proteins 
due to the changes in pH associated with proteins stored in phosphate buffers. The effects 
of this pH change can be suppressed by limiting the number of freeze/thaw cycles and 
increasing the freezing and thawing rate (Pikal-Cleland et al., 2000). One must also 
consider the thickness of the sample and the influence of the sub-zero temperatures on 
the underlying smooth muscle cells of the ex-vivo specimen. Should intracellular ice 
crystals form within the intimal region, smooth muscles cells will undoubtedly share the 
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same fate as the endothelial cells, hence the basement membrane will not be stably 
anchored to the specimen, leading to an undesirable injury model. Furthermore, the 
sample will have to be inverted before placed onto the cryostage to expose the 
endothelium to the cold surface. The freezing and thawing of the entire surface could 
lead to rupture of the sample. A more ideal solution would be to use a cryoprobe, similar 
to that used in the medical industry to concentrate the treatment to a small area. 
 
7.6 Conclusion 
In conclusion, the biodegradable microcapsules developed in chapter 6 did not function 
as expected in an ex-vivo environment. It would be wrong, however, to suggest that this 
result arose from a problem with the microcapsules themselves. The IHC and 
immunofluorescence analysis of ex-vivo cross sections indicated that the antibody, which 
was used to functionalise the microcapsules were cross-reacting with nearby tissues, 
rendering the functionalisation of these capsules purposeless. Furthermore, due to the 
lack of a repeatable damage model, it was impossible to test the microcapsules under 
controlled conditions. It is yet to be seen whether these biofunctionalised microcapsules 
would work in an in-vivo environment by adhering to the collagen type IV-rich basement 
membrane exposed due to angioplasty injury. More experimentation with different 
antibodies and a reliable injury model is required to provide a deeper insight into this 
matter. Regardless, a significant advancement has been made with respect to the 
exclusive protein targeting of polyelectrolyte microcapsules, as shown in chapter 6. 
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8. Summary 
The initial work presented in this thesis has shown that self-degradable microcapsules 
can be successfully fabricated by encapsulating enzymes within layer-by-layer assembled 
polyelectrolyte microcapsules. More specifically, only one of the layer-by-layer 
constituents are required to be degradable by the encapsulated enzyme in order to 
produce noticeable capsule degradation and subsequent release of contents. The rate of 
release of the encapsulated contents can be controlled by increasing/decreasing the 
number of polyelectrolyte layers used. Furthermore, the rate of release can be altered by 
switching between biodegradable and non-biodegradable polyelectrolytes. 12 layer 
microcapsules are less affected by the relatively low concentration of proteinase within 
the capsules, with a release of less than 10% (at t = 24hrs) of the encapsulated proteinase 
recorded; hence both of these parameters must be set with precision in order to accurately 
control the rate of release. 
 
Chapter 4 has successfully demonstrated that microcapsules can be functionalised to 
enhance cell binding using inexpensive biomaterials. This was achieved by 
functionalising basic PSS/PAH microcapsules with WGA. An average of 6 WGA-
terminated microcapsules was recorded per endothelial cell with intact glycocalyces, 
showing a significant level of retention. The mechanism behind the interaction is unclear 
and further analysis of these microcapsules in an in-vitro environment is required. In 
addition, the site-specific targeting pilot tests conducted have shown that simple 
techniques can be used to target specific proteins. Furthermore, modifications can be 
made to polyelectrolyte microcapsules to increase or reduce binding to cells in-vitro. 
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However, these studies do not offer a definitive method for true specific binding to target 
proteins which includes the suppression to other proteins and cell membrane surfaces. 
 
A system whereby microcapsules can be functionalised to specifically and exclusively 
bind to a streptavidin substrate has been developed, as shown in chapter 5. By preventing 
unspecific adsorptions via PEGylation and functionalising the capsules with biotin, the 
goal of producing a targeted microcapsule delivery technique has been accomplished. 
Results show at least a 9-fold increase in capsule retention when in contact with 
streptavidin, compared to control proteins. Furthermore, the capsules remain fully 
functional after 2 weeks, indicating good stability required for long-term use e.g. long-
term therapy.  
 
We have successfully manufactured microcapsules which incorporate a protein resistant 
polymer (PEG), with approximately 50% of the surface functionalised with antibodies, as 
demonstrated in chapter 6. By applying the microcapsules to various protein micro-
patterns, we have demonstrated that these microcapsules specifically and exclusively 
bind to their complementary target area, with a 600 fold increase in microcapsule 
retention compared to control proteins. Furthermore, the model that has been developed 
for this study is versatile since similar results were noticed when a different antibody was 
used. This study allows for further research involving in-vitro and in-vivo experiments to 
analyse whether microcapsules can be used as a targeted drug-carriers. 
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8.1 Future work 
In order to control the rate of release of proteinase from the self-degradable 
microcapsules fabricated in chapter 3, the experiments could be carried out at different 
temperatures. This would give a greater insight into the function of these capsules and 
would determine whether temperature plays a significant role in the rate of degradation 
and the subsequent release of contents. Indeed, the optimal working temperature range 
for proteinase is between 30°C and 40°C (Borodina et al., 2007). The all experiments 
were halted after a period of 24 hours since the rate of release remained relatively 
constant at this point in time. Furthermore, prolonging the experiments are likely to lead 
to an increase in proteinase adsorption to the Eppendorf tubes, thus resulting in false UV 
spectrophotometer readings. Glass tubes are known to have better non-fouling properties 
than polypropylene, hence by substituting the propylene tubes for glass tubes, proteinase 
release can be monitored over a longer period of time without proteinase-tube adsorption 
affecting the results.  
With regard to site-specific delivery, PEG-biotin may be incorporated into microcapsules 
which are targeted towards more complex structures such as cell membranes. By 
functionalising PEG-biotinylated microcapsules with specific ligands that recognise a 
unique type of cell, one could potentially target specific cells, including cancer cells, thus 
providing a promising solution to cancer treatment. 
  
183 
 
References 
 
2000. Water soluble multi-biotin-containing compounds. Google Patents. 
2011a, Inflation of Balloon Inside a Coronary Artery, viewed 20/12/12, 
http://med.stanford.edu/stanfordhospital/images/greystone/heartCenter/images/ei_
2253.gif 
2011b, Tetramer of Avidin Binding the Biotin Ligands, viewed 12/10/2013, 
http://proteopedia.org/wiki/index.php/Molecular_Playground/Biotin_binding_avi
din 
ALBERTS, B., JOHNSON, A., LEWIS, J., WALTER, P., RAFF, M. & ROBERTS, K. 
2002. Molecular Biology of the Cell 4th Edition: International Student Edition, 
Routledge. 
ANAND, G., SHARMA, S., DUTTA, A. K., KUMAR, S. K. & BELFORT, G. 2010. 
Conformational transitions of adsorbed proteins on surfaces of varying polarity. 
Langmuir, 26, 10803-11. 
ANGELATOS, A. S., RADT, B. & CARUSO, F. 2005. Light-responsive 
polyelectrolyte/gold nanoparticle microcapsules. Journal of Physical Chemistry 
B, 109, 3071-3076. 
ANTIPINA, M. N., KIRYUKHIN, M. V., CHONG, K., LOW, H. Y. & 
SUKHORUKOV, G. B. 2009. Patterned microcontainers as novel functional 
elements for mu TAS and LOC. Lab on a Chip, 9, 1472-1475. 
AREVALO, J. H., TAUSSIG, M. J. & WILSON, I. A. 1993. Molecular basis of 
crossreactivity and the limits of antibody–antigen complementarity. Nature, 365, 
859-863. 
184 
 
ASLAN, F. M., YU, Y., VAJDA, S., MOHR, S. C. & CANTOR, C. R. 2007. 
Engineering a novel, stable dimeric streptavidin with lower isoelectric point. 
Journal of Biotechnology, 128, 213-225. 
AUMAILLEY, M., BATTAGLIA, C., MAYER, U., REINHARDT, D., NISCHT, R., 
TIMPL, R. & FOX, J. W. 1993. Nidogen Mediates the Formation of Ternary 
Complexes of Basement-Membrane Components. Kidney International, 43, 7-12. 
AZARMI, S., ROA, W. H. & LÖBENBERG, R. 2008. Targeted delivery of 
nanoparticles for the treatment of lung diseases. Advanced Drug Delivery 
Reviews, 60, 863-875. 
AZZAM, T., ELIYAHU, H., SHAPIRA, L., LINIAL, M., BARENHOLZ, Y. & DOMB, 
A. J. 2002. Polysaccharide-oligoamine based conjugates for gene delivery. 
Journal of medicinal chemistry, 45, 1817-1824. 
BAE, Y. M., OH, B. K., LEE, W., LEE, W. H. & CHOI, J. W. 2005. Study on 
orientation of immunoglobulin G on protein G layer. Biosens Bioelectron, 21, 
103-10. 
BAI, K. & WANG, W. 2012. Spatio-temporal development of the endothelial glycocalyx 
layer and its mechanical property in vitro. Journal of The Royal Society Interface, 
9, 2290-2298. 
BAILEY, S. R., MITRA, S., FLAVAHAN, S., BERGDALL, V. K. & FLAVAHAN, N. 
A. 2007. In vivo endothelial denudation disrupts smooth muscle caveolae and 
differentially impairs agonist-induced constriction in small arteries. J Cardiovasc 
Pharmacol, 49, 183-90. 
BARENHOLZ, Y. 2001. Liposome application: problems and prospects. Current 
Opinion in Colloid & Interface Science, 6, 66-77. 
185 
 
BARKER, A. L., KONOPATSKAYA, O., NEAL, C. R., MACPHERSON, J. V., 
WHATMORE, J. L., WINLOVE, C. P., UNWIN, P. R. & SHORE, A. C. 2004. 
Observation and characterisation of the glycocalyx of viable human endothelial 
cells using confocal laser scanning microscopy. Physical chemistry chemical 
physics, 6, 1006-1011. 
BARRETT, A. J., RAWLINGS, N. D. & WOESSNER, J. F. 2012. Handbook of 
Proteolytic Enzymes, Elsevier Science. 
BAUST, J. G. & GAGE, A. A. 2005. The molecular basis of cryosurgery. Bju 
International, 95, 1187-1191. 
BENHABBOUR, S. R., SHEARDOWN, H. & ADRONOV, A. 2008. Protein Resistance 
of PEG-Functionalized Dendronized Surfaces: Effect of PEG Molecular Weight 
and Dendron Generation. Macromolecules, 41, 4817-4823. 
BORODINA, T., MARKVICHEVA, E., KUNIZHEV, S., MOEHWALD, H., 
SUKHORUKOV, G. B. & KREFT, O. 2007. Controlled release of DNA from 
self-degrading microcapsules. Macromolecular Rapid Communications, 28, 
1894-1899. 
BOUGHTON, B. J. 1985. Fibronectin assays and their clinical application: a review. Cell 
Biochem Funct, 3, 79-90. 
BOUGHTON, B. J. & SIMPSON, A. 1982. Plasma fibronectin in acute leukaemia. 
British journal of haematology, 51, 487-91. 
BOUGHTON, B. J., SIMPSON, A. & WHARTON, C. 1984. Conformational changes 
and loss of opsonic function in frozen or heat-treated plasma fibronectin. Vox 
Sanguinis, 46, 254-9. 
186 
 
BOUGHTON, B. J. & SIMPSON, A. W. 1984. The biochemical and functional 
heterogeneity of circulating human plasma fibronectin. Biochem Biophys Res 
Commun, 119, 1174-80. 
CARREGAL-ROMERO, S., GUARDIA, P., YU, X., HARTMANN, R., PELLEGRINO, 
T. & PARAK, W. J. 2015. Magnetically triggered release of molecular cargo 
from iron oxide nanoparticle loaded microcapsules. Nanoscale, 7, 570-576. 
CARUSO, F., TRAU, D., MÖHWALD, H. & RENNEBERG, R. 2000. Enzyme 
Encapsulation in Layer-by-Layer Engineered Polymer Multilayer Capsules. 
Langmuir, 16, 1485-1488. 
CHAN, J. M., ZHANG, L., TONG, R., GHOSH, D., GAO, W., LIAO, G., YUET, K. P., 
GRAY, D., RHEE, J. W., CHENG, J., GOLOMB, G., LIBBY, P., LANGER, R. 
& FAROKHZAD, O. C. 2010. Spatiotemporal controlled delivery of 
nanoparticles to injured vasculature. Proceedings of the National Academy of 
Sciences, 107, 2213-2218. 
CHANNON, K. M. 2002. The Endothelium and the Pathogenesis of Atherosclerosis. 
Medicine, 30, 54-58. 
CHRISTOV, C. & KARABENCHEVA-CHRISTOVA, T. 2012. Structural and 
Mechanistic Enzymology:: Bringing Together Experiments and Computing, 
Elsevier Science. 
CORTEZ, C., TOMASKOVIC-CROOK, E., JOHNSTON, A. P. R., RADT, B., CODY, 
S. H., SCOTT, A. M., NICE, E. C., HEATH, J. K. & CARUSO, F. 2006. 
Targeting and uptake of multilayered particles to colorectal cancer cells. 
Advanced Materials, 18, 1998-+. 
187 
 
CRUZ-CHU, EDUARDO R., MALAFEEV, A., PAJARSKAS, T., PIVKIN, IGOR V. & 
KOUMOUTSAKOS, P. 2014. Structure and Response to Flow of the Glycocalyx 
Layer. Biophysical Journal, 106, 232-243. 
DARSAUT, T., BOUZEGHRANE, F., SALAZKIN, I., LEROUGE, S., SOULEZ, G., 
GEVRY, G. & RAYMOND, J. 2007. The effects of stenting and endothelial 
denudation on aneurysm and branch occlusion in experimental aneurysm models. 
Journal of Vascular Surgery, 45, 1228-1235. 
DARZYNKIEWICZ, Z., ROBINSON, J. P. & ROEDERER, M. 2009. Essential 
Cytometry Methods, Elsevier Science. 
DE GEEST, B. G., DE KOKER, S., SUKHORUKOV, G. B., KREFT, O., PARAK, W. 
J., SKIRTACH, A. G., DEMEESTER, J., DE SMEDT, S. C. & HENNINK, W. 
E. 2009a. Polyelectrolyte microcapsules for biomedical applications. Soft Matter, 
5, 282-291. 
DE GEEST, B. G., DE KOKER, S., SUKHORUKOV, G. B., KREFT, O., PARAK, W. 
J., SKIRTACH, A. G., DEMEESTER, J., DE SMEDT, S. C. & HENNINK, W. 
E. 2009b. Polyelectrolyte microcapsules for biomedical applications. Soft Matter, 
5, 282. 
DE GEEST, B. G., SANDERS, N. N., SUKHORUKOV, G. B., DEMEESTER, J. & DE 
SMEDT, S. C. 2007. Release mechanisms for polyelectrolyte capsules. Chemical 
Society reviews, 36, 636-49. 
DE GEEST, B. G., VANDENBROUCKE, R. E., GUENTHER, A. M., SUKHORUKOV, 
G. B., HENNINK, W. E., SANDERS, N. N., DEMEESTER, J. & DE SMEDT, S. 
C. 2006. Intracellularly degradable polyelectrolyte microcapsules. Advanced 
Materials, 18, 1005-+. 
188 
 
DE KOKER, S., NAESSENS, T., DE GEEST, B. G., BOGAERT, P., DEMEESTER, J., 
DE SMEDT, S. & GROOTEN, J. 2010. Biodegradable polyelectrolyte 
microcapsules: antigen delivery tools with Th17 skewing activity after pulmonary 
delivery. Journal of Immunology, 184, 203-11. 
DE TEMMERMAN, M. L., DEMEESTER, J., DE VOS, F. & DE SMEDT, S. C. 2011. 
Encapsulation Performance of Layer-by-Layer Microcapsules for Proteins. 
Biomacromolecules, 12, 1283-9. 
DE GEEST, B. G., VANDENBROUCKE, R. E., GUENTHER, A. M., SUKHORUKOV, 
G. B., HENNINK, W. E., SANDERS, N. N., DEMEESTER, J. & DE SMEDT, S. 
C. 2006. Intracellularly Degradable Polyelectrolyte Microcapsules. Advanced 
Materials, 18, 1005-1009. 
DE KOKER, S., DE GEEST, B. G., CUVELIER, C., FERDINANDE, L., DECKERS, 
W., HENNINK, W. E., DE SMEDT, S. C. & MERTENS, N. 2007. In vivo 
Cellular Uptake, Degradation, and Biocompatibility of Polyelectrolyte 
Microcapsules. Advanced Functional Materials, 17, 3754-3763. 
DECHER, G. & SCHLENOFF, J. B. 2012. Multilayer Thin Films: Sequential Assembly 
of Nanocomposite Materials, Wiley. 
DEJANA, E., BAZZONI, G. & LAMPUGNANI, M. G. 1999. Vascular endothelial 
(VE)-cadherin: only an intercellular glue? Experimental cell research, 252, 13-
19. 
DISPINAR, T., COLARD, C. A. L. & DU PREZ, F. E. 2013. Polyurea microcapsules 
with a photocleavable shell: UV-triggered release. Polymer Chemistry, 4, 763-
772. 
189 
 
FARB, A., SANGIORGI, G., CARTER, A. J., WALLEY, V. M., EDWARDS, W. D., 
SCHWARTZ, R. S. & VIRMANI, R. 1999. Pathology of acute and chronic 
coronary stenting in humans. Circulation, 99, 44-52. 
FARRELL, D., LIMAYE, S. Y. & SUBRAMANIAN, S. 2008. Silicon nanosponge 
particles. Google Patents. 
FRIEDMAN, L., HIGGIN, J. J., MOULDER, G., BARSTEAD, R., RAINES, R. T. & 
KIMBLE, J. 2000. Prolyl 4-hydroxylase is required for viability and 
morphogenesis in Caenorhabditis elegans. Proceedings of the National Academy 
of Sciences of the United States of America, 97, 4736-4741. 
GABIZON, A. A. 2001. Stealth Liposomes and Tumor Targeting: One Step Further in 
the Quest for the Magic Bullet. Clinical Cancer Research, 7, 223-225. 
GAO, C., LEPORATTI, S., DONATH, E. & MÖHWALD, H. 2000. Surface texture of 
poly (styrenesulfonate sodium salt) and poly (diallyldimethylammonium chloride) 
micron-sized multilayer capsules: a scanning force and confocal microscopy 
study. The Journal of Physical Chemistry B, 104, 7144-7149. 
GAUTROT, J. E., TRAPPMANN, B., OCEGUERA-YANEZ, F., CONNELLY, J., HE, 
X. M., WATT, F. M. & HUCK, W. T. S. 2010. Exploiting the superior protein 
resistance of polymer brushes to control single cell adhesion and polarisation at 
the micron scale. Biomaterials, 31, 5030-5041. 
GE, S., KOJIO, K., TAKAHARA, A. & KAJIYAMA, T. 1998. Bovine serum albumin 
adsorption onto immobilized organotrichlorosilane surface: influence of the phase 
separation on protein adsorption patterns. Journal of Biomaterials Science, 
Polymer Edition, 9, 131-150. 
190 
 
GHOSTINE, R. A., MARKARIAN, M. Z. & SCHLENOFF, J. B. 2013. Asymmetric 
Growth in Polyelectrolyte Multilayers. Journal of the American Chemical 
Society, 135, 7636-7646. 
GONZÁLEZ, M., BAGATOLLI, L. A., ECHABE, I., ARRONDO, J. L. R., 
ARGARAÑA, C. E., CANTOR, C. R. & FIDELIO, G. D. 1997. Interaction of 
Biotin with Streptavidin: THERMOSTABILITY AND CONFORMATIONAL 
CHANGES UPON BINDING. Journal of Biological Chemistry, 272, 11288-
11294. 
GRIMSLEY, G. R. & PACE, C. N. 2004. Spectrophotometric determination of protein 
concentration. Current protocols in protein science, 3.1. 1-3.1. 9. 
GUO, Y., GENG, W. & SUN, J. 2009. Layer-by-layer deposition of polyelectrolyte-
polyelectrolyte complexes for multilayer film fabrication. Langmuir, 25, 1004-10. 
GUYTON, J. R., DAO, D. T. & LINDSAY, K. L. 1984. Endothelial denudation and 
myointimal thickening in the rat carotid artery induced by the passage of bubbles. 
Exp Mol Pathol, 40, 340-8. 
HALBLEIB, J. M. & NELSON, W. J. 2006. Cadherins in development: cell adhesion, 
sorting, and tissue morphogenesis. Genes & development, 20, 3199-3214. 
HARNEK, J., ZOUCAS, E., CARLEMALM, E. & CWIKIEL, W. 1999. Differences in 
endothelial injury after balloon angioplasty, insertion of balloon-expanded stents 
or release of self-expanding stents: An electron microscopic experimental study. 
Cardiovascular and interventional radiology, 22, 56-61. 
HAUTANEN, A., GAILIT, J., MANN, D. M. & RUOSLAHTI, E. 1989. Effects of 
modifications of the RGD sequence and its context on recognition by the 
fibronectin receptor. Journal of Biological Chemistry, 264, 1437-42. 
191 
 
HAYNIE, D. T., PALATH, N., LIU, Y., LI, B. & PARGAONKAR, N. 2005. 
Biomimetic Nanostructured Materials:  Inherent Reversible Stabilization of 
Polypeptide Microcapsules. Langmuir, 21, 1136-1138. 
HEUBERGER, M., DROBEK, T. & SPENCER, N. D. 2005a. Interaction forces and 
morphology of a protein-resistant poly(ethylene glycol) layer. Biophys J, 88, 495-
504. 
HEUBERGER, R., SUKHORUKOV, G., VOROS, J., TEXTOR, M. & MOHWALD, H. 
2005b. Biofunctional polyelectrolyte multilayers and microcapsules: Control of 
non-specific and bio-specific protein adsorption. Advanced Functional Materials, 
15, 357-366. 
HORLITZ, M., SIGWART, U. & NIEBAUER, J. 2002. Fighting restenosis after 
coronary angioplasty: contemporary and future treatment options. International 
Journal of Cardiology, 83, 199-205. 
HUDSON, B. G., REEDERS, S. T. & TRYGGVASON, K. 1993. Type-Iv Collagen - 
Structure, Gene Organization, and Role in Human-Diseases - Molecular-Basis of 
Goodpasture and Alport Syndromes and Diffuse Leiomyomatosis. Journal of 
Biological Chemistry, 268, 26033-26036. 
IHRCKE, N. S., WRENSHALL, L. E., LINDMAN, B. J. & PLATT, J. L. 1993. Role of 
heparan sulfate in immune system-blood vessel interactions. Immunology today, 
14, 500-505. 
JANEWAY, C. 2001. Immunobiology Five, Garland Pub. 
JOHANSSON, S., SVINENG, G., WENNERBERG, K., ARMULIK, A. & 
LOHIKANGAS, L. 1997. Fibronectin-integrin interactions. Front Biosci, 2, 
d126-46. 
192 
 
JONES, D. M., BROWN, A. A. & HUCK, W. T. S. 2002. Surface-initiated 
polymerizations in aqueous media: Effect of initiator density. Langmuir, 18, 
1265-1269. 
JULIANO, R. L., ALAM, R., DIXIT, V. & KANG, H. M. 2009. Cell‐targeting and cell‐
penetrating peptides for delivery of therapeutic and imaging agents. Wiley 
Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 1, 324-335. 
JUNUTULA, J. R., RAAB, H., CLARK, S., BHAKTA, S., LEIPOLD, D. D., WEIR, S., 
CHEN, Y., SIMPSON, M., TSAI, S. P., DENNIS, M. S., LU, Y., MENG, Y. G., 
NG, C., YANG, J., LEE, C. C., DUENAS, E., GORRELL, J., KATTA, V., KIM, 
A., MCDORMAN, K., FLAGELLA, K., VENOOK, R., ROSS, S., SPENCER, S. 
D., LEE WONG, W., LOWMAN, H. B., VANDLEN, R., SLIWKOWSKI, M. X., 
SCHELLER, R. H., POLAKIS, P. & MALLET, W. 2008. Site-specific 
conjugation of a cytotoxic drug to an antibody improves the therapeutic index. 
Nat Biotech, 26, 925-932. 
KALASIN, S. & SANTORE, M. M. 2009. Non-specific adhesion on biomaterial surfaces 
driven by small amounts of protein adsorption. Colloids Surf B Biointerfaces, 73, 
229-36. 
KALLURI, R. 2003. Basement membranes: structure, assembly and role in tumour 
angiogenesis. Nat Rev Cancer, 3, 422-433. 
KARLSSON, M., EKEROTH, J., ELWING, H. & CARLSSON, U. 2005. Reduction of 
irreversible protein adsorption on solid surfaces by protein engineering for 
increased stability. Journal of Biological Chemistry, 280, 25558-25564. 
KARSTEN, U., PAPSDORF, G., ROLOFF, G., STOLLEY, P., ABEL, H., WALTHER, 
I. & WEISS, H. 1985. Monoclonal anti-cytokeratin antibody from a hybridoma 
193 
 
clone generated by electrofusion. European Journal of Cancer and Clinical 
Oncology, 21, 733-740. 
KAYITMAZER, A. B., SEEMAN, D., MINSKY, B. B., DUBIN, P. L. & XU, Y. S. 
2013. Protein-polyelectrolyte interactions. Soft Matter, 9, 2553-2583. 
KELLY, C., JEFFERIES, C. & CRYAN, S.-A. 2011. Targeted Liposomal Drug Delivery 
to Monocytes and Macrophages. Journal of Drug Delivery, 2011, 11. 
KERDJOUDJ, H., BERTHELEMY, N., RINCKENBACH, S., KEARNEY-
SCHWARTZ, A., MONTAGNE, K., SCHAAF, P., LACOLLEY, P., STOLTZ, 
J.-F., VOEGEL, J.-C. & MENU, P. 2008. Small Vessel Replacement by Human 
Umbilical Arteries With Polyelectrolyte Film-Treated Arteries: In Vivo Behavior. 
Journal of the American College of Cardiology, 52, 1589-1597. 
KIVELA, A. & HARTIKAINEN, J. 2006. Restenosis related to percutaneous coronary 
intervention has been solved? Annals of Medicine, 38, 173-187. 
KÖHLER, K., SHCHUKIN, D. G., SUKHORUKOV, G. B. & MÖHWALD, H. 2004. 
Drastic Morphological Modification of Polyelectrolyte Microcapsules Induced by 
High Temperature. Macromolecules, 37, 9546-9550. 
KOLÁŘOVÁ, H., AMBRŮZOVÁ, B., ŠVIHÁLKOVÁ ŠINDLEROVÁ, L., KLINKE, 
A. & KUBALA, L. 2014. Modulation of Endothelial Glycocalyx Structure under 
Inflammatory Conditions. Mediators of Inflammation, 2014. 
KOLIAKOS, G. G., KOUZIKOLIAKOS, K., FURCHT, L. T., REGER, L. A. & 
TSILIBARY, E. C. 1989. The Binding of Heparin to Type-Iv Collagen - Domain 
Specificity with Identification of Peptide Sequences from the Alpha-1(Iv) and 
Alpha-2(Iv) Which Preferentially Bind Heparin. Journal of Biological Chemistry, 
264, 2313-2323. 
194 
 
KOUTSOUKOS, P., NORDE, W. & LYKLEMA, J. 1983. Protein adsorption on 
hematite (α-Fe< sub> 2</sub> O< sub> 3</sub>) surfaces. Journal of Colloid 
and Interface Science, 95, 385-397. 
KREFT, O., JAVIER, A. M., SUKHORUKOV, G. B. & PARAK, W. J. 2007. Polymer 
microcapsules as mobile local pH-sensors. Journal of Materials Chemistry, 17, 
4471-4476. 
KUNKEL, E. J. & LEY, K. 1996. Distinct Phenotype of E-Selectin–Deficient Mice E-
Selectin Is Required for Slow Leukocyte Rolling In Vivo. Circulation Research, 
79, 1196-1204. 
KURKI, P., KARJALAINEN, J., HAUTANEN, A. & VIRTANEN, I. 1989. Desmin 
antibodies in acute infectious myopericarditis. APMIS, 97, 527-32. 
LAUNES, J. & HAUTANEN, A. 1988. Nephropathia epidemica encephalitis. Acta 
Neurol Scand, 78, 234-5. 
LEINONEN, A. 1999. Human type IV collagen: characterization of primary structures 
of alpha3(IV) and alpha4(IV) chains, structure of COL4A5 gene, and expression 
of recombinant alpha3(IV) chain, Oulun yliopisto. 
LEPORATTI, S., GAO, C., VOIGT, A., DONATH, E. & MOHWALD, H. 2001. 
Shrinking of ultrathin polyelectrolyte multilayer capsules upon annealing: A 
confocal laser scanning microscopy and scanning force microscopy study. 
European Physical Journal E, 5, 13-20. 
LI, Y., WANG, F. & WANG, H. 2010. Cell death along single microfluidic channel after 
freeze-thaw treatments. Biomicrofluidics, 4, 014111. 
LIEDBERG, B., LUNDSTROM, I. & STENBERG, E. 1993. Principles of Biosensing 
with an Extended Coupling Matrix and Surface-Plasmon Resonance. Sensors and 
Actuators B-Chemical, 11, 63-72. 
195 
 
LINDMAN, S., XUE, W. F., SZCZEPANKIEWICZ, O., BAUER, M. C., NILSSON, H. 
& LINSE, S. 2006. Salting the Charged Surface: pH and Salt Dependence of 
Protein G B1 Stability. Biophys J, 90, 2911-21. 
LIU, W., WANG, X., BAI, K., LIN, M., SUKHORUKOV, G. & WANG, W. 2014. 
Microcapsules functionalized with neuraminidase can enter vascular endothelial 
cells in vitro. 
LOUGHNEY, J. W., LANCASTER, C., HA, S. & RUSTANDI, R. R. 2014. Residual 
bovine serum albumin (BSA) quantitation in vaccines using automated Capillary 
Western technology. Analytical biochemistry. 
LOWE, H. C., CHESTERMAN, C. N. & KHACHIGIAN, L. M. 2001. Does thrombus 
contribute to in-stent restenosis in the porcine coronary stent model? Thromb 
Haemost, 85, 1117-8. 
LV, H., ZHANG, S., WANG, B., CUI, S. & YAN, J. 2006. Toxicity of cationic lipids 
and cationic polymers in gene delivery. Journal of Controlled Release, 114, 100-
109. 
LVOV, Y., ARIGA, K., ICHINOSE, I. & KUNITAKE, T. 1995. Assembly of 
Multicomponent Protein Films by Means of Electrostatic Layer-by-Layer 
Adsorption. Journal of the American Chemical Society, 117, 6117-6123. 
MANISH, G. & VIMUKTA, S. 2011. Targeted drug delivery system: A Review. 
Research Journal of Chemical 
Sciences_____________________________________________Vol, 1, 2. 
MANJU, S. & SREENIVASAN, K. 2011. Hollow microcapsules built by layer by layer 
assembly for the encapsulation and sustained release of curcumin. Colloids and 
Surfaces B-Biointerfaces, 82, 588-593. 
196 
 
MAZUR, P. 1963. Kinetics of water loss from cells at subzero temperatures and the 
likelihood of intracellular freezing. The Journal of General Physiology, 47, 347-
369. 
MAZUR, P., LEIBO, S. & CHU, E. 1972. A two-factor hypothesis of freezing injury: 
evidence from Chinese hamster tissue-culture cells. Experimental cell research, 
71, 345-355. 
MEDINA, O. P., ZHU, Y. & KAIREMO, K. 2004. Targeted liposomal drug delivery in 
cancer. Curr Pharm Des, 10, 2981-9. 
MERMUT, O., LEFEBVRE, J., GRAY, D. G. & BARRETT, C. J. 2003. Structural and 
Mechanical Properties of Polyelectrolyte Multilayer Films Studied by AFM. 
Macromolecules, 36, 8819-8824. 
MICHEL, M., TONIAZZO, V., RUCH, D. & BALL, V. 2012. Deposition Mechanisms 
in Layer-by-Layer or Step-by-Step Deposition Methods: From Elastic and 
Impermeable Films to Soft Membranes with Ion Exchange Properties. ISRN 
Materials Science, 2012, 13. 
MÜLLER, M., VÖRÖS, J., CSUCS, G., WALTER, E., DANUSER, G., MERKLE, H., 
SPENCER, N. & TEXTOR, M. 2003. Surface modification of PLGA 
microspheres. Journal of Biomedical Materials Research Part A, 66, 55-61. 
NAGATA, Y. & BURGER, M. M. 1972. Wheat germ agglutinin isolation and 
crystallization. Journal of Biological Chemistry, 247, 2248-2250. 
NOLTE, M. & FERY, A. 2004. Coupling of individual polyelectrolyte capsules onto 
patterned substrates. Langmuir, 20, 2995-2998. 
PAHAKIS, M. Y., KOSKY, J. R., DULL, R. O. & TARBELL, J. M. 2007. The role of 
endothelial glycocalyx components in mechanotransduction of fluid shear stress. 
Biochemical and Biophysical Research Communications, 355, 228-233. 
197 
 
PALAMÀ, I. E., LEPORATTI, S., LUCA, E. D., RENZO, N. D., MAFFIA, M., 
GAMBACORTI-PASSERINI, C., RINALDI, R., GIGLI, G., CINGOLANI, R. & 
COLUCCIA, A. M. 2010. Imatinib-loaded polyelectrolyte microcapsules for 
sustained targeting of BCR-ABL+ leukemia stem cells. Nanomedicine, 5, 419-
431. 
PARGAONKAR, N., LVOV, Y. M., LI, N., STEENEKAMP, J. H. & DE VILLIERS, M. 
M. 2005. Controlled release of dexamethasone from microcapsules produced by 
polyelectrolyte layer-by-layer nanoassembly. Pharm Res, 22, 826-35. 
PASTORINO, L., EROKHINA, S., SOUMETZ, F. C., BIANCHINI, P., KONOVALOV, 
O., DIASPRO, A., RUGGIERO, C. & EROKHIN, V. 2011. Collagen containing 
microcapsules: smart containers for disease controlled therapy. J Colloid 
Interface Sci, 357, 56-62. 
PATEL, E. & OSWAL, R. 2012. Nanosponge and micro sponges: a novel drug delivery 
system. Int J Research Pharmacy Chemistry, 2, 237-44. 
PATEL, H. 1991. Serum opsonins and liposomes: Their interaction and 
opsonophagocytosis. Critical reviews in therapeutic drug carrier systems, 9, 39-
90. 
PETERS, B. P., EBISU, S., GOLDSTEIN, I. J. & FLASHNER, M. 1979. Interaction of 
wheat germ agglutinin with sialic acid. Biochemistry, 18, 5505-5511. 
PEYRATOUT, C. S. & DÄHNE, L. 2004. Tailor-Made Polyelectrolyte Microcapsules: 
From Multilayers to Smart Containers. Angewandte Chemie International 
Edition, 43, 3762-3783. 
PHIPPS, R. P. 2000. Atherosclerosis: the emerging role of inflammation and the CD40-
CD40 ligand system. Proc Natl Acad Sci U S A, 97, 6930-2. 
198 
 
PIERSCHBACHER, M. D. & RUOSLAHTI, E. 1987. Influence of stereochemistry of 
the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion. Journal of 
Biological Chemistry, 262, 17294-8. 
PIKAL-CLELAND, K. A., RODRIGUEZ-HORNEDO, N., AMIDON, G. L. & 
CARPENTER, J. F. 2000. Protein denaturation during freezing and thawing in 
phosphate buffer systems: monomeric and tetrameric beta-galactosidase. Archives 
of Biochemistry and Biophysics, 384, 398-406. 
PILERI, S. A., RONCADOR, G., CECCARELLI, C., PICCIOLI, M., BRISKOMATIS, 
A., SABATTINI, E., ASCANI, S., SANTINI, D., PICCALUGA, P. P. & 
LEONE, O. 1997. Antigen retrieval techniques in immunohistochemistry: 
comparison of different methods. The Journal of pathology, 183, 116-123. 
POTIER, P., DREVET, P., GOUNOT, A.-M. & HIPKISS, A. R. 1990. Temperature-
dependent changes in proteolytic activities and protein composition in the 
psychrotrophic bacterium Arthrobacter globiformis S155. Journal of general 
microbiology, 136, 283-291. 
PRESCOTT, M. F., SAWYER, W. K., VON LINDEN-REED, J., JEUNE, M., CHOU, 
M., CAPLAN, S. L. & JENG, A. Y. 1999. Effect of matrix metalloproteinase 
inhibition on progression of atherosclerosis and aneurysm in LDL receptor-
deficient mice overexpressing MMP-3, MMP-12, and MMP-13 and on restenosis 
in rats after balloon injury. Annals of the New York Academy of Sciences, 878, 
179-90. 
QIAN, J., XU, B., CHEN, J. L., YANG, Y. J., QIAO, S. B., LI, J. J., QIN, X. W., YAO, 
M., LIU, H. B., WU, Y. J., YUAN, J. Q., CHEN, J., YOU, S. J., DAI, J. & GAO, 
R. L. 2009. Persistent Inhibition of Neointimal Hyperplasia after Firebird2 
199 
 
Sirolimus-Eluting Stent Implantation Long-Term (Up to 3 Years) Clinical 
Follow-Up a Single Center Experience. Cardiology, 114, 1-1. 
RADT, B., SMITH, T. A. & CARUSO, F. 2004. Optically addressable nanostructured 
capsules. Advanced Materials, 16, 2184-+. 
RAGNETTI, M. & OBERTHÜR, R. C. 1986. Conformation of a chain polyelectrolyte in 
solution with low molecular weight salt: small angle neutron scattering 
measurements. Colloid and Polymer Science, 264, 32-45. 
ROQUE, M., FALLON, J. T., BADIMON, J. J., ZHANG, W. X., TAUBMAN, M. B. & 
REIS, E. D. 2000. Mouse model of femoral artery denudation injury associated 
with the rapid accumulation of adhesion molecules on the luminal surface and 
recruitment of neutrophils. Arterioscler Thromb Vasc Biol, 20, 335-42. 
RUOSLAHTI, E. 1991. Integrins. Journal of Clinical Investigation, 87, 1. 
RUOSLAHTI, E. 1996. RGD and other recognition sequences for integrins. Annu Rev 
Cell Dev Biol, 12, 697-715. 
SAH, H., TODDYWALA, R. & CHIEN, Y. W. 1995. Continuous Release of Proteins 
from Biodegradable Microcapsules and in-Vivo Evaluation of Their Potential as a 
Vaccine Adjuvant. Journal of Controlled Release, 35, 137-144. 
SAHA, K., BENDER, F. & GIZELI, E. 2003. Comparative study of IgG binding to 
proteins G and A: nonequilibrium kinetic and binding constant determination 
with the acoustic waveguide device. Analytical Chemistry, 75, 835-42. 
SALMON, A. H., FERGUSON, J. K., BURFORD, J. L., GEVORGYAN, H., NAKANO, 
D., HARPER, S. J., BATES, D. O. & PETI-PETERDI, J. 2012. Loss of the 
endothelial glycocalyx links albuminuria and vascular dysfunction. Journal of the 
American Society of Nephrology, 23, 1339-1350. 
200 
 
SANTOS, J. L., NOURI, A., FERNANDES, T., RODRIGUES, J. & TOMAS, H. 2012. 
Gene delivery using biodegradable polyelectrolyte microcapsules prepared 
through the layer-by-layer technique. Biotechnol Prog, 28, 1088-94. 
SATO, K., YOSHIDA, K., TAKAHASHI, S. & ANZAI, J.-I. 2011. pH- and sugar-
sensitive layer-by-layer films and microcapsules for drug delivery. Advanced 
Drug Delivery Reviews, 63, 809-821. 
SAURER, E. M., FLESSNER, R. M., BUCK, M. E. & LYNN, D. M. 2011. Fabrication 
of Covalently Crosslinked and Amine-Reactive Microcapsules by Reactive 
Layer-by-Layer Assembly of Azlactone-Containing Polymer Multilayers on 
Sacrificial Microparticle Templates. Journal of Materials Chemistry, 21, 1736-
1745. 
SCHAEFFER, H., BREITFELLER, J. & KROHN, D. 1982. Lectin-mediated attachment 
of liposomes to cornea: influence on transcorneal drug flux. Investigative 
Ophthalmology & Visual Science, 23, 530-533. 
SCHWEFEL, D., MAIERHOFER, C., BECK, J. G., SEEBERGER, S., DIEDERICHS, 
K., M LLER, H. M., WELTE, W. & WITTMANN, V. 2010. Structural basis of 
multivalent binding to wheat germ agglutinin. Journal of the American Chemical 
Society, 132, 8704-8719. 
SHAH, G. 1998. Why do we still use serum in the production of biopharmaceuticals? 
Developments in biological standardization, 99, 17-22. 
SHE, Z., ANTIPINA, M. N., LI, J. & SUKHORUKOV, G. B. 2010a. Mechanism of 
Protein Release from Polyelectrolyte Multilayer Microcapsules. 
Biomacromolecules, 11, 1241-1247. 
201 
 
SHE, Z., ANTIPINA, M. N., LI, J. & SUKHORUKOV, G. B. 2010b. Mechanism of 
protein release from polyelectrolyte multilayer microcapsules. 
Biomacromolecules, 11, 1241-7. 
SHRINGIRISHI, M., PRAJAPATI, S. K., MAHOR, A., ALOK, S., YADAV, P. & 
VERMA, A. Nanosponges: a potential nanocarrier for novel drug delivery-a 
review. 
SINGH, R. & LILLARD JR, J. W. 2009. Nanoparticle-based targeted drug delivery. 
Experimental and Molecular Pathology, 86, 215-223. 
SKIRTACH, A. G., DEJUGNAT, C., BRAUN, D., SUSHA, A. S., ROGACH, A. L., 
PARAK, W. J., MOHWALD, H. & SUKHORUKOV, G. B. 2005. The role of 
metal nanoparticles in remote release of encapsulated materials. Nano Letters, 5, 
1371-1377. 
SKIRTACH, A. G., KARAGEORGIEV, P., DE GEEST, B. G., PAZOS-PEREZ, N., 
BRAUN, D. & SUKHORUKOV, G. B. 2008. Nanorods as Wavelength-Selective 
Absorption Centers in the Visible and Near-Infrared Regions of the 
Electromagnetic Spectrum. Advanced Materials, 20, 506-510. 
SKOOG, D., WEST, D., HOLLER, F. & CROUCH, S. 2013. Fundamentals of 
Analytical Chemistry, Cengage Learning. 
SKOOG, D. A., WEST, D. M. & HOLLER, F. J. 2000. Analytical Chemistry: An 
Introduction, Saunders College Pub. 
SMITH, R. N., MCCORMICK, M., BARRETT, C. J., REVEN, L. & SPIESS, H. W. 
2004. NMR Studies of PAH/PSS Polyelectrolyte Multilayers Adsorbed onto 
Silica. Macromolecules, 37, 4830-4838. 
202 
 
SOCHYNSKY, R. A., BOUGHTON, B. J., BURNS, J., SYKES, B. C. & MCGEE, J. O. 
1980. The effect of human fibronectin on platelet-collagen adhesion. Thromb Res, 
18, 521-33. 
SONG, W., HE, Q., MOHWALD, H., YANG, Y. & LI, J. 2009a. Smart polyelectrolyte 
microcapsules as carriers for water-soluble small molecular drug. J Control 
Release, 139, 160-6. 
SONG, W., HE, Q., MÖHWALD, H., YANG, Y. & LI, J. 2009b. Smart polyelectrolyte 
microcapsules as carriers for water-soluble small molecular drug. Journal of 
Controlled Release, 139, 160-166. 
STUBER, W., KNOLLE, J. & BREIPOHL, G. 1989. Synthesis of peptide amides by 
Fmoc-solid-phase peptide synthesis and acid labile anchor groups. International 
journal of peptide and protein research, 34, 215-21. 
SUKHORUKOV, G. B., BRUMEN, M., DONATH, E. & MOHWALD, H. 1999. 
Hollow polyelectrolyte shells: Exclusion of polymers and donnan equilibrium. 
Journal of Physical Chemistry B, 103, 6434-6440. 
SUKHORUKOV, G. B., ROGACH, A. L., GARSTKA, M., SPRINGER, S., PARAK, 
W. J., MUÑOZ-JAVIER, A., KREFT, O., SKIRTACH, A. G., SUSHA, A. S., 
RAMAYE, Y., PALANKAR, R. & WINTERHALTER, M. 2007. 
Multifunctionalized Polymer Microcapsules: Novel Tools for Biological and 
Pharmacological Applications. Small, 3, 944-955. 
SUKHORUKOV, G. B., ROGACH, A. L., ZEBLI, B., LIEDL, T., SKIRTACH, A. G., 
KÖHLER, K., ANTIPOV, A. A., GAPONIK, N., SUSHA, A. S., 
WINTERHALTER, M. & PARAK, W. J. 2005. Nanoengineered Polymer 
Capsules: Tools for Detection, Controlled Delivery, and Site-Specific 
Manipulation. Small, 1, 194-200. 
203 
 
SUKHORUKOV, G. B., VOLODKIN, D. V., GUNTHER, A. M., PETROV, A. I., 
SHENOY, D. B. & MOHWALD, H. 2004. Porous calcium carbonate 
microparticles as templates for encapsulation of bioactive compounds. Journal of 
Materials Chemistry, 14, 2073-2081. 
SZE, A., ERICKSON, D., REN, L. & LI, D. 2003. Zeta-potential measurement using the 
Smoluchowski equation and the slope of the current–time relationship in 
electroosmotic flow. Journal of Colloid and Interface Science, 261, 402-410. 
TARONE, G., HIRSCH, E., BRANCACCIO, M., DE ACETIS, M., BARBERIS, L., 
BALZAC, F., RETTA, S. F., BOTTA, C., ALTRUDA, F. & SILENGO, L. 2000. 
Integrin function and regulation in development. Int J Dev Biol, 44, 725-31. 
THOMPSON, E. G., 2008, Atherosclerosis, viewed 04/06/12, 
http://edu.westpenncardio.com/ItemPopup.aspx?HWID=tp10638&SEC=tp10638-
sec 
TONG, H., MA, W., WANG, L., WAN, P., HU, J. & CAO, L. 2004. Control over the 
crystal phase, shape, size and aggregation of calcium carbonate via a l-aspartic 
acid inducing process. Biomaterials, 25, 3923-3929. 
TONG, W. J., GAO, C. Y. & MOEHWALD, H. 2008. pH-responsive protein 
microcapsules fabricated via glutaraldehyde mediated covalent layer-by-layer 
assembly. Colloid and Polymer Science, 286, 1103-1109. 
TOUBLAN, F. J., BOPPART, S. & SUSLICK, K. S. 2006. Tumor targeting by surface-
modified protein microspheres. Journal of the American Chemical Society, 128, 
3472-3. 
TRMCIC-CVITAS, J., HASAN, E., RAMSTEDT, M., LI, X., COOPER, M. A., 
ABELL, C., HUCK, W. T. S. & GAUTROT, J. E. 2009. Biofunctionalized 
204 
 
Protein Resistant Oligo(ethylene glycol)-Derived Polymer Brushes as Selective 
Immobilization and Sensing Platforms. Biomacromolecules, 10, 2885-2894. 
TROTTA, F., ZANETTI, M. & CAVALLI, R. 2012. Cyclodextrin-based nanosponges as 
drug carriers. Beilstein journal of organic chemistry, 8, 2091-2099. 
TSILIBARY, E. C., KOLIAKOS, G. G., CHARONIS, A. S., VOGEL, A. M., REGER, 
L. A. & FURCHT, L. T. 1988. Heparin Type-Iv Collagen Interactions - 
Equilibrium Binding and Inhibition of Type-Iv Collagen Self-Assembly. Journal 
of Biological Chemistry, 263, 19112-19118. 
VENKATRAMAN, S. S., HUANG, Y. Y., BOEY, F. Y. C., LAHTI, E. M., 
UMASHANKAR, P. R., MOHANTY, M., ARUMUGAM, S., KHANOLKAR, 
L. & VAISHNAV, S. 2010. In vitro and in vivo performance of a dual drug-
eluting stent (DDES). Biomaterials, 31, 4382-4391. 
VERGARO, V., SCARLINO, F., BELLOMO, C., RINALDI, R., VERGARA, D., 
MAFFIA, M., BALDASSARRE, F., GIANNELLI, G., ZHANG, X., LVOV, Y. 
M. & LEPORATTI, S. 2011. Drug-loaded polyelectrolyte microcapsules for 
sustained targeting of cancer cells. Advanced Drug Delivery Reviews, 63, 847-
864. 
VILASECA, P., DAWSON, K. A. & FRANZESE, G. 2012. Understanding surface-
adsorption of proteins: the Vroman effect. arXiv preprint arXiv:1202.3796. 
WANG, C., YE, W., ZHENG, Y., LIU, X. & TONG, Z. 2007a. Fabrication of drug-
loaded biodegradable microcapsules for controlled release by combination of 
solvent evaporation and layer-by-layer self-assembly. Int J Pharm, 338, 165-73. 
WANG, C., YE, W., ZHENG, Y., LIU, X. & TONG, Z. 2007b. Fabrication of drug-
loaded biodegradable microcapsules for controlled release by combination of 
205 
 
solvent evaporation and layer-by-layer self-assembly. International Journal of 
Pharmaceutics, 338, 165-173. 
WANG, S., LI, X., PARRA, M., VERDIN, E., BASSEL-DUBY, R. & OLSON, E. N. 
2008. Control of endothelial cell proliferation and migration by VEGF signaling 
to histone deacetylase 7. Proc Natl Acad Sci U S A, 105, 7738-43. 
WATTENDORF, U., KOCH, M. C., WALTER, E., VOROS, J., TEXTOR, M. & 
MERKLE, H. P. 2006. Phagocytosis of poly(L-lysine)-graft-poly(ethylene glycol) 
coated microspheres by antigen presenting cells: Impact of grafting ratio and 
poly(ethylene glycol) chain length on cellular recognition. Biointerphases, 1, 123-
33. 
WATTENDORF, U., KREFT, O., TEXTOR, M., SUKHORUKOV, G. B. & MERKLE, 
H. P. 2008. Stable stealth function for hollow polyelectrolyte microcapsules 
through a poly(ethylene glycol) grafted polyelectrolyte adlayer. 
Biomacromolecules, 9, 100-108. 
WEINBAUM, S., TARBELL, J. M. & DAMIANO, E. R. 2007. The structure and 
function of the endothelial glycocalyx layer. Annu. Rev. Biomed. Eng., 9, 121-
167. 
WIETHOFF, C. M., SMITH, J. G., KOE, G. S. & MIDDAUGH, C. R. 2001. The 
Potential Role of Proteoglycans in Cationic Lipid-mediated Gene Delivery: 
STUDIES OF THE INTERACTION OF CATIONIC LIPID-DNA COMPLEXES 
WITH MODEL GLYCOSAMINOGLYCANS. Journal of Biological Chemistry, 
276, 32806-32813. 
WILSON, L., MATSUDAIRA, P. T., DARZYNKIEWICZ, Z., ROBINSON, J. P. & 
CRISSMAN, H. A. 2000. Cytometry, Elsevier Science. 
206 
 
XIONG, J.-P., STEHLE, T., ZHANG, R., JOACHIMIAK, A., FRECH, M., 
GOODMAN, S. L. & ARNAOUT, M. A. 2002. Crystal structure of the 
extracellular segment of integrin αVβ3 in complex with an Arg-Gly-Asp ligand. 
Science, 296, 151-155. 
YADAV, G. V. & PANCHORY, H. P. 2013. Nanosponges - A Boon the the targeted 
drug delivery system. Journal of Drug Delivery and Therapeutics, 3. 
YANG, G., ZHANG, A. & XU, L. X. 2009. Experimental study of intracellular ice 
growth in human umbilical vein endothelial cells. Cryobiology, 58, 96-102. 
YANG, J.-C., ZHAO, C., HSIEH, I. F., SUBRAMANIAN, S., LIU, L., CHENG, G., LI, 
L., CHENG, S. Z. D. & ZHENG, J. 2012a. Strong resistance of poly (ethylene 
glycol) based L-tyrosine polyurethanes to protein adsorption and cell adhesion. 
Polymer International, 61, 616-621. 
YANG, J. C., ZHAO, C., HSIEH, I. F., SUBRAMANIAN, S., LIU, L. Y., CHENG, G., 
LI, L. Y., CHENG, S. Z. D. & ZHENG, J. 2012b. Strong resistance of poly 
(ethylene glycol) based L-tyrosine polyurethanes to protein adsorption and cell 
adhesion. Polymer International, 61, 616-621. 
YEUNG, T., GILBERT, G. E., SHI, J., SILVIUS, J., KAPUS, A. & GRINSTEIN, S. 
2008. Membrane phosphatidylserine regulates surface charge and protein 
localization. Science, 319, 210-213. 
YI, Q. & SUKHORUKOV, G. B. 2013. Photolysis Triggered Sealing of Multilayer 
Capsules to Entrap Small Molecules. Acs Applied Materials & Interfaces, 5, 
6723-6731. 
ZHAO, Q. H. & LI, B. Y. 2008. pH-controlled drug loading and release from 
biodegradable microcapsules. Nanomedicine-Nanotechnology Biology and 
Medicine, 4, 302-310. 
207 
 
ZHOU, C., FRIEDT, J. M., ANGELOVA, A., CHOI, K. H., LAUREYN, W., 
FREDERIX, F., FRANCIS, L. A., CAMPITELLI, A., ENGELBORGHS, Y. & 
BORGHS, G. 2004. Human immunoglobulin adsorption investigated by means of 
quartz crystal microbalance dissipation, atomic force microscopy, surface 
acoustic wave, and surface plasmon resonance techniques. Langmuir, 20, 5870-
5878. 
 
 
